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Chapter 1
Introduction
Desmoid-type fibromatosis (DF) is a rare disease, also known as aggressive fibromatosis 
or desmoid tumor. It is a fibroblastic proliferation arising in deep soft tissues. DF is 
characterized by infiltrative growth with a tendency towards local recurrence but an inability 
to metastasize1. Therefore, they are labeled as an “intermediate (locally aggressive)” tumor 
by the World Health Organization. These tumors typically present as a deep, firm mass 
which causes little or no pain.
Etiology
The pathogenesis of DF is not fully understood. Genetic mutations, hormonal influences and 
a history of trauma are all involved factors2-4. Genetic mutations are seen in the majority 
of patients, mostly in the APC and CTNNB1 gene. Both genes are part of the canonical Wnt-
pathway and influence gene transcription and cell adhesion5. A distinction is made between 
these types of mutations. In most cases of sporadic disease, the CTNNB1 gene is involved, 
whereas mutations in the APC gene are associated with familiar adenomatous polyposis 
(FAP)6,7. This association is called Gardner syndrome. Approximately 7.5% of all desmoid 
patients have FAP, whereas approximately 14% of FAP patients develop DF8,9. 
Hormonal influences are implied by the peak occurrence of tumors among fertile females 
and the behavior of disease during pregnancies. Pregnant patients often report tumor 
growth during pregnancy, with spontaneous regression after delivery. 
A history of trauma is documented in a large group of patients. In particular, surgical 
trauma is believed to influence pathogenesis, as DF often arises in scars. 
Classification
There are three subgroups of DF:
●● Extra-abdominal. A scale of anatomic locations can be involved, though mainly the 
extremities, chest wall, back, head and neck. The origin is mostly sporadic.
●● Abdominal. Tumors arising from the abdominal wall. The origin is both sporadic and 
associated with FAP. Also associated with pregnancies and cesarean sections. 
●● Intra-abdominal. Tumors arising in the pelvis or mesentery. The origin is associated 
with FAP. 
This thesis is focused on the extra-abdominal and abdominal DF. Due to the different 
10 Chapter 1
 biology, treatment options and consideration in relation to FAP, intra-abdominal DF will  
not be discussed.
Part 1 - Epidemiology
DF accounts for approximately 0.03% of all neoplasms and less than 3% of all soft tissue 
tumors. Mostly females are affected by this disease, with a peak around 38 years of age.
The incidence of DF is low. Descriptive articles by a Finnish group, dated around 1982, 
report an incidence of two to four individuals per million people per year2,3. They found 
different distributions of gender and tumor localization among age groups. In the pediatric 
population, extra-abdominal lesions prevailed, equally among the genders. Abdominal wall 
lesions were predominantly found in young adolescents till the age of 40. The majority of 
the group was female. Among older patients, tumors were distributed equally between 
abdominal and extra-abdominal lesions and equally among gender. These studies date 
three decades ago. More insight in current epidemiologic trends and treatment related 
trends was imperative. In chapter 2 we analyzed the trends in incidence and treatment  
of extra-abdominal and abdominal DF in a population based study.
Part 2 – Treatment modalities
The treatment options for DF are dependent on the localization of the tumor. Extra- 
abdominal and abdominal disease is often treated similarly, whereas intra-abdominal 
 disease poses different challenges. Organ involvement and the often large size of the 
tumor limit surgical and radiotherapeutic options for intra-abdominal disease. In addition, 
the frequent association with FAP in intra-abdominal disease is related to a high mortality 
rate, partially due to organ compression by the tumor10. 
The classical treatment of extra-abdominal and abdominal DF implies primary surgery, 
with radiotherapy on indication. During the past decade, this advice switched based on 
accumulating evidence to active surveillance and in case of progressive disease surgery, 
radiotherapy or systemic treatment based on localization. 
Surgery
DF cannot metastasize and is therefore not considered malignant. However, the tumor can 
be locally aggressive and surgeons may be inclined to remove the tumor at the earliest 
possible stage. Complete resection is challenging due to the infiltrative growth pattern. 
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In addition, pathology characteristics mimic scar tissue, hindering evaluation of repeated 
surgery to achieve complete resection. Literature on the benefit of complete resection is 
ambivalent. Studies supporting the significance of resection margin on local control are 
reported by Ballo et al. and Huang et al.11,12. In contrast, Guadagnolo et al., Stoeckle et al. and 
Gluck et al. did not find statistical significant benefit of microscopic radical resection (R0) over 
microscopic irradical resection (R1)13-15. A large study by Gronchi et al. (n=203) reported a 
discrimination16. They found no benefit of radical resection on local recurrence for primary 
disease, but is was statistical significant for recurrent disease. Salas et al. described the 
largest study on the subject (n=426), reporting a significant benefit of R0/R1 over R2, but 
none for R0 over R1 and no statistical significance in multivariate analysis17. In chapter 3 
we describe a retrospective study among a large patient cohort. We analyzed the risk of 
recurrence following complete or incomplete resection, as well as the value of adjuvant 
radiotherapy. 
Radiotherapy
Radiotherapy can be applied neo-adjuvant or adjuvant in candidates for surgery, or as an 
option for inoperable patients. The advised therapeutic dose is set at 56 Gy18. The benefit 
of radiotherapy is however disputed, in particular the value of (neo-) adjuvant radiotherapy. 
Whereas Ballo et al. and Baumert et al. described an added value for adjuvant radiotherapy 
on local control11,19, Guadagnolo et al. and Gluck et al. did not find the same results13,15. 
The value of radiotherapy as primary treatment is more supported in the literature. 
 Zlotecki et al. reported a 5-year local control rate of 96% for primary disease and 75% 
in recurrent disease among 72 patients20. EORTC study 92991-22998 reported by Keus 
et al. showed complete response in 13.6%, partial response in 36.4% and stable disease 
in 40.9% of patients after 3 years18. In addition, continuing regression was seen after 
3 years of follow-up. Radiotherapy is a very aggressive treatment modality for a relatively 
benign disease, as it can induce malignancy and other complications. Therefore, careful 
considerations must be made before applying this treatment modality. The value of 
radiotherapy following surgery is discussed in chapter 4.
Isolated limb perfusion 
Another form of local treatment is isolated limb perfusion (ILP). With this technique, high 
dose chemotherapy can be delivered to the tumor. During the procedure, the targeted 
blood circuit is isolated and connected to an oxygenated extracorporeal circuit. Tumor 
necrosis factor alpha and melphalan are injected into the limb vascular system. After 
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60-90 minutes of perfusion, the vascular system is rinsed and circulation restored. This 
technique is the European standard of care for patients with limb-threatening sarcoma. 
It is a highly aggressive treatment due to the toxicity. For patients with DF, this treatment 
is only considered for a very select group of patients. Patients need to have advanced 
disease, in which surgery would lead to severe mutilation or amputation. This treatment 
is only performed in specialized sarcoma centers after careful consideration, often in a 
multidisciplinary setting. In chapter 5, we report the outcome of this technique in DF in 
3 specialized EORTC sarcoma centers. 
Systemic treatment 
Besides local treatment, several drugs have been applied as systemic treatment for DF. 
Anti-hormonal drugs, non-steriodal anti-inflammatory drugs (NSAIDs), tyrosine kinase 
inhibitors and several types of chemotherapy have been reported as treatment for DF. 
Literature on the outcome of these drugs in DF is very scarce. Usually small patient cohorts 
are described, with overall good response of treatment. A systematic review of systemic 
treatment has been reported by Janinis et al., concluding that the evidence in the literature 
supports the opinion that both non-cytotoxic and cytotoxic chemotherapies are effective 
against DF21. However, the lack of sufficient patient numbers and randomized trials 
compromises the validity of the reported results. Recently, an European consensus on the 
treatment of DF has been published22. Systemic treatment is mentioned among the options 
stating that ‘(…), it is reasonable to employ the less toxic therapies before the more toxic ones 
in a stepwise fashion. However, due to the lack of randomized or comparative data, we are 
not in the situation to propose a definitive order of the existing systemic treatment options.’ 
Overall, toxicity of treatment is balanced against the intermediate nature of this disease. 
Active surveillance
As DF is not an aggressive disease, active surveillance (also known as wait-and-see policy 
or watchful waiting) can be applied in patients with limited or no complaints. During active 
surveillance, frequent follow-up visits will be made, to monitor potential tumor growth. 
This treatment modality has gained popularity during the past decade. Reports from 
several research groups show promising numbers of disease stabilization and spontaneous 
regression17,23. This has led to a shift in treatment from primarily surgery and radiotherapy 
to more conservative management. Currently, active surveillance is advised as primary 
management for all DF by the European Organization for Research and Treatment of Cancer 
(EORTC)22.
Chapter 1
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This shift has resounded in the Netherlands, where initial surgery for primary DF has 
decreased. In addition to the epidemiologic study described in chapter 2, we have traced 
treatment modalities for these patients. In chapter 6 we report the results of first-line 
non-surgical management of DF in the Netherlands. 
Part 3 – Predicting tumor behavior
The natural behavior of DF ranges from spontaneous regression to rapid invasive growth. 
It is challenging to predict the behavior of a tumor in an individual. Several factors have 
been analyzed, mostly related to risk of recurrence after surgery. Age, localization and  
size of the tumor are commonly accepted as predictive factors of recurrence, with young 
age, large tumors and localization in extremity or chest wall associated with high risk 
of recurrence. Crago et al. constructed an nomogram to predict risk of recurrence after 
 surgery, based on data from 495 patients24. 
Mutations in the CTNNB1 gene correlate to DF. As these mutations play a role in 
pathogenesis, a role in biologic behavior seems natural. Several groups have analyzed 
CTNNB1  mutation as a predictive factor for recurrence after surgery. Although Mullen et 
al. did not find a statistical significant prognostic value25, several other groups reported 
a higher risk of recurrence for patients with an S45F mutation26-28, even in multivariate 
analysis26. We analyzed the predictive value of CTNNB1 mutations on the risk of recurrence 
in chapter 7. For this study, the previously formed cohort of patients undergoing surgical 
treatment was used. 
To tailor treatment of DF, a staging system is needed designed to be applied at diagnosis. 
Present knowledge is mostly based on retrospective data, with a lack of comparative 
research. As such, it is not sufficient to create a staging system. Knowledge on natural 
behavior can best be obtained during active surveillance. Three research groups have 
initiated prospective studies to provide insight on natural behavior; a French group 
(NCT01801176), an Italian group (NCT02547831) and our group (NTR4714). The study 
 protocol for the Dutch study is presented in chapter 8. This protocol was designed in 
 collaboration with the Italian group, in order to improve generalizability of the data. 
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Part 4 – General discussion, summary and appendices
This thesis is about tailoring the treatment of DF. Knowledge on DF has increased greatly 
during the last decade. More information is available on natural behavior, genetics and 
the effects of treatments. Current medical care is patient oriented, with a trend toward 
individualized treatment strategies. In addition, one must keep in mind the intermediate 
nature of DF. Mortality due to DF is reported for intra-abdominal disease, but not for extra- 
abdominal or abdominal tumors. Quality of life is very important when treating DF. Active 
surveillance is advised in a first-line setting, although surgery might be a better option for 
some patients. When DF has advanced, toxicity of treatment and expected results must be 
balanced. In chapter 9 and 10 we discuss current knowledge, considerations for treatment 
strategies and provide our vision for the future. 
Chapter 1
15 Introduction
Chapter 1
References
1. Fletcher C.D.M. BJA, Hogendoorn P., Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 
Fourth Edition.2013. 468 p
2. Reitamo JJ, Häyry P, Nykyri E, Saxén E. The desmoid tumor. I. Incidence, sex-, age- and anatominal 
 distribution in the Finnish population. Am J Chlin Pathol. 1982 Jun;77(6):665-73.
3. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of 
 factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77(6):674-80.
4. Reitamo JJ, Schelnin TM, Häyry P. The desmoid syndrome. New aspects in the cause, pathogenesis and 
treatment of the desmoid tumor. American Journal of Surgery. Am J Surg. 1986 Feb;151(2):230-7.
5. Jilong Y, Jian W, Xiaoyan Z, Xiaoqiu L and Xiongzeng Z. Analysis of APC/beta-catenin genes mutations and 
Wnt signaling pathway in desmoid-type fibromatosis. Pathology. 2007 Jun;39(3):319-25.
6. Gurbuz AK, Giardiello FM, Petersen GM et al. Gut 1994 Mar;35(3):377-81.
7. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in 
sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-20.
8. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A Nation-
wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. 
Int J Cancer 2011 Jul;129(1):256-61.
9. Campos FG, Martinez CA, Novaes M, Cecconello I. Desmoid tumors: clinical features and outcome of 
an unpredictable and challenging manifestation of familial adenomatous polyposis. Fam Cancer 2015 
Jun;14(2):211-9. 
10. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG et al. Evaluation of management of desmoid tumours 
associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011 Jan;104(1):37-42. 
11. Ballo MT, Zagars GK, Pollack A, Pisters PWT and Pollock RA. Desmoid tumor: prognostic factors and 
outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999 
Jan;17:158-67. 
12. Huang K, Wang CM, Chen JG, Du CY, Zhou Y, Shi YQ and Fu H. Prognostic factors influencing event-free 
survival and treatments in desmoid-type fibromatosis:analysis from a large institution. Am J Surg 2014 
Jun;207(6):847-54. 
13. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation 
therapy. Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):441-7. 
14. Stoeckle E, Coindre JM, Longy M et al. A critical analysis of treatment strategies in desmoid tumors:  
a review of a series of 106 cases. EJSO 2009;35:129-34.
15. Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR and Ben-Josef E. Role of radiotherapy in the 
 management of desmoid tumors. Int J Radiation Oncology Biol Phys 2011;80(3):787-92.
16. Gronchi A, Casali PG, Mariani S et al. Quality of surgery and outcome in eztra-abdominal  aggressive 
 fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003 Apr:21(7);1390-7. 
17. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from 
a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(26):3553-8.
16 Chapter 1
Chapter 1
18. Keus, R. B., et al. (2013). “Results of a phase II pilot study of moderate dose radiotherapy for inoperable 
desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998).” Ann Oncol 24(10): 
2672-2676.
19. Baumert BG, Spahr MO, von Hochstetter A et al. The impact of radiotherapy in the treatment of desmoid 
tumours. An international survey of 110 patient. A study of the Rare Cancer Network. Radiat Oncol 2007 
Mar;2:12. 
20. Zlotecki RA, Scarborough MT, Morris CG et al. External beam radiotherapy for primary and adjuvant 
 management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):177-181.
21. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS: The pharmacological treatment of aggressive 
 fibromatosis: a systematic review. Ann Oncol 2003;14:181–190.
22. Kasper B, Baumgarten C, Bonvalot S et al. Management of sporadic desmoid-type fibromatosis: a 
 European consensus approach based on patients’ and professionals’ expertise – A Sarcoma Patients 
 EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Boven 
 Sarcoma Group initiative. EJC 2015;51:127-36. 
23. Fiore M, RImareix F, Mariani L, et al. Desmoid-Type fibromatisis: a front-line conservative approach to 
select patients for surgical treatment. Ann Surg Oncol (2009) 16:2587-2593
24. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence in desmoid 
fibromatosis. Annals of Surgery. 2013;258(2):347-353.
25. Mullen JT, DeLaney TF, Rosenberg AE et al. B-catenin mutation status and outcomes in sporadic desmoid 
tumors. Oncologist. 2013;18(9):1043-9.
26. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations  
in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.  
The American journal of pathology. 2008;173(5):1518-27. 
27. Domont J, Salas S, Lacroix L, Brouste V, Saulnier P, Terrier P, et al. High frequency of beta-catenin  
heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease 
 management. British journal of cancer. 2010;102(6):1032-6. 
28. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation is a  molecular 
prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, 
multicenter validation study. Cancer. 2013 Oct 15;119(20):3696-702.
17 Introduction
Chapter 1

Epidemiology
Part 1

Chapter 2
Time trends in the incidence and treatment of extra-abdominal 
and abdominal aggressive fibromatosis: a population-based 
study.
Danique L.M. van Broekhoven
Dirk J. Grünhagen
Michael A. den Bakker
Thijs van Dalen
Cornelis Verhoef
  Annals of Surgical Oncology, 2015
Abstract
Background
Aggressive fibromatosis (AF) is a locally infiltrating soft-tissue tumor. In a population-based 
study in the Netherlands, we evaluated time trends in the incidence and treatment of AF. 
Methods
In PALGA: Dutch Pathology Registry, all patients diagnosed between 1993 and 2013 as 
having extra-abdominal or abdominal wall aggressive fibromatosis were identified and 
available pathology data of the patients were evaluated. Epidemiological and treatment-
related factors were analyzed with Chi-square and regression analysis. 
Results 
During the study period, 1134 patients were identified. The incidence increased from 2.10 
to 5.36 per million people per year. Median age at the time of diagnosis increased annually 
by B 0.285 (P=0.001). Female gender prevailed and increased over time (annual odds ratio 
(OR) 1.022; P=0.058). All anatomic localizations, but in particular truncal tumors, became 
more frequent. 
During the study period diagnostic histological biopsies were performed more often 
(annual OR 1.096; P<0.001). The proportion of patients who underwent surgical treatment 
decreased (annual OR 0.928; P<0.001). When resection was preceded by biopsy, 49.8% of 
the patients had R0-resection versus 30.7% in patients without biopsy (P<0.001). 
Conclusion
In this population-based study, an increasing incidence of extra-abdominal and abdominal 
wall aggressive fibromatosis was observed. The workup of patients improved and a trend 
towards a nonsurgical treatment policy was observed.
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Introduction
Aggressive fibromatosis (AF; or desmoid-type fibromatosis) is a rare soft-tissue tumor 
that lacks the capacity to metastasize but may behave in a locally aggressive fashion. 
Knowledge on its epidemiology and etiology is limited. The Wingless/Wnt-pathway is 
involved although the mechanism is not fully understood1-3. Three different subtypes 
are recognized as entities in the WHO-classification of desmoid-type fibromatose: extra-
abdominal, abdominal and intra-abdominal tumors4. The first two mostly occur sporadic 
whereas the latter has a correlation with familiar adenomatous polyposis (FAP)5.
The incidence of AF was reported previously by Reitamo et al. in 1982, estimated at  
2.4-4.3 per million people per year6. Their studies on the etiology and epidemiology are 
often referred to in the current literature6-8. The correlation of intra-abdominal AF with 
FAP has been subject of more recent studies9-11. Current research on AF mainly focuses 
on treatment strategies. Surgery has until recently been the primary treatment modality. 
Data regarding the prognostic value of surgical margins and adjuvant radiotherapy 
is conflicting12-15. New insights suggest that asymptomatic patients can be carefully 
watched without active treatment and this is suggested by international (NCCN and 
ESMO) guidelines16,17. Symptomatic patients with tumors that can be resected completely 
with acceptable morbidity should be offered surgery. In patients with symptomatic and 
“unresectable” disease, radiotherapy may be considered18. Isolated limb perfusion can 
be considered for irresectable AF of the extremities19. Systemic treatment can also be 
considered, although response rates are rather low20-22. 
We evaluated time trends of the incidence and treatment of extra-abdominal and 
abdominal wall AF within the Dutch population.
Methods
Data collection
The Dutch Pathology Registry PALGA was searched for patients with extra-abdominal 
or abdominal AF, whereas patients with intra-abdominal tumors were excluded23. 
The epidemiology and treatment of intra-abdominal tumors are linked to FAP and are 
considered a different entity. Data on this entity in the Dutch population have recently been 
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analyzed9. The PALGA database contains encoded excerpts of all pathology examinations 
obtained by a diagnostic procedure, including tissue biopsy or resection since 1979 in 
selected laboratories and expanded to nationwide inclusion in 1991. The conclusion sections 
of all pathology reports were queried for available information concerning patient, tumor 
and treatment characteristics. Age was categorized as <20, 20-44, 45-64, 65-79 and >80 
years old. Tumor localization was categorized as head/neck, trunk (including breast, thoracic 
aperture and back), abdominal wall, extremity and others. Reports were scored based on 
the encoding of procedures and details in the report as biopsy, resection or re-resection 
and on manifestation of the tumor (primary or recurrence). All patients undergoing 
re-resection were considered to have had a prior resection, even when pathology reports 
of the resection were missing. In case of patient records documenting recurrent disease, 
an attempt was made to retrieve details on the primary tumor. Due to incomplete data 
registration, patients with disease presentation before 1993 were excluded. The years of 
diagnoses were categorized as 1993-1998, 1999-2003, 2004-2008, 2009-2013. 
The primary objective was to analyze time trends in the incidence of AF. Trends of 
clinicopathological factors were analyzed as well as possible associations between the 
factors. The secondary objective was to analyze time trends in type of treatment, to which 
end the rate of resection was evaluated. Due to constrains in the pathology database 
structure, only data on pathology specimens such as biopsy of resection were available. 
Information on other treatment strategies or outcome was not available.
In order to compare the patient cohort with the Dutch population, data from Statistics 
Netherlands were obtained. This is a registry for all general population data. We used 
information on demographics to calculate annual incidence rates and information on 
surgical treatments, hormonal drugs and newborns to analyze possible etiological 
correlations. 
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 21. Continuous variables are 
shown as median with interquartile range (IQR), and categorical variables as numbers 
with percentages. Associations between clinicopathological variables were determined by 
Chi-square analysis. Univariate logistic and linear regression analysis was performed to 
analyze trends over time, results are shown as odds ratios (OR) or regression coefficient 
B (B) and with 95 % confidence intervals (CI). For all analyses, two-sided P<0.050 was 
considered statistically significant. 
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Results
A total of 1134 patients were diagnosed with extra-abdominal or abdominal wall AF 
between January 1993 and December 2013; there were 326 men and 808 women. Median 
age was 37 years (IQR 30-50). The distribution of demographic factors is shown in Table 1.
In addition to the 1134 patients diagnosed as having AF, an uncertain diagnosis of AF was 
stated in the pathology excerpt in 213 patients. This latter group of patients did not change 
significantly over the years (P=0.730). These patients were not included in the analyses for 
the present series. 
Table 1. Distribution of epidemiologic factors
  1993-1998 1999-2003 2004-2008 2009-2013
  N % N % N % N %
Gender
Male
Female
56
124
31.1
68.9
50
135
27.0
73.0
105
226
31.7
68.3
115
323
26.3
73.7
Age (years)
<20 
20-44
45-64
65-79
80+
18
115
37
10
0
10.0
63.9
20.6
5.6
0.0
14
124
33
11
3
7.6
67.0
17.8
5.9
1.6
29
170
85
39
8
8.8
51.4
25.7
11.8
2.4
39
239
112
43
5
8.9
54.6
25.6
9.8
1.1
Localization
Head/neck
Trunk
Abdominal wall
Extremity
Other
Unknown
14
29
77
45
7
2
8.0
16.7
44.3
25.9
4.0
1.1
13
39
88
32
6
4
7.1
21.4
48.4
17.6
3.3
2.2
20
102
113
68
22
5
6.1
30.9
34.2
20.6
6.7
1.5
27
152
151
85
22
0
6.2
34.8
34.6
19.5
5.0
0.0
Pathology reports
Biopsy
Biopsy + Resection
Resection
Unkn own
13
39
114
14
7.2
21.7
63.3
7.8
39
40
101
5
21.1
21.6
54.6
2.7
69
98
163
1
20.8
29.6
49.2
0.3
130
161
147
0
29.7
36.8
33.6
0.0
Epidemiologic factors 
The incidence of extra-abdominal and abdominal wall AF increased over the study period, 
from 2.10 to 5.36 per one million people (P<0.001; Figure 1). 
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Figure 1. Incidence of aggressive fibromatosis, per million people.
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Figure 2a. Distribution among age during study period.
Figure 2b. Percentage of age distribution.
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Age
The median age increased annually by B 0.285 (95%CI 0.114-0.455; P=0.001). The median 
age in 1993-1998 was 34 years (IQR 27-45) and was 39 years (IQR 30-51) in 2009-2013. The 
absolute numbers increased in all age groups over time (Figure 2a). However, the percentage 
of patients per age groups changed, mostly in patients aged 20-79 years (Figure 2b). Analysis 
of the distribution among age groups showed a significant annual decrease in the percentage 
of patients aged 20-45 years (OR 0.977; 95%CI 0.957-0.997; P=0.027) and a trend towards an 
annual increase in the percentage of patients aged 45-65 years and 65-80 years (OR 1.017; 
95%CI 0.993-1.042; P=0.173 and OR 1.035; 95%CI 0.997-1.074; P=0.069 respectively).
Figure 2c. Distribution among localization during study period.
Figure 2d. Distribution of localization per age group.
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Gender 
The absolute numbers of both male and female patients increased over the years.  
The male-female ratio showed an increasing female predominance, ranging from 68.6%  
in 1993-1998 to 73.6% in 2009-2013. 
Anatomic tumor localization
Tumor localization was distributed as: 6.7% head/neck, 29.0% trunk, 38.6% abdominal wall, 
20.7% extremity and 5.1% other (localization details were missing for 22 patients). Over the 
years, the absolute incidence in all groups increased (Figure 2c). Analysis of the distribution 
Figure 3. Type of pathology records per patient
45
40
35
30
25
20
15
10
5
0
Biopsy without surgery
Biopsy and surgery
Surgery without biopsy
1993 1998 2003 2008 2013
Figure 4. Absolute number of most common abdominal wall surgery, in relation  
to the absolute number of patients with abdominal wall AF (on secondary axis).
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of tumor localization showed a significant proportional increase in the percentage of 
patients with truncal localization (OR 1.057; 95%CI 1.032-1.083; P<0.001) whereas the 
percentage of patients with tumors in the abdominal wall decreased (OR 0.972; 95%CI 
0.952-0.993; P=0.008). 
Associations between clinicopathological factors
The distribution of tumor localization varied per age group (Figure 2d). Extremity-based 
tumors were most common in patients under 20 years of age (45.0%), whereas patients 
between 20 and 45 years most commonly harbored abdominal wall tumors (52.6%); 
truncal tumors were predominantly seen in patients between 45 and 80 years of age 
(41.5%). For patients over 80 years of age, no dominant localization could be identified.  
The distribution of age groups and localization changed over the study period. 
Workup and treatment
In 251 patients (22.1%) solely a biopsy report was retrieved; for 338 patients (29.8%) a biopsy 
report and a pathology resection specimen report was retrieved and for 525 patients (46.3%) 
solely a pathology resection specimen report was retrieved. For 20 patients, the type of 
report was unknown (Figure 3). From 1993-1998 to 2008-2013, the biopsy rate increased more 
than twofold: from 31.1% to 66.4% (OR 1.096; 95% CI 1.072-1.121, P<0.001). The proportion of 
patients who underwent surgical resection decreased annually (OR 0.928; 95%CI 0.902-0.954, 
P<0.001). It was not known what treatment was offered to the patients who did not undergo 
surgery due to the nature of the database. Over time, surgical resection was increasingly 
Figure 5. Abdominal surgery in the Netherlands.
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preceded by biopsy. If a resection was preceded by biopsy, the resection margin status 
improved significantly (49.8% R0-resection versus 30.7% in patients without biopsy; P<0.001). 
Pathology reports did not discriminate between diagnostic or therapeutic resections. Median 
time between biopsy and resection was 1.6 months (IQR 0.9 -2.7). The date of either biopsy 
or resection was missing for 2 patients. A substantial number of patients (210; 18.5%) had a 
history of surgery in the same area where AF subsequently developed. 
Dutch population 
Since the abdominal wall was the most common tumor localization, we analyzed surgical 
trends in the Netherlands for the most common surgeries in this area (caesarean section, 
cholecystectomy, appendectomy and colectomy)24. During the study period, surgical 
trauma to the abdominal wall increased (Figures 4 and 5). Due to minimal invasive 
techniques for many surgical interventions, the rate of laparotomy decreased and the rate 
of laparoscopic surgery increased. 
Data on hormonal drugs was available for the period 2006-2012. During this period, the 
overall use of hormonal medication in the Netherlands remained stable. 
The number of pregnancies of any gestational age was not available. The number of 
newborns per year was used as a surrogate, and during the study period this number 
decreased from 195.748 in 1993 to 171.341 in 2013. 
Discussion
The reference standard on the incidence and epidemiology of AF are Finnish studies by 
Reitamo et al6-8. An incidence of 2.4-4.3 per million people was reported in those studies, 
using 3 methods of estimation (local, regional and national). Distribution of disease 
was reported with a dominance of abdominal wall tumors (49%) with variations per age 
group. In the present population-based study, a rising incidence of extra-abdominal and 
abdominal wall AF was observed from 2.1 to 5.36 per million people during the period 
1993 – 2013. The distribution among age groups was similar to the Finnish studies, with a 
predominance of abdominal wall tumors in females ages 20-44 years. Remarkably, median 
age and female predominance increased over the years and the distribution of tumor 
localization shifted. The driving factor for these observed changes is unclear.
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The PALGA database provided an elaborate overview of AF in the Netherlands. The 
nationwide coverage enabled epidemiological research on this rare disease. Then again, 
the available information was limited to the date and conclusion of the pathology reports. 
Although there was information on biopsy and resection, no information was available 
for nonsurgical treatments, which is a limitation of the present study. Still, important 
information could be extracted. 
Time trends in incidence
Explanations for the observed rising incidence of AF are not evident. If a rise in incidence 
occurs, this can be due to improved diagnostic modalities (i.e. for instance detection of 
previously unrecognized tumors by improved imaging, improved recognition of the disease 
by pathologists, or the start of a screening program), or due to a true rise in the incidence 
of the disease. 
Improved registration and diagnostic tools are likely to have influenced the incidence 
figures to some extent. The changes in distribution of tumor localization might be an 
indication for a true change in disease. However, there are possible biases: other reasons 
could be an increased frequency of trunk computer-tomography scan or higher awareness 
due to screening programs.
Dutch guidelines on registration of neoplasms have changed over the years. The 
introduction of the third edition of the WHO Classification for Soft Tissue and Bone Tumours 
stimulated improvement of coding, enabling a better pathology registration25. Due to the 
benign nature, this neoplasm is not registered among soft tissue tumors in the national 
cancer registries precluding verification of our data. The overall incidence of sarcomas has 
remained stable over the years at approximately 30-35 patients per million people, with a 
slight increase to around 40 patients per million people over the past 5 years26. 
Knowledge on β-catenin and its application in the diagnostic setting around 2005 aided 
the pathologist in diagnosing AF with more confidence27-29. Nevertheless, the percentage 
of uncertain diagnoses has not changed significantly over the years, indicating that some 
difficulty to distinguish AF from low-grade and reactive spindle cell proliferations remains. 
Awareness of the presence of AF and the realization of the importance of a correct 
diagnosis have improved. In addition, the association with FAP is better understood.  
Lastly, screening programs may have influenced the stage of diagnosis, such as the breast 
cancer screening program in asymptomatic people. 
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Documented etiological factors are surgical trauma, hormonal influences and pregnancy6-8. 
National data on these factors was obtained to provide some context for the study data. 
A hypothesis could be that the increased rate of surgical trauma would lead to an increase 
in AF. On the contrary, a limitation of surgical trauma by means of minimal invasive 
techniques could possibly decrease the risk of AF. The analyses of abdominal surgery 
and abdominal AF both showed increasing rates over the study period, which might be 
supportive of the first hypothesis. 
The peak in occurrence of AF among fertile females is supportive of hormonal influences 
as an etiological factor. To test the hypothesis that a rise in hormonal levels would lead to 
an increase in AF, we compared data on hormonal drug use from Statistics Netherlands 
with the data from PALGA. Although the information on drug use was from a small period 
(2006-2012), the incidence of AF was rising during this period while the rate of hormonal 
drug use remained stable. 
Pregnancy is seen as an etiological factor within the hormonal influences. Because no  
data on pregnancies in the patient cohort was available, we obtained the rate of newborns 
in the Netherlands during the study period. The rate of pregnancies of any gestational 
age was not available. The hypothesis that an increase in pregnancies (represented by the 
number of newborns) would lead to an increase in AF was not supported, as the rate of 
newborns was decreasing. 
A more sensitive approach to test hormonal influences on AF, like analyzing hormonal 
receptors on the tumor, could provide more information but was not possible for the 
current study. 
We would like to emphasize that the presented comparisons between data from PALGA 
and Statistics Netherlands are all based on hypotheses. Direct correlations for these 
etiological factors could not be explored and possible biases should be taken into 
consideration. 
Time trends in diagnosis and treatment
Despite the aforementioned advances in diagnostic tools, the diagnosis of AF poses 
remaining challenges to the treating physicians. Although the rising incidence is most likely 
biased by diagnostic modalities and improved registration, the presented results showed 
an increasing number of patients being treated for AF. 
The presented results suggest an improved workup procedure of patients as histological 
biopsies were more often obtained. Surgical resection following a biopsy diagnosis 
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resulted in a significant higher rate of negative resection margins, underscoring the 
importance of the diagnostic process.
 
Treatment strategies changed in recent years and this is reflected in the present data. 
There has been a paradigm shift in the surgical treatment for AF patients. Before 
2000, surgery with negative margins had been considered the standard of care for 
patients affected by AF, reflecting the same approach to extremity soft-tissue sarcomas. 
A reassessment has taken place by several groups, advocating a more conservative 
approach30,31. The European consensus is currently set at an initial wait-and-see 
approach32. The increasing number of patients undergoing nonsurgical treatment in 
the presented study indicated a tendency to adhere to this policy in the Netherlands. 
The growing knowledge and understanding of the etiology and involvement of CTNNB1 
mutations will improve the diagnostic process. 
During the past 25 years, developments in the available diagnostic modalities and 
changing treatment insights had an impact on the workup and treatment of extra-
abdominal and abdominal wall AF. More insight in current epidemiologic trends and 
treatment-related trends was imperative. This population-based study reflected these 
changes and showed an overall incidence rise of AF. The reasons for the changing 
incidence, age distribution and anatomic localization distribution remain to be further 
elucidated. 
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Abstract
Background
Desmoid-type fibromatosis is a locally aggressive soft tissue tumour with a biological 
behavior that varies between relatively indolent and progressive growth. Although there is 
a trend towards conservative treatment, surgery remains the standard treatment.
Methods
Databases of three hospitals were searched to identify patients who had been treated 
for desmoid-type fibromatosis between November 1989 and May 2011. The risk of local 
recurrence was evaluated and predictive factors were assessed in patient who underwent 
surgical resection as initial treatment for a primary tumour.
Results
A total of 132 patients had surgical treatment for a primary tumour. A complete 
resection (R0) was achieved in 87 patients (65.9 per cent), macroscopic residual tumour 
remained in 4 patients. In addition to surgery, 54 patients received radiotherapy. During 
a median follow-up of 38 months, 18 local recurrences were detected. The estimated 
5-year cumulative risk of local recurrence was 17.6 per cent. Univariable Cox regression 
demonstrated that the risk of local recurrence increased for extremity lesions compared 
with desmoids on the trunk (odds ratio 6.69, 95 per cent confidence interval 1.45 to 31.54). 
No significant influence of age, resection margins or adjuvant radiotherapy on the risk for 
local recurrence was observed. 
Conclusion
Following surgical treatment of a primary extra-abdominal desmoid tumour, the 5-year 
risk of local recurrence is modest and not influenced by microscopically clear resection 
margins or adjuvant radiotherapy. 
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Introduction
Desmoid-type or aggressive fibromatosis involves rare, non-metastasizing, locally 
aggressive, soft tissue tumours that may occur in nearly any part of the body. Desmoid-
type fibromatosis is usually sporadic, although several factors are associated with the 
development of the tumours. Abdominal wall involvement is frequently seen in women of 
reproductive age1, and familial adenomatous polyposis is associated with an increased risk 
of developing desmoid tumours, particularly in the abdomen2. The biological behaviour is 
unpredictable and varies considerably between relatively indolent and progressive growth, 
which in turn may halt spontaneously3. The reported frequency of recurrence following 
local treatment ranges from 5 to 63 per cent4,5.
Surgery is considered the standard treatment for desmoid-type fibromatosis6, but 
radiotherapy and medical treatment have also been employed7,8. The influence of 
resection margin, tumour size and adjuvant radiotherapy on the risk of local recurrence 
is disputed5,9–12. The considerable number of patients who develop local recurrence 
represent, for some authors, a reason to advocate extensive local treatment13, although 
others support a more conservative approach with a wait-and-see policy in the majority  
of patients5.
In the present study, the 5-year cumulative risk of local recurrence after operative 
treatment for primary extra-abdominal desmoid-type fibromatosis was evaluated and  
the effect of possible risk factors for local recurrence was assessed.
Methods
Data collection
Patients with desmoid-type fibromatosis were identified from the institutional databases at 
University Medical Centre Utrecht, and the affiliated Diakonessenhuis, and at the Erasmus 
MC Cancer Institute in Rotterdam, The Netherlands. Patients diagnosed between November 
1989 and May 2011 as having primary extra-abdominal desmoid-type fibromatosis were 
included in the study. Patients who did not undergo surgical resection as the initial treatment 
were excluded.
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Patient and tumour characteristics
The following demographic and clinical variables were recorded: sex, age at diagnosis, 
localization of the tumour, tumour size and relation to the fascia (superficial or deep). Age 
was categorized into quartiles. Tumour localization was categorized as: trunk, extremity, 
head/neck/thoracic aperture, and other. Tumour size was categorized as 0–50, 51–100 or 
more than 100 mm. The soft-tissue pathology boards at University Medical Centre Utrecht 
and Erasmus MC Cancer Institute reviewed the histopathological diagnosis for all patients. 
The following information regarding primary treatment was recorded: number of operative 
procedures, surgical resection margins, and adjuvant radiotherapy.
The result of surgery was categorized based on the histological examination of surgical 
margins and the operative report, using the classification of the International Union 
Against Cancer (UICC), as R0 (microscopic radical resection), R1 (microscopic tumour-
positive margins) or R2 (macroscopic residual disease). After the first operation in patients 
with microscopically involved margins (R1), reoperation was undertaken when re-resection 
was judged feasible without unacceptable morbidity or loss of function. In the case of 
multiple operations, surgical margins were classified according to histopathological 
findings after the last operation.
Local recurrence was the main endpoint, defined as tumour relapse following R0 or R1 
excision of the primary tumour. For patients with an R2 resection, tumour progression was 
assessed. The end of follow-up was marked by tumour relapse (event), the last registered 
contact within the hospital or date of death (censored).
There were institutional differences regarding the follow-up strategy. At Erasmus MC 
Cancer Institute, patients were evaluated in accordance with the national guidelines, with 
physical examination every 3 months during the first year, every 6 months in the second 
year, and then once a year until 5 years after surgery. Magnetic resonance imaging (MRI) 
was performed only at 6 months after surgery, and in the event of symptoms suggestive of 
recurrence. At University Medical Centre Utrecht, and the Diakonessenhuis, the frequency 
of patient visits was the same, but MRI was performed additionally as part of the annual 
follow-up. After 5 years of follow-up, patients were encouraged to contact the hospital only 
in the case of local symptoms.
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Statistical analysis
Continuous variables are shown as median with range, and categorical variables as numbers 
with percentages. Associations between clinicopathological variables were determined 
by Chi-square analysis. The overall cumulative 5-year risk of local recurrence following R0 
or R1 resection was estimated using the Kaplan–Meier method, and differences between 
clinicopathological variables were analysed with the log rank test. To support these 
analyses, univariable Cox regression analysis was used; results are presented as hazard 
ratios (HRs) compared with a reference category and with 95 per cent confidence intervals 
(c.i.). The total number of local recurrences was too small to allow multivariable analysis. As 
the number of deceased patients also was very small, survival analysis was not performed. 
For all analyses, two-sided P < 0.050 was considered statistically significant.
Results
A total of 132 patients who underwent surgery as the initial treatment for primary extra-
abdominal desmoid-type fibromatosis were identified (Table 1). Their median age was 
36 (range 1–80) years, and 84 patients (63.6 per cent) were female. The most common 
localization of the tumour was the trunk (45.5 per cent); median tumour size was 53 mm.
Following attempted curative resection, additional operative procedures were performed 
in 33 patients (25.0 per cent). A complete resection (R0) was achieved in 87 patients 
(65.9 per cent); in 28 (32 per cent) of these patients, a second or third operation were 
performed to obtain microscopically clear resection margins. In 36 patients, surgery 
resulted in a microscopically incomplete resection (R1); in five patients, the tumour was 
removed completely according to the operative report but data regarding resection 
margins were lacking in the histopathological report. The tumour was macroscopically 
incompletely excised (R2) in four patients (3.0 per cent).
Postoperative radiotherapy was given to 54 patients (40.9 per cent). Data on definitive 
application of advised radiotherapy were lacking for three patients (2.3 per cent); in 
the other patients, doses of more than 50 Gy were given, in fractions of 2 Gy. Between 
the institutions, there were no differences in the proportions of patients who received 
radiotherapy (data not shown). Radiotherapy was applied following R1 or R2 resection 
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in 20 (50 per cent) of 40 patients following R1 or R2 resection versus 34 (39 per cent) of 
87 patients who had an R0 resection (P=0.205).
The median length of follow-up was 38 (1–222) months. Forty-six patients (34.8 per cent) 
were followed beyond 5 years. During follow-up, three patients (2.3 per cent) died without 
recurrence from unrelated causes.
Table 1. Characteristics of patients operated on for primary  
extra-abdominal desmoid-type fibromatosis
No. of patients
(n=132)
Median age (years) 36
Age group (years)
1–28
29–35
36–45
46–80
Sex ratio (M : F)
33 (25.0)
32 (24.2 )
35 (26.5)
32 (24.2)
48 : 84
Involved anatomical area
Trunk
Extremity
Head/neck/thoracic aperture
Other
60 (45.5)
32 (24.2)
33 (25.0)
7 (5.3)
Relation to fascia
Superficial
Deep
24 (18.2)
108 (81.8)
Size of lesion (mm)
0–50
51–100
> 100
Data missing
74 (56.1)
43 (32.6)
11 (8.3)
4 (3.0)
Values in parentheses are percentages.
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Table 2. Risk of local recurrence after attempted curative surgery for primary extra-
abdominal desmoid-type fibromatosis
Kaplan-Meier  
analysis
Cox proportional  
hazards analysis
No. of 
subjects
No. of 
events
5-yr local 
recurrence 
risk (%)
P-valuea Hazard ratio P-valueb
Age group (years)
1-28
29-35
36-44
45-80
31
34
30
33
7
3
3
3
34
10
14
15
0.139
1.00 (reference)
0.28 (0.07-1.10)
0.36 (0.09-1.39)
0.35 (0.09-1.36)
0.068
0.139
0.129
Sex ratio 
M
F
46
82
8
8
23
14
0.381
1.00 (reference)
0.65 (0.24-1.73) 0.384
Involved anatomical area
Trunk
Extremity
Head/neck/thoracic aperture
Other
59
32
30
7
2
8
5
1
4
29
25
20
0.024#
1.00 (reference)
6.69 (1.42-31.54)
5.07 (0.98-26.13)
3.50 (0.32-38.56)
0.016
0.052
0.307
Relation to fascia
Superficial 
Deep
24
104
1
15
11
19
0.300
1.00 (reference)
2.79 (0.37-21.12) 0.321
Size of lesion (mm) *
0-50
51-100
>100
72
42
10
9
5
2
19
15
25
0.761
1.00 (reference)
0.84 (0.28-2.52)
1.56 (0.34-7.21)
0.762
0.571
Surgical margin **
R0
R1
87
36
10
4
15
20
0.736
1.00 (reference)
1.22 (0.38-3.90) 0.736
Radiotherapy ***
No
Yes
74
51
10
6
21
13
0.362
1.00 (reference)
0.63 (0.23-1.73) 0.366
Values in parentheses are 95 per cent confidence intervals. Data missing for * 4, ** 5 (with either R0 of R1 
resection) and *** 3 patients. a Log rank test. b Wald test. # Excluding the “other” group; including this group 
of patients, P=0.056.
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Local recurrence following R0/R1 resection
Local recurrence was observed in 18 patients (14.1 per cent) of 128 patients. The 5-year 
cumulative risk of local recurrence was 17.6 (95 per cent c.i. 9.9 to 25.6) per cent. The 
median time to recurrence was 18 months. Sixteen of the 18 diagnosed recurrences 
occurred before 5 years. Two of the 33 reoperated patients developed recurrent disease, 
both after R0 resection. Univariable analysis showed a difference in the risk of recurrence 
depending on tumour localization (P=0.024) (Table 2, Fig. 1), with a higher recurrence risk 
for lesions located on the extremities compared with the trunk (HR 6.69, 1.42 to 31.54); 
the 5-year risk of local recurrence was 29 per cent versus 4 per cent respectively. Of the 
60 patients with desmoid-type fibromatosis on the trunk, 44 (73 per cent) had tumour 
Figure 1. Kaplan–Meier analysis showing the association between the anatomical area and 
local recurrence following surgery for extra-abdominal desmoid-type fibromatosis. 
P=0·024 (log rank test) 
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localized in the abdominal wall. Thirty-nine of these 44 patients were female, compared 
with 84 in the entire cohort (P<0.001). None of these 44 patients developed a local 
recurrence during follow-up.
The youngest age group of patients had the highest risk of local recurrence (34 per cent), 
but this was not significant (Table 2, Fig. 2). Tumour size, sex, relation to the fascia, resection 
margins and adjuvant radiotherapy were not associated with the risk of local recurrence. 
Univariable analysis of the risk of local recurrence after an initial R0 resection with R0 
resection following repeated surgery revealed no statistically significant difference in local 
recurrence (P=0.575, log rank test).
Figure 2. Kaplan–Meier analysis showing the association between age and local 
recurrence following surgery for extra-abdominal desmoid-type fibromatosis. P=0·139 
(log rank test)
Time after surgery (months)
No. at risk
1-28 years 31 19 14 12 10 8
29-35 years 34 29 23 21 18 15
36-44 years 30 22 20 18 14 9
45-80 years 33 23 19 16 14 12
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Disease progression following R2 resection
None of the four patients who had R2 resection developed tumour progression during 
follow-up. The patients initially had desmoid tumours localized on the left hemithorax 
(two patients), at the right scapula (one patient) and in the neck (one). R2 resection was 
accepted to avoid unacceptable morbidity following more extensive surgery with loss of 
arm function. Three of the patients with R2 resection received additional radiotherapy. 
During follow-up of 22, 37, 65 and 68 months respectively, stable disease was confirmed by 
annual computed tomography or MRI.
Discussion
After surgical treatment of aggressive extra-abdominal fibromatosis, the 5-year risk of 
local recurrence was 17.6 per cent. Tumour localization on the trunk was associated with a 
decreased risk, and patients with tumours of the abdominal wall did particularly well.
The present study evaluated the outcome of surgically treated patients without induction 
or neoadjuvant therapy. By excluding patients with intra-abdominal desmoid tumours, 
recurrent disease, and those in whom an initial wait-and-see policy was adhered to, a 
relatively uniform patient cohort has been presented. A strength of the study is also that 
the histopathology of the specimens was reviewed by experts in soft tissue pathology at 
two tertiary referral centres, thus enhancing the consistency of the diagnosis and report.
The study has several limitations inherent to retrospective research, such as the lack of 
information on the precise indications for radiotherapy and data regarding a history of 
pregnancy and caesarean section for the women included. The latter information could 
have contributed to a more thorough analysis of the risk of recurrence of tumours of the 
abdominal wall in women of reproductive age, as these factors appear to be of aetiological 
and prognostic significance1,6,14. A further weakness is the modest duration of follow-up 
(median 38 months), with different types of follow-up at the three participating centres for 
a disorder that may recur after many years.
The observed 5-year risk of local recurrence is modest in comparison with data reported 
by others. A systematic review reported recurrence rates varying between 6 and 59 per 
cent9. Many studies analyse primary and secondary tumours, or evaluate intra- and 
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extra-abdominal tumours together. However, recurrent and intra-abdominal tumours 
are to be considered distinct clinical entities, and are difficult to compare with primary 
musculoskeletal desmoid tumours. These tumours were, therefore, not included in the 
present investigation. In comparison with other reports that focus on primary extra-
abdominal disease, the recurrence rate in the present study was still relatively low5. The 
limited follow-up period in the present study may have contributed to this finding, but only 
18 (14.1 per cent) of the 128 patients with R0 or R1 resection had recurrence. The estimated 
95 per cent c.i. of the 5-year cumulative recurrence rate was 9.9 to 25.6 per cent.
A significant influence of the involved anatomical area on the risk of local recurrence was 
observed. The trunk, and the abdominal wall in particular, were predictive of a low risk 
of recurrence, and have also been associated with a low risk of local recurrence by other 
investigators5,13,14. In the present study, abdominal wall tumours constituted the majority 
of the desmoid lesions on the trunk, and the patients were predominantly women. This 
finding supports an aetiological role for hormonal factors in desmoid tumours arising 
in the abdominal wall1,6,15. There was a trend towards a higher risk of recurrence in the 
youngest age group, confirming a higher risk of recurrence in younger patients, which has 
been found by several investigators11,13,16.
Microscopically involved resection margins and the additional use of adjuvant radiotherapy 
were not identified as factors influencing the local recurrence rate. The number of events 
in the study may have been too low to reach statistical significance. In addition, the 
limited number of events precluded multivariable analysis for proper evaluation of the 
independent effect of these variables on the risk of recurrence.
It is important to emphasize that data regarding the precise indications for radiotherapy 
were lacking in the present study. The value of radiotherapy has been disputed in recent 
literature. Although a systematic review showed a decreased recurrence rate after 
postoperative radiotherapy9, other studies have not demonstrated an effect5,10–12,17. More 
convincing data have been reported regarding the use of radiotherapy without surgery on 
response rates and progression-free survival11,17,18. A multicentre randomized clinical trial is 
currently investigating the effect of radiotherapy as a single treatment modality in patients 
with aggressive fibromatosis; data from this trial have demonstrated a 3-year progression-
free survival of 81.5 per cent19.
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Surgical margin status was not associated with recurrence in the present investigation. 
Although some authors have reported better long-term local control following R0 
resection10,16, others have questioned the importance of microscopic tumour-free resection 
margins5,11,12,17,20. In a recent large cohort study, R2 resection was associated with a higher 
risk of tumour recurrence, but a microscopically tumour-free resection margin (R0 resection) 
was not associated with a better local control than R1 resection5. In agreement, Gronchi and 
colleagues21 observed no additional benefit of microscopic tumour-free resection margins in 
patients treated for primary extra-abdominal desmoid-type fibromatosis.
The study by Salas and co-workers5 has contributed to the current shift of paradigm 
towards less aggressive local surgical treatment in patients with extra-abdominal 
desmoid-type fibromatosis. A considerable proportion of patients who were not operated 
on had tumours that did not progress, whereas the recurrence rate following surgery was 
exceedingly high: half of all patients developed a recurrence within 5 years5. These findings 
are in line with the observation of Bonvalot et al.22, who reported a tumour progression 
rate of 39 per cent in patients in whom a wait-and-see policy was adopted. Medical 
treatment versus a wait-and-see policy was compared in one investigation23. In this study, 
47–53 per cent of the patients developed progressive disease. Again, in approximately half 
of the patients the tumour did not progress.
The effectiveness of medical therapy is beyond the scope of the present study, although 
several agents have been used, including cyclo-oxygenase 2 inhibitors24, hormonal 
therapy7,8, chemotherapy25 and tyrosine kinase inhibitors26. Complete or partial tumour 
response varies in these studies between 6 and 36 per cent. 
The cohort described in the present study was treated during a period when aggressive 
local surgical treatment for desmoid-type fibromatosis was performed routinely. The 
present data demonstrate that microscopically clear resection margins do not necessarily 
decrease the local recurrence rate and that adjuvant radiotherapy may be omitted in 
selected patients.
Disclosure
The authors declare no conflict of interest.
50 Part 2 | Chapter 3
References
1.  Reitamo JJ, Häyry P, Nykyri E, Saxén E. The desmoid tumour. I. Incidence, sex- age- and anatomical 
distribution in the Finnish population. Am J Clin Pathol 1982; 77: 665-673
2.  Nieuwenhuis MH, Lefevre JH, Bülow S, Järvinen H, Bertario L, Kernéis S, et al. Family history, surgery and 
APS mutation are risk factors for desmoid tumours in familial adenomatous polyposis: an international 
cohort study. Dis Colon Rectum 2011; 54: 1229-1234. 
3. Mitchell G, Thomas JM, Harmer CL. Aggressive fibromatosis: evidence for a stable phase. Sarcoma 1998; 
2: 3-4.
4.  Baumert BG, Spahr MO, Von Hochstetter A, Beauvois S, Landmann C, Fridrich K, et al. The impact of 
radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of 
the rare cancer network. Radiat Oncol 2007; 2: 12. 
5. Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, et al. Prognostic factors influencing 
progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy 
according to tumor presentation. J Clin Oncol 2011; 29: 3553-3558. 
6.  De Bree E, Keus R, Melissas J, Tsiftsis D, van Coevorden F. Desmoid tumors: need for an individualized 
approach. Expert Rev Anticancer Ther 2009; 9: 525-535.
7.  Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line 
treatment for desmoids tumors. Cancer 2004; 100: 612-620. 
8.  De Camargo VP, Keohad ML, D’Adamo DR, Antonescu CR, Brennan MF, Singer S, et al. Clinical outcomes  
of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116: 2258-2265
9.  Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients  
with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer 2000;  
88: 1517-1523. 
10. Huang K, Fu H, Shi YQ, Zhou Y, Du CY. Prognostic factors for extra-abdominal and abdominal wall 
desmoids: A 20-year experience at a single institution. J Surg Oncol 2009; 100: 563-569. 
11. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation 
therapy. Int J Radiat Oncol Biol Phys 2008; 71: 441-447. 
12. Stoeckle E, Coindre JM, Longy M, Binh MB, Kantor G, Kind M, et al. A critical analysis of treatment 
strategies in desmoid tumours: A review of a series of 106 cases. Eur J Surg Oncol 2009; 35: 129-134. 
13. Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, et al. Management and recurrence 
patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol 2012;  
19: 4036-4042.
14. Pencavel T, Strauss DC, Thomas JM, Hayes AJ. The surgical management of soft tissue tumours arising  
in the abdominal wall. Eur J Surg Oncol 2010; 36: 489-495. 
15. Bertani E, Chiappa A, Testori A, Mazzarol G, Biffi R, Martella S, et al. Desmoid tumors of the anterior 
abdominal wall: results from a monocentric surgical experience and review of the literature. Ann Surg 
Oncol 2009; 16: 1642-1649.
16. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: Prognostic factors and outcome 
after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17: 158-167. 
17. Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of radiotherapy in the management 
of desmoid tumors. Int J Radiat Oncol Biol Phys 2011; 80: 787-792. 
51Local recurrence following surgical treatment 
Chapter 3
18. Rüdiger HA, Ngan SY, Ng M, Powell GJ, Choong PF. Radiation therapy in the treatment of desmoid tumours 
reduces surgical indications. Eur J Surg Oncol 2010; 36: 84-88. 
19. Keus RB, Nout RA, Blay JY, de Jong JM, Saran F, Sokal M, et al. Results of a phase II pilot study of moderate 
dose radiotherapy for inoperable desmoid-type fibromatosis - EORTC 62991-22998. Paper presented at: 
The Connective Tissue Oncology Society Meeting; 2012 November 14-17; Prague, Czech Republic.
20. Jelinek JA, Stelzer KJ, Conrad E, Bruckner J, Kliot M, Koh W, et al. The efficacy of radiotherapy as 
postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 2001; 50: 121-125. 
21. Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, et al. Quality of surgery and outcome in 
extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution.  
J Clin Oncol 2003; 21: 1390-1397.
22. Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary 
fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 
34: 462-468.
23. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, et al. Desmoid-type fibromatosis: A front-
line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16: 2587-2593. 
24. Nishida Y, Tsukushi S, Shido Y, Wasa J, Ishiguro N, Yamada Y. Successful treatment with meloxicam,  
a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol 
2010; 28: e107-109. 
25. Garbay D, Le CesneA, Penel N, Chevreau C, Marec-Berard P, Blay JY, et al. Chemotherapy in patients  
with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012; 23: 182-186.
26. Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, et al. Efficacy of imatinib in aggressive 
fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration 
(SARC) trial. Clin Cancer Res 2010; 16: 4884-4891.
52 Part 2 | Chapter 3
Chapter 4
Meta-analysis of the influence of surgical margin and adjuvant 
radiotherapy on local control after resection of sporadic 
desmoid-type fibromatosis.
Matthijs L. Janssen
Danique L.M. van Broekhoven
Justin M. M. Cates
Wichor M. Bramer
Joost J.M.E. Nuyttens
Alessandro Gronchi
Brigitta G. Baumert
Sebastien Salas
Sylvie Bonvalot
Hanna R. Ihalainen
Dirk J. Grünhagen
Cornelis Verhoef
  Accepted for publication by British Journal of Surgery, November 2016
Abstract
Background
Extra-abdominal desmoid-type fibromatosis (DF) is a rare, locally aggressive neoplasm 
that is managed primarily in a conservative manner. When treatment is indicated, it usually 
involves surgical resection, possibly with adjuvant radiotherapy. The indications for post-
operative radiotherapy and its effectiveness are unclear. The objectives of this systematic 
review and meta-analysis are to estimate the effect of surgical resection margins and 
adjuvant radiotherapy on recurrence rates in DF.
Methods
Literature published between 1999 and 2015 was extracted from MEDLINE, EMBASE, 
Cochrane, Web of Science and Google Scholar. Recurrence rate was analysed by meta-
analysis and compared between subgroups. 
Results
Sixteen reports were included, consisting of a total of 1295 patients with DF. In patients 
treated by surgical resection only, the risk of local recurrence was almost two-fold 
higher for patients with microscopically positive resection margins (risk ratio (RR)=1.78, 
95%CI 1.40-2.26). Adjuvant radiotherapy after surgery with negative margins showed no 
detectable benefit on recurrence. In contrast, after incomplete surgical resection with 
positive margins, adjuvant radiotherapy improved recurrence rates in both primary 
(RR=1.54, 95%CI 1.05-2.27) and recurrent patients (RR=1.60, 95%CI 1.12-2.28).
Conclusion
DF resected with microscopically positive margins has a higher risk of recurrence 
compared to negative resection margins. According to this analysis, adjuvant radiotherapy 
does not alter recurrence rates after complete surgical resection. Radiotherapy appears to 
reduce the recurrence rate for DF after incomplete surgical resection, mainly in recurrent 
tumours. Due to the benign nature of the disease, any invasive or harmful therapy should 
be carefully weighed in multidisciplinary teams in specialised centres.
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Introduction
Desmoid-type fibromatosis (DF) is a locally aggressive tumour of fibroblastic origin that 
most commonly arises in young adults. With an incidence rate of approximately 5 cases per 
million people annually, it is uncommon (representing approximately 0.3% of all soft tissue 
neoplasms)1,2. The majority (approximately 85%) of sporadic tumours are characterized 
by mutations in the CTNNB1 gene, whereas hereditary tumours often harbor mutations in 
the APC gene3,4. Syndromic cases are usually associated with intra-abdominal disease and 
familial adenomatous polyposis (FAP), and thus require a different therapeutic approach5,6. 
Distinction between intra-abdominal and extra-abdominal tumours (including abdominal 
wall tumours) is clinically important because of differences in etiology, biological behavior, 
and the morbidity associated with surgical resection7-9.
Even though DF does not metastasize and is rarely lethal, patients suffer substantial 
morbidity due to the invasive growth and recurrence of the tumour10. A subset of DF 
patients have indolent disease, with spontaneous growth arrest or tumour regression11-13. 
Historically, complete surgical resection with negative resection margins was the standard 
of care, with or without adjuvant radiotherapy. Convincing evidence for this management 
protocol is lacking, as the results in the literature are conflicting. Since complete surgical 
resection may result in substantial morbidity due to sacrifice of critical musculoskeletal 
structures or peripheral nerves and retrospective analyses of patients managed expectantly 
show optimistic results, a conservative front-line approach has been advocated11,12,14-18.
A recent consensus paper from Europe supported this strategy of expectant management 
with close observation for all patients with primary DF18. Prospective studies investigating 
this strategy are currently being conducted in France (ClinicalTrials.gov identifier: 
NCT01801176), Italy (ClinicalTrials.gov identifier: NCT02547831), and the Netherlands 
(Dutch Trial Registry identifier NTR4714)19-21.
While there is an ongoing trend towards non-surgical management, especially in centres 
of expertise, surgery remains a therapeutic modality for symptomatic patients. The 
association between status of surgical resection margins and risk of local recurrence 
remains subject to discussion, as many studies have reported conflicting conclusions. 
Microscopic resection margin seems to influence recurrence rates in some series, but this 
association is disputed in others22-27. Similarly, supporting evidence for the effectiveness of 
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adjuvant radiotherapy after surgery is limited to several small studies with contradictory 
results27-30. Since DF lacks the capability to metastasize and most patients have a normal 
life expectancy, any possible therapeutic benefits should be weighed against the long term 
side effects associated with this treatment. 
In order to critically reassess the therapeutic benefits of aggressive surgical resection 
with negative resection margins and adjuvant radiotherapy for extra-abdominal DF, this 
systematic review and meta-analysis was carried out. Specifically, local recurrence rates 
are compared between patients with surgery with (in)complete resection margins and 
adjuvant radiotherapy.
Methods
This study was reported according to the PRISMA guidelines for reporting systematic 
reviews and meta-analyses31.
Literature search
A comprehensive literature search was last performed on September 3, 2015. The 
databases from MEDLINE via Ovid, EMBASE.com, Cochrane Central Registry of Trials, Web 
of Science, and Google Scholar were searched from inception. The following search terms, 
including synonyms and truncations, were applied: “extra-abdominal”, “desmoid tumour” 
or “aggressive fibromatosis”, and “radiotherapy” or “surgery”. The complete search is 
shown in the appendix. 
According to protocol, inclusion criteria were papers written in English, reporting on 
extra-abdominal DF treated by surgical resection, with or without adjuvant radiotherapy, 
published from 1999 onwards. Data on referral status, use of adjuvant radiotherapy or not, 
and disease recurrence was also required for papers to be included. Articles specifically 
reporting on pediatric or syndromic patients, intra-abdominal or mesenteric tumours, or 
interventions other than surgery and external beam radiotherapy were excluded. 
Assessment of study quality and bias
The level of evidence of each article was determined using the Oxford Centre for Evidence-
Based Medicine level of evidence32. Quality assessment of included non-randomised 
studies was established according to the Newcastle-Ottawa Scale (NOS) criteria33. Funnel 
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plots were constructed in order to assess risk of several types of reporting bias, among 
which publication bias34.
Data collection
Data was collected in standard forms by one researcher. In case of any doubts, a second 
researcher was consulted. Unpublished, but required data was requested from authors of 
eligible articles to assemble a complete and homogeneous cohort with minimal selection 
bias. This was done by sending a standard form which could be completed by the author. 
Patients were categorized based on referral status, treatment regimen, and surgical 
resection margin status. Referral status was considered primary when patients presented 
without history of prior therapeutic interventions. Patients were considered as having 
recurrent DF when presenting with regrowth of DF after at least one therapeutic intervention 
after which the tumour was removed. Prior treatment was unknown for most of cases of 
recurrent disease. Treatment was categorized as surgery alone (S) or surgery with adjuvant 
radiotherapy (S+R). Surgical resection margins were scored using AJCC guidelines as R0, R1, 
R2 or RX35. Patients were divided in subgroups according to the aforementioned treatment 
group (S or S+R), surgical resection margin and referral status (primary or recurrent DF at 
presentation), see also Table 3 for further clarification of the subgroups.
Outcome
The outcome of interest was recurrence rate. Recurrence was defined as local tumour 
regrowth after macroscopic complete surgical resection or tumour progression after 
macroscopic incomplete surgical resection. Recurrence rates were compared between 
subgroups by means of the risk ratio (RR) for recurrence. The RR for recurrence was 
calculated in meta-analysis. Event-free survival (EFS) was defined as period that patients 
were free of recurrence after surgical resection. Forest plots were constructed using 
Cochrane RevMan version 5.3 software36. 
Statistical Analysis
RR estimates were considered statistically significant when their 95% confidence interval 
(CI) excluded 1.0. Meta-analysis of RR of recurrence was calculated by pooled point 
estimates of Mantel-Haenszel weighted RR’s. Both fixed effect (FE) and random effect (RE) 
models were used to account for inter-study heterogeneity34. Statistical analyses were 
conducted using IBM SPSS Statistics v20 and Cochrane RevMan v5.336,37.
57Meta-analysis of surgical margin and adjuvant radiotherapy
Chapter 4
Results
Literature search results and study characteristics
The database search yielded 2875 articles, of which 52 were eligible for inclusion. Those 
52 studies described approximately 3500 potentially eligible patients in total. This number 
of 3500 patients included a significant amount of patients who violated at least one of the 
exclusion criteria. Sufficient data for analysis were published in 2 articles; authors from the 
other 50 articles were contacted and requested to provide the additional data needed for 
analysis. Of these 50 authors, 14 responded, bringing the total number of included studies 
to 1611,22-25,38-48. A flowchart which shows detailed description of the selection process is 
provided in Figure 1. 
Figure 1: Flowchart of the selection process for inclusion
All included studies were retrospective cohort studies. According to the Oxford 2011 Levels 
of Evidence these references are assigned Level 2b evidence. All included studies scored 
between 5 and 7 on the NOS criteria and were included in the meta-analysis. Results from 
the quality NOS quality assessment are displayed in Table 1.
Assessment of publication bias across studies was done using funnel plots. Visual analysis 
of these funnel plots showed no big asymmetries, reflecting absence of any significant 
publication bias.
n=2994 references in 
literature search
n=79 full text screened
n=52 data requested  
by authors
N=16 final inclusion
Exclusion (n=27):
- Previous publication of same cohort: 7
- Familial Adenomatous Polyposis related: 4
- <10 cases: 6
- meeting abstract: 7
- not about treatment: 3
No response / data lost / not willing to participate: n=36
Exclusion based on publishing date <1999: n=899 
Exclusion based on title & abstract: n=2016
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Table 1: Patient characteristics per inclusion
Publication
Primary 
patients
Recurrent 
patients
Surgery Surgery & 
radio- 
therapy
Median dose 
(range), 
in Gy
Median 
follow-up, 
in months
Overall local 
control rate 
(%)
Baumert, 
200735
42 22 31 33 59.4 
(3.4 - 72)
72.0 76.6
Bertani, 
201236
50 8 51 7 Unknown 66.0 89.7
Bonvalot 
200811
80 0 67 13 50.0 
(45 - 60)
76.0 62.5
Cates,
201424
98 0 83 15 Unknown 
(50 - 60)
38.4 70.4
Eastley,
201437
38 0 36 2 60.0 
(60.0)
58.8 78.9
Gronchi,
200322
128 75 163 40 57.0 
(45 - 65)
135.0 72.9
Huang,
200938
97 29 106 20 Unknown 
(45 - 55)
102.0 81.7
Ihalainen,
201539
76 28 82 22 Unknown 25.0 77.9
Kriz,
201440
29 8 0 37 50.0 
(50 - 65)
44.0 86.5
Pignatti,
200041
35 46 64 17 Unknown 
(35 - 66)
134.4 55.6
Prodinger,
201342
17 4 8 13 54.0
(50 -60) 
39.0 57.1
Salas,
201125
127 0 113 14 50.0 
(Unknown)
52.0 33.9
Stoeckle, 
200943
42 21 61 2 Unknown 123.0 55.6
V.Broekhoven 
201323
129 0 75 54 Unknown 38.0 85.3
Wang 
200644
16 0 15 1 Unknown 38.0 87.5
Wilkinson
201445
49 1 50 0 NA 72.0 92.0
Total 1053 242 1005 290 NA NA Median: 77.3
Description of patient characteristics of all included articles. Abbreviations: Gy: Gray, NA: Not applicable
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Table 2: 5-year Event-free survival (in %) for different subgroups
Publication Overall Primary* Surgery Surgery 
Primary
Surgery 
Recurrent 
S+R
Baumert, 200735 63.5
Bertani, 201236 94.2 83.3
Bonvalot, 200811 47.0 47.0 50.0 60.0
Cates, 201424
Eastley, 201437 81.0 81.0
Gronchi, 200322 73.0 81.0 71.7 78.3
Huang, 200938 80.7 85.4 
(rec. 63.7%)*
82.3 86.5 59.5 63.0
Ihalainen, 201539 77.0 100.0 91.0 100.0 22.0 23.0
Kriz, 201440 81.0 84.0
Pignatti, 200041
Prodinger, 201342 70.7 64.2 
(rec. 50.0%)*
64.5
Salas, 201125 42.9
Stoeckle, 200943 57.1 84.5
(rec. 10.5%)*
57.1 84.5 10.5
V.Broekhoven, 201323 87.5 87.5 86.7 88.9
Wang, 200644 100.0 100.0 100.0
Wilkinson, 201345 94.0
Median 77.0 85.0 77.0 86.5 40.8 64.5
Description of follow-up data of all included articles. 
Abbreviations: S+R=surgery with adjuvant radiotherapy.
*5-year event-free survival for recurrent tumors is also presented in 3 articles, in parentheses.
Overall study cohort
The 16 included studies constituted a total cohort of 1295 DF patients. Table 1 shows the 
total number of patients included per article. The majority of patients had primary disease 
(n=1053, 81%). Treatment consisted of surgery alone in 1005 patients (S group, 78%) and 
surgery with adjuvant radiotherapy in 290 patients (S+R group, 22%). Tumour recurrence 
developed in 376 patients (29%), of which 297 occurred in the S group and 79 in the S+R 
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group. The overall recurrence rate was 25% in patients with primary disease and 46%  
in patients with recurrent disease. Median follow-up time ranged between 25 and 
135 months (Table 2).
Influence of surgical margin on recurrence
Risk ratio for recurrence
Forest plots showing the association between microscopic resection margin and 
recurrence risk from each individual study were constructed. Only patients treated with 
surgery alone (S) were included and patients with primary (n=761) or recurrent tumours 
(n = 133) were analysed separately (Figure 2a and Figure 2b). The point estimate of the 
pooled and weighted RR among all studies showed a significant relationship between 
microscopic surgical margin and the risk for recurrence of primary tumours (RR=1.51, 
95% CI 1.13-2.01; Figure 2a). A similar analysis was performed for patients with recurrent 
DF (Figure 2b), although only 4 articles reporting on 133 patients were eligible for inclusion. 
Similar to primary tumours, the pooled and weighted RR showed a significant relation 
between microscopic surgical margin and the risk for recurrence in recurrent tumours 
(RR = 1.57, 95% CI 1.10-2.24). Comparison of results from random effects (RE) model is 
shown in the appendix. Pooled analysis with primary and recurrent tumours together 
showed an even stronger relationship between margin and recurrence risk (RR=1.78, 
95% CI 1.40-2.26, plot not shown).
The role of adjuvant radiotherapy
Risk ratio for recurrence
The RRs for S and S+R groups for 481 primary DF patients with positive or indeterminate 
resection margins are presented in Figure 3a, where Figure 3b shows the same analysis 
for 119 patients with recurrent DF. The pooled and weighted RRs showed a significant 
relationship between treatment regimen and recurrence rate, with a higher risk for 
recurrence in the S group in both primary (RR=1.54, 95% CI 1.05-2.27) and recurrent 
patients (RR=1.60, 95% CI 1.12-2.28). Comparisons between the FE and RE models are 
described in the appendix. The pooled and weighted RR for recurrence in 695 primary 
and recurrent patients with R0 resections are displayed in Figure 4, which showed a 
significantly lower risk for recurrence in the S group: RR=0.67, 95% CI 0.46-0.97. Because of 
considerable heterogeneity (I2=62%), results were compared with those from a RE model, 
which did not alter any conclusions: RR=0.50, 95% CI 0.26-0.94. 
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Figure 2a. Forest Plot comparing RR for recurrence between R0 and R1 margins in primary 
tumors treated with surgery alone
R1 R0 Risk Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
Baumert et al. 2 5 5 17 4.4% 1.36 (0.37-5.00)
Bertani et al. 1 9 1 36 0.8% 4.00 (0.28-57.98)
Bonvalot et al. 22 50 4 17 11.4% 1.87 (0.75-4.66)
Cates et al. 9 36 10 34 19.7% 0.85 (0.39-1.83)
Eastley et al. 2 15 4 20 6.6% 0.67 (0.14-3.17)
Gronchi et al. 5 21 18 87 13.4% 1.15 (0.48-2.74)
Huang K et al. 8 17 4 71 3.0% 8.35 (2.84-24.53)
Ihalainen et al. 0 8 0 64 Not estimated
Kirz et al. 0 0 0 0 Not estimated
Pignatti et al. 2 7 5 18 5.4% 1.03 (0.26-4.12)
Prodinger et al. 0 1 1 6 1.3% 1.17 (0.07-18.96)
Salas et al. 14 22 14 31 22.3% 1.41 (0.85-2.32)
Stoeckle et al. 5 23 1 15 2.3% 3.26 (0.42-25.23)
Van Broekhoven et al. 2 16 7 53 6.2% 0.95 (0.22-4.11)
Wang CP et al. 1 4 1 9 1.2% 2.25 (0.18-27.66)
Wilkinson et al. 3 28 1 21 2.2% 2.25 (0.25-20.13)
Total (95% CI) 262 499 100.0% 1.51 (1.13-2.01)
Total events 76 76
Heterogeneity: Chi2=15.57, df=13 (P=0.27); I2=16%
Test for overall effect: Z=2.82 (P=0.005)
Abbreviations: RR: Relative Risk
Figure 2b. Forest Plot comparing RR for recurrence between R0 and R1 margins in 
recurrent tumors treated with surgery alone
R1 R0 Risk Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
Baumert et al. 0 1 0 1 Not estimated
Bertani et al. 0 0 1 6 Not estimated
Bonvalot et al. 0 0 0 0 Not estimated
Cates et al. 0 0 0 0 Not estimated
Eastley et al. 0 0 0 0 Not estimated
Gronchi et al. 8 16 15 39 48.6% 1.30 (0.69-2.44)
Huang K et al. 4 5 2 13 6.2% 5.20 (1.35-20.02)
Ihalainen et al. 6 6 3 3 24.8% 1.00 (0.98-1.53)
Kirz et al. 0 0 0 0 Not estimated
Pignatti et al. 4 5 11 25 20.4% 1.82 (0.98-3.39)
Prodinger et al. 0 0 0 1 Not estimated
Salas et al. 0 0 0 0 Not estimated
Stoeckle et al. 11 11 0 0 Not estimated
Van Broekhoven et al. 0 0 0 0 Not estimated
Wang CP et al. 0 0 0 0 Not estimated
Wilkinson et al. 0 1 0 0 Not estimated
Total (95% CI) 45 88 100.0% 1.57 (1.10-2.24)
Total events 33 32
Heterogeneity: Tau2=7.97; Chi2=7.97, df=3 (P=0.05); I2=62%
Test for overall effect: Z=2.50 (P=0.01)
Abbreviations: RR: Relative Risk
Risk Ratio
M-H, Fixed, 95% CI
1
Favours R1   Favours R0
0.10.02 10 50
Risk Ratio
M-H, Fixed, 95% CI
1
Favours R1   Favours R0
0.10.02 10 50
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Figure 3a. Forest Plot comparing RR for recurrence between S and S+R groups for primary 
patients with R1, R2 or RX margins
S S+R Risk Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
Baumert et al. 5 12 1 5 4.2% 2.08 (0.32-13.61)
Bertani et al. 1 9 1 2 4.9% 0.22 (0.02-2.24)
Bonvalot et al. 22 50 4 13 19.0% 1.43 (0.60-3.42)
Cates et al. 15 49 2 9 10.1% 1.38 (0.38-5.02)
Eastley et al. 3 16 0 0 Not estimated
Gronchi et al. 5 21 2 10 8.1% 1.19 (0.28-5.11)
Huang K et al. 8 17 1 5 4.6% 2.35 (0.38-14.58)
Ihalainen et al. 0 9 0 1 Not estimated
Kirz et al. 0 0 3 29 Not estimated
Pignatti et al. 5 12 2 4 9.0% 0.83 (0.25-2.73)
Prodinger et al. 0 1 5 8 6.0% 0.41 (0.04-4.77)
Salas et al. 65 82 14 14 25.5% 2.22 (1.09-4.52)
Stoeckle et al. 6 26 0 0 Not estimated
Van Broekhoven et al. 5 22 2 20 6.3% 2.27 (0.50-10.43)
Wang CP et al. 1 6 0 1 2.3% 0.86 (0.05-13.93)
Wilkinson et al. 3 28 0 0 Not estimated
Total (95% CI) 360 121 100% 1.54 (1.05-2.27)
Total events 144 28
Heterogeneity: Chi2=6.77, df=10 (P=0.75); I2=0%
Test for overall effect: Z=2.21 (P=0.03)
Abbreviations: RR: Relative Risk, S: Surgery, S+R: Surgery with adjuvant radiotherapy.
Figure 3b. Forest Plot comparing RR for recurrence between S and S+R groups for 
recurrent patients with R1, R2 or RX margins 
S S+R Risk Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
Baumert et al. 0 1 1 7 3.1% 1.33 (0.08-21.94)
Bertani et al. 0 0 2 2 Not estimated
Bonvalot et al. 0 0 0 0 Not estimated
Cates et al. 0 0 0 0 Not estimated
Eastley et al. 0 0 0 0 Not estimated
Gronchi et al. 8 16 4 10 25.5% 1.25 (0.51-3.09)
Huang K et al. 4 5 1 8 4.0% 6.40 (0.97-42.15)
Ihalainen et al. 6 6 9 12 34.5% 1.27 (0.86-1.87)
Kirz et al. 0 0 2 8 Not estimated
Pignatti et al. 7 9 4 11 18.7% 2.14 (0.91-5.04)
Prodinger et al. 0 0 1 2 Not estimated
Salas et al. 0 0 0 0 Not estimated
Stoeckle et al. 20 20 1 1 14.2% 1.00 (0.45-2.23)
Van Broekhoven et al. 0 0 0 0 Not estimated
Wang CP et al. 0 0 0 0 Not estimated
Wilkinson et al. 0 1 0 0 Not estimated
Total (95% CI) 58 61 100.0% 1.60 (1.12-2.28)
Total events 45 25
Heterogeneity: Chi2=5.45, df=5 (P=0.36); I2=8%
Test for overall effect: Z=2.57 (P=0.01)
Abbreviations: RR: Relative Risk, S: Surgery, S+R: Surgery with adjuvant radiotherapy. 
Risk Ratio
M-H, Fixed, 95% CI
1
Favours S   Favours S+R
0.10.02 10 50
Risk Ratio
M-H, Fixed, 95% CI
1
Favours S   Favours S+R
0.10.02 10 50
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Discussion 
In this systematic review and meta-analysis, the published outcomes of 1295 patients with 
extra-abdominal DF from 16 studies were combined to determine the effect of surgical 
resection margin and adjuvant radiotherapy on recurrence. 
 
The current study suggests that the microscopic margin status does indeed influence 
the recurrence rate. Pooled results of patients treated with surgery alone demonstrate 
that recurrence rates were significantly lower after negative surgical resection margins 
(R0) for both primary and recurrent tumours. These results imply that a R0 resection is 
the desired situation, but when a R1 resection has been carried out, recurrence rates 
are still very acceptable in primary tumours. A conservative approach in such a situation 
seems preferable, given the benign nature of this disease. Especially in recurrent tumours, 
re-resection can be considered in cases where morbidity is expected to be little, given the 
significant difference in recurrence rate.
 
Figure 4. Forest Plot comparing RR for recurrence between S and S+R groups in primary 
and recurrent tumours
S S+R Risk Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
Baumert et al. 5 18 3 21 6.5% 1.94 (0.54-7.03)
Bertani et al. 2 42 0 3 2.1% 0.47 (0.03-8.11)
Bonvalot et al. 4 17 0 0 Not estimated
Cates et al. 10 34 2 6 7.9% 0.88 (0.25-3.07)
Eastley et al. 4 20 1 2 4.2% 0.40 (0.08-2.06)
Gronchi et al. 33 126 3 20 12.1% 1.75 (0.59-5.16)
Huang K et al. 6 84 3 7 12.9% 0.17 (0.05-0.53)
Ihalainen et al. 3 67 5 9 20.6% 0.08 (0.02-0.28)
Kirz et al. 0 0 0 0 Not estimated
Pignatti et al. 16 43 2 2 10.9% 0.45 (0.24-0.85)
Prodinger et al. 1 7 2 3 6.5% 0.21 (0.03-1.56)
Salas et al. 14 31 0 0 Not estimated
Stoeckle et al. 1 15 0 1 2.1% 0.38 (0.02-6.44)
Van Broekhoven et al. 7 53 5 34 14.2% 0.90 (0.31-2.60)
Wang CP et al. 1 9 0 0 Not estimated
Wilkinson et al. 1 21 0 0 Not estimated
Total (95% CI) 587 108 100.0% 0.67 (0.46-0.97)
Total events 108 26
Heterogeneity: Chi2=26.12, df=10 (P=0.004); I2=62%
Test for overall effect: Z=2.12 (P=0.03)
Abbreviations: RR: Relative Risk, S: Surgery, S+R: Surgery with adjuvant radiotherapy. 
Risk Ratio
M-H, Fixed, 95% CI
10.10.02 10 50
Favours S   Favours S+R
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Several previous studies have addressed the issue of surgical resection margins for DF, 
with conflicting results. In some retrospective studies, microscopically negative margins 
were significantly associated with a better surgical outcomes29-31. On the contrary, other 
large retrospective studies show no overall positive effect of microscopically negative 
margins on recurrence rates22,25,49,50. Some of these reports did not separate intra-
abdominal and extra-abdominal DF or account for different treatment regimens among 
study cases. Unfortunately, these studies could not be included in the present analysis, as 
additional data were not available. These studies might have had influence on the results 
of this analysis. Crago et al.49 studied a single-centre cohort of almost 400 patients with 
extra-abdominal DF and showed that microscopic negative margins have a favourable 
recurrence rate in subgroups with small tumours. Ballo et al.30 retrospectively reviewed 
189 patients from the MD Anderson Cancer Centre, this report was updated by Lev et 
al.50. In the former study, negative microscopic resection margins were associated with 
lower recurrence rates, but this result was not repeated in the latter. In both reports, 
intra-abdominal tumours and FAP-related tumours were analysed together with extra-
abdominal tumours.
Adjuvant radiotherapy appears to reduce the risk of local recurrence of DF after surgical 
resection with positive resection margins. Its effect in reducing the risk of local recurrence 
was particularly strong after R1/R2 resection of recurrent DF. Adjuvant radiation therapy is 
expected to be indicated in patients at risk for a poor outcome, thereby potentially causing 
indication bias. There appears to be no additional value of adjuvant radiotherapy in case of 
complete surgical resection.
 
Guadagnolo et al.51 described 74 primary and recurrent cases of DF in which a 10-year 
local control rate of 78% was achieved with addition of adjuvant radiotherapy. Keus et 
al.52 studied the effect of moderate dose radiotherapy for inoperable DF in a prospective 
cohort study. This pilot study showed a 81.5% 3-year local control rate and mild side 
effects after a median follow-up of 4.8 years. Nuyttens et al.53 also reviewed this question 
among 381 patients treated with surgery alone and 297 with surgery and radiotherapy 
and concluded that adjuvant radiotherapy improved recurrence rates significantly. In the 
present study, the most pronounced benefit was observed among patients with positive 
surgical resection margins; similar findings were reported by Nuyttens. A systematic 
review conducted by Yao et al.54 also concluded that surgery with adjuvant radiotherapy, 
compared to surgery alone, resulted in favourable recurrence rates. Therefore adjuvant 
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radiotherapy was recommended for all patients, even those with negative resection 
margins. In contrast to studies reviewed by Yao et al., the current review does not include 
any DF patients treated with systemic therapy, patients with intra-abdominal disease, or 
patients with FAP or Gardners syndrome. In this meta-analysis, stronger evidence was 
given for the absence of benefit of adjuvant radiotherapy for patients after R0 resection. 
 
DF is a benign disease and resection does not alter survival in the majority of cases. 
The main reason for treatment is pain, discomfort and impairment of quality of life. 
Therefore, avoidance of morbidity of treatment is of utmost importance. In patients with 
symptomatic, disabling disease or progressive disease under non-surgical treatment, 
resection is still a valuable option, given that expected morbidity is little and patients 
are carefully counseled. Therefore, this systematic review and meta-analysis offers 
information for physicians and patients about the importance of surgical resection 
margins in their shared decision model in clinical practice, once surgery has been chosen 
as the primary treatment option.
Resection with the least morbidity should be the goal of surgical resection. Microscopic 
complete resection margins are associated with lower recurrence rates compared to 
microscopic residual disease, but may result in substantial morbidity due to sacrifice 
of critical musculoskeletal structures or peripheral nerves. R1 resection is preferable 
in such a case because a substantial proportion of these patients will not develop a 
significant recurrence according the current data. In case of an unexpected R1 resection, 
an expectant management, re-resection or adjuvant radiotherapy are optional. Given 
the current guidelines and acceptable recurrence rate, expectant management might 
be the most appropriate strategy. Nonetheless, patients should be discussed in a 
multidisciplinary team of specialised centres to carefully make these treatment decisions. 
In agreement with current management guidelines for patients with DF18, it is 
acknowledged that aggressive treatment can result in poor functional outcomes that may 
harm patients more than the disease itself. Re-operation and adjuvant radiotherapy is 
therefore not advised in patients in which this could result in mutilation, functional loss 
or cosmetic disfigurement. As DF usually has an indolent clinical behavior and is not a life-
threatening disease complete eradication of disease should not be dogmatically pursued 
without regard for preservation of quality of life. Therefore, it may often be preferable 
to simply monitor patients with a primary close clinical observation, according to the 
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consensus18. Multiple retrospective studies have shown that an expectant management 
is suitable for many patients11,12,14,15,17. In case of symptomatic disease requiring treatment, 
recurrence, or progression of disease, local treatment can be applied as needed, including 
radiotherapy as single treatment. As earlier mentioned, Keus et al.52 and Nuyttens et al.53 
conclude that radiotherapy can be applied as single treatment with acceptable morbidity 
and recurrence rates.
This systematic review and meta-analysis describes a large cohort of surgically treated DF 
patients from the literature. Many studies that were otherwise ineligible for inclusion were 
able to be incorporated after directly requesting additional data from the original authors, 
thereby minimizing selection bias. The status of surgical resection margins, referral status, 
and outcome data were available for all patients in both treatment groups. None of the 
prior studies, including a comprehensive comparative analysis performed by Leithner et 
al.55 investigated the impact of surgical resection margins in a cohort of extra-abdominal 
DF as large as presented here. 
It should be considered that most patients in this cohort received treatment before the 
general consensus of expectant management had become standardized. This has to be 
taken into account very carefully, as today’s practice is to avoid any unnecessary invasive 
treatment in DF patients. As a corollary, patients presently undergoing surgical resection 
compose a selected population of progressive patients and thus are not completely 
equivalent to the cohort described in this paper. 
 
The current study has other limitations. For instance, the magnitude of tumour clearance, 
or the distance from tumour to the resection margin was not accounted for in most 
studies. Thus, the group with negative resection margins surely encompass negative 
margins of variable extent (i.e., narrow margins <1 mm vs. wider margins of >1 mm). This 
factor could be related to recurrence rates18,24. Moreover, the group with negative resection 
margins might represent a selection of patients in which resection was less difficult than 
the groups with positive margins. This possibly explains the beneficial recurrence rate 
for negative compared to microscopically positive resection margins. The authors admit 
that carefully selected, more comparable patient groups would be favourable to answer 
this question, but such cohort is not available. Second, although all patients in the cohort 
have extra-abdominal or abdominal wall tumours, this paper does not include data on 
other important parameters who have showed to be of influence on recurrence rate, 
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such as age, tumour size and precise anatomic location25,49. These data were lacking in 
the vast majority of the described cohort and therefore this is considered as a significant 
limitation of the study. Thus, the inferences made here may not necessarily be applicable 
to other patient cohorts. On the other hand, the present cohort is large enough such that 
patient age and tumour size and localization may be assumed to be distributed normally. 
Furthermore, the length of follow-up intervals varied among different investigations, which 
perhaps influenced reported recurrence rates. However, most relapses of DF occur within 
2 years of surgical resection12,25. Since only one paper included in this analysis reported 
a median follow-up interval less than 3 years, the follow-up is considered sufficient to 
observe recurrences42. Another point of consideration is the wide variation in the origin 
of study cases. This cohort consists of patients treated in a variety of countries and 
hospitals. Different management protocols in these various treatment centres may have 
resulted in treatment heterogeneity. For recurrent patients in particular, information 
regarding the initial treatment modality was unavailable. Treatment heterogeneity is 
almost inherent to literature studies describing patients from many different centres. 
Another weakness of the study is that the radiation dose is not reported for 121 of the 290 
patients (42%) who received postoperative radiotherapy. A radiation dose below 50 Gy is 
considered ineffective and current recommendations advise a dose of 56 Gy in 2 Gy per 
fraction. Finally, only retrospective observational studies were included, as there are few 
if any prospective, experimental studies on surgery and radiotherapy for DF patients. It 
is recognised that meta-analysis in itself has limited power to answer clinical issues as in 
the present study. A meta-analysis of retrospective studies with all their inherent biases 
it subject to bias itself. The lack of prospective series makes that a careful analysis of all 
known data may give the best available guidance for clinical management.
In conclusion, microscopic residual disease after surgical resection of primary or recurrent 
DF is associated with higher recurrence rates than complete surgical resection. Adjuvant 
radiotherapy improves recurrence rates after incomplete surgical resection of DF, but does 
not appear to be of additional value after surgical resections of primary or recurrent DF 
with negative resection margins. Due to the benign nature of the disease, any invasive or 
potentially harmful therapy should be carefully weighed in a multidisciplinary team and 
only be offered in specialised centres. 
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Appendix
Complete Search
Embase.com
(‘desmoid tumor’/exp OR (((aggressive* OR extra-abdominal OR extraabdominal ) NEAR/3 
(fibromatos*)) OR desmoid*)) AND (‘radiotherapy’/exp OR radiotherapy:lnk OR ‘surgery’/
exp OR surgery:lnk OR (radiotreat* OR radiotherap* OR operati* OR resect* OR surg* OR 
((irradiation OR radiation OR fractionated OR radio ) NEAR/3 (therap* OR treat*))):ab,ti)
Medline (OvidSP)
(Fibromatosis, Aggressive/ OR (((aggressive* OR extra-abdominal OR extraabdominal ) 
ADJ3 (fibromatos*)) OR desmoid*)) AND (exp radiotherapy/ OR radiotherapy.xs. OR Surgical 
Procedures, Operative/ OR surgery.xs. OR (radiotreat* OR radiotherap* OR operati* OR 
resect* OR surg* OR ((irradiation OR radiation OR fractionated OR radio ) ADJ3 (therap* OR 
treat*))).ab,ti.)
Cochrane
((((aggressive* OR extra-abdominal OR extraabdominal ) NEAR/3 (fibromatos*)) OR 
desmoid*)) AND ((radiotreat* OR radiotherap* OR operati* OR resect* OR surg* OR 
((irradiation OR radiation OR fractionated OR radio ) NEAR/3 (therap* OR treat*))):ab,ti)
Web-of-science 
TS=(((((aggressive* OR extra-abdominal OR extraabdominal ) NEAR/3 (fibromatos*)) OR 
desmoid*)) AND ((radiotreat* OR radiotherap* OR operati* OR resect* OR surg* OR 
((irradiation OR radiation OR fractionated OR radio ) NEAR/3 (therap* OR treat*)))))
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PubMed publisher 
(Fibromatosis, Aggressive[mh] OR (((aggressive*[tiab] OR extra-abdominal OR 
extraabdominal ) AND (fibromatos*[tiab])) OR desmoid*[tiab])) AND (radiotherapy[mh] 
OR radiotherapy[sh] OR Surgical Procedures, Operative[mh] OR surgery[sh] OR 
(radiotreat*[tiab] OR radiotherap*[tiab] OR operati*[tiab] OR resect*[tiab] OR surg*[tiab] 
OR ((irradiation OR radiation OR fractionated OR radio ) AND (therap*[tiab] OR 
treat*[tiab])))) AND publisher[sb]
Google scholar
“aggressive|extraabdominal fibromatosis|fibromatoses” | ”extra abdominal fibromatosis 
| fibromatoses” | desmoid radiotreatment | radiotherapy | operation | operative | 
resection | surgery | surgical | ”irradiation | radiation | fractionated | radio therapy | 
treatment”
Influence of surgical margin: Meta-analysis with random effects model
Here we compare results from the fixed effects (FE) model from Figure 2a and Figure 2b to 
the random effects (RE) models (Figures not shown). The results were not different from 
the analysis in the FE model in case of primary tumors with R0 and R1 resection margins 
(risk ratio (RR) =1.51, 95% CI 1.07-2.14). In recurrent tumors, using the RE model did show a 
similar effect estimate but had lower confidence (RR=1.53, 95% CI 0.89-2.63). The RE model 
gives in this case higher weight to studies with smaller sample size and shorter follow 
up period. This explains the difference in results between the RE and FE analyses. Since 
the study from Ihalainen et al.(42) has the shortest follow-up period, but is assigned the 
highest weight factor in the RE model, the FE model is preferable in this case.
Role of adjuvant radiotherapy: Meta-analysis with random effects model
Here we compare results from the FE model from Figure 3a and Figure 3b to the random 
effects RE model (Figures not shown). The results were not different from the analysis in 
the FE model in case of primary tumors with positive or indeterminate resection margins 
(RR=1.48, 95% CI 1.00-2.18). In recurrent tumors, using the RE model did show a similar 
effect estimate but had lower confidence (RR=1.38, 95% CI 0.99-1.94). The results from the 
meta-analysis with a RE model did not alter any conclusion in case of primary tumors. In 
recurrent tumors, a different result was obtained with the RE model. But, in this case a FE 
model is preferable because of the very low heterogeneity between studies (I2=8%).
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Abstract
Background
Aggressive fibromatoses (desmoid tumours) may be locally aggressive, but do not 
metastasize. Although a conservative approach is advocated for most patients, pain and 
functional impairment are indications for active treatment. Tumour necrosis factor (TNF) α 
and melphalan-based isolated limb perfusion (TM-ILP) is a limb-saving treatment modality 
for soft tissue tumours. This study reports the results of TM-ILP treatment in patients with 
aggressive fibromatosis.
Methods
Institutional databases of three European centres were searched. All patients who received 
TM-ILP treatment for aggressive fibromatosis between 1990 and 2012 were included. 
Before therapy, the patients were discussed at multidisciplinary tumour board meetings.
Results
Twenty-five patients received 28 TM-ILP treatments. The median age of patients was 28 
(i.q.r. 19–34) years and median hospital stay was 8 (7–12) days. Median follow-up was 84 
(34–114) months. A complete response was achieved after two TM-ILP treatments, and 
a partial response after 17 treatments in 16 patients. Stable disease was reported after 
eight treatments in seven patients, including a patient with stable disease after the first 
treatment and progression after the second TM-ILP. Toxicity was modest after most 
treatments; Wieberdink grade IV (extensive epidermolysis, and threatening or manifest 
compartment syndrome) was seen after two TM-ILP treatments. Systemic leakage was 
reported after one treatment, but did not lead to systemic toxicity. Functional outcome 
was good; 16 patients had no physical limitations, and six patients had some limitations 
but did not need medical aids. Amputation was prevented in all but three patients.
Conclusion 
TNF-α-based ILP is effective in patients with aggressive fibromatosis.
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Introduction
Aggressive fibromatosis, or desmoid tumour, is a rare benign soft tissue tumour that 
is localized throughout the body. Aggressive fibromatosis does not metastasize, but 
locally advanced or recurrent disease is frequently seen in tumours localized in the 
extremities1–3. Extra-abdominal aggressive fibromatosis is not associated with mortality, 
unlike intra-abdominal tumours4. Current literature advocates a conservative approach 
for these benign tumours, owing to compelling evidence of disease stabilization and 
spontaneous tumour regression in many patients5,6. Despite the benign nature, some 
tumours behave aggressively, leading to pain and functional impairment. In patients with 
severely impaired quality of life, a conservative approach may no longer be an option. The 
choice of treatment depends on many factors, and an algorithm was proposed recently6. 
Involvement or proximity of vital structures, for instance major nerves and vessels, may 
lead to mutilating surgery or even amputation. In these patients, a limb-saving strategy 
that results in relief of symptoms should be preferred.
In 1958, isolated limb perfusion (ILP) was introduced as a treatment modality for extremity 
malignancies, such as locally advanced sarcomas and melanoma in-transit metastases7. 
In patients with sarcoma this technique appeared ineffective with cytostatics alone, but 
gained markedly in efficacy when tumour necrosis factor (TNF) α was added8,9. Currently, 
TNF-α and melphalan-based ILP (TM-ILP) is the standard of care in Europe for patients with 
limb-threatening sarcomas, and leads to limb salvage in up to 89 per cent of patients10.
The present study reports data from three sarcoma centres of the European Organization 
for Research and Treatment of Cancer (EORTC) relating to patients with locally advanced 
aggressive fibromatosis treated with TM-ILP to avoid limb amputation.
Methods
Consecutive patients with aggressive fibromatosis who underwent treatment with 
TM-ILP in participating EORTC centres between 1990 and 2012 were included in the 
study. Participating centres were: Gustave Roussy Cancer Campus, Villejuif, Paris, France, 
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and Erasmus Medical Centre 
Cancer Institute, Rotterdam, The Netherlands.
Owing to the benign tumour biology of aggressive fibromatosis, only patients suffering 
from intolerable pain or functional impairment are considered for surgical treatment in 
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these institutions. The safety and efficacy of conservative treatment is currently being 
evaluated in prospective trials in all three centres. For patients in the present study, a 
variety of treatments had been performed previously, and radical resection was deemed 
possible only with mutilating surgery or amputation. In these patients, TM-ILP treatment 
was considered. Before TM-ILP, all patients were discussed at a multidisciplinary tumour 
board meeting.
Perfusion
The ILP technique has been described extensively8,11. The procedure is performed 
under general anaesthesia. After heparinization, the targeted blood circuit is isolated by 
clamping and cannulation of the major artery and vein, and connected to an oxygenated 
extracorporeal circuit. A tourniquet compresses collateral vessels to prevent leakage. 
Using a precordial scintillation probe to detect technetium-labelled albumin, leakage is 
monitored throughout the procedure. TNF-α and melphalan are used; after 60–90min 
of perfusion, the active compounds are rinsed from the vascular system of the limb and 
the circulation is restored. There were minimal differences in the ILP protocols of the 
contributing institutions; details of the procedures have been described previously9,12,13.
Response and toxicity
Response was evaluated by clinical examination and MRI 4–8 weeks after ILP treatment, 
and reported according to World Health Organization criteria14. Complete response 
(CR) was defined as complete disappearance of the tumour; partial response (PR) was a 
decrease in tumour size of more than 50 per cent; and stable disease (SD) was recorded 
when the criteria for neither PR nor progressive disease were met. Disease progression 
was defined as a 25 per cent increase in tumour size with no initial documentation of CR, 
PR or SD. In patients with incomplete radiographic measurements, the response was based 
on available radiological information and clinical judgement.
Acute regional toxicity after perfusion was classified according to Wieberdink et al.15: grade 
I, no reaction; grade II, slight erythema or oedema; grade III, considerable erythema or 
oedema with some blistering, slightly disturbed motility permissible; grade IV, extensive 
epidermolysis, and threatening or manifest compartment syndrome; and grade V, reaction 
that may necessitate amputation.
Functional outcome was based on clinical assessment and categorized as perfect, 
impairment without the necessity for medical aids, and impairment with the need for 
medical aids or amputation. Continuous data are presented as median (i.q.r.).
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Results
A total of 25 patients received 28 TM-ILP treatments. The median age of the patients at the 
time of TM-ILP was 28 (19–34) years and median hospital stay after treatment was 8 (7–12) 
days. The majority of patients were female. Median length of follow-up was 84 (34–114) 
months. Baseline characteristics of the patients are summarized in Table1. Five patients 
were treated for a primary tumour; two of these had previously received systemic anti-
inflammatory treatment for inoperable disease, but this did not lead to sufficient reduction 
or relief of complaints. The indication for choosing ILP as a primary treatment in the other 
three patients was bone involvement, sciatic nerve involvement, and refusal of systemic 
treatment by the patient.
Table 1. Baseline characteristics of patients with aggressive fibromatosis
No. of patients 
(n= 25)
Sex ratio (M : F) 8 : 17
Age (years)† 28 (19–34)
Localization
Arm
Leg
4
21
Size of lesion (cm)† 12 (8.5–15)
No. of tumours
Single
Multiple
14
11
Tumour treated 
Primary tumour
Primary recurrence
Secondary recurrence
5
10
10
Previous treatment 
None
Surgery
Radiotherapy
Systemic treatment
Surgery + radiotherapy
Surgery + radiotherapy + systemic treatment
Surgery + systemic treatment
3
7
2
2
3
4
4
†values are median (i.q.r.).
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Treatment outcomes
An overall response was seen after 19 of 28 TM-ILP treatments (Table2). CR was achieved in 
two patients; both patients had TM-ILP as a single treatment modality for recurrent disease 
after previous surgical resections, and one patient had also undergone radiotherapy. These 
two patients had a sustained CR to the end of follow-up at 94 and 36 months. 
PR was recorded after 17 TM-ILP treatments in 16 patients. For 11 patients, TM-ILP led 
to control of disease and symptoms that was sustained to the end of follow-up with no 
need for additional treatment; an example is shown in Fig.1. Of the other five patients, one 
received adjuvant radiotherapy to achieve disease control. Surgical resection of residual 
disease was performed after the first TM-ILP in one patient presenting with recurrent 
disease. A second recurrence, treated by further TM-ILP 32 months after the first treatment, 
also resulted in a PR and disease control to the end of follow-up. Three patients with an 
initial PR after TM-ILP developed progression of remaining disease during follow-up. One 
of these patients had tumour deposits throughout one leg and had previously undergone 
extensive radiotherapy. The patient was included in a phase I study (GW786034) of 
treatment with paclitaxel and pazopanib. During this treatment, the patient developed 
necrosis of the foot and a below-knee amputation was performed 3years after TM-ILP. 
Several tumour deposits were still insitu and stable at the end of follow-up. The other two 
patients with progression received systemic treatment for the progressive disease, which 
led to disease control.
SD was recorded after eight TM-ILP treatments in seven patients. The response to TM-ILP 
was sufficient to achieve disease control in four of these patients, which was sustained 
in two to the end of follow-up. One patient with initial disease control developed tumour 
progression after 24 months and received systemic treatment; the other developed a 
new lesion after 57 months, with SD of the primary tumour. After systemic treatment, 
both lesions remained stable to the end of follow-up. In the other three patients with 
SD, the response was sufficient to perform limb-sparing surgery. One of these patients, 
with a 30 per cent tumour response after TM-ILP, had macroscopically negative margins 
after surgical (R1) resection. Four years after resection, disease progression led to a 
second treatment with TM-ILP. After treatment, the leg was amputated above the knee 
owing to healing problems. However, a new recurrence occurred in the stump, for which 
exarticulation of the hip was performed with postoperative adjuvant radiotherapy. 
At the end of follow-up, the patient was free from disease. Another patient, who had 
an R1 resection after TM-ILP, developed recurrence that was treated successfully with 
chemotherapy.
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Table 2. Characteristics of the 28 treatments with isolated limb perfusion
No. of treatments
Type of ILP
Axillar
Brachial
Iliacal
Femoral
Popliteal
3
1
10
10
4
Response 
Complete
Partial
Stable disease
Progression
2
17
8
1
Wieberdink grade
I
II
III
IV
4
16
6
2
Duration of hospital stay (days)† 8 (7–12)
Treatment after ILP‡
None
Resection
Radiotherapy
Amputation
21
3
2
3
Local recurrence after ILP
No
Yes
17
11
Limb function§
Perfect
Limited
Amputated
16
6
3
†values are median (i.q.r.). ‡One patient had both amputation and radiotherapy. §For the 25 patients at end 
of follow-up. ILP, isolated limb perfusion.
In the last patient with SD, disease control was achieved after surgery (R1 resection). 
After 19 months a second recurrence was diagnosed. Systemic treatment was ineffective, 
and a second TM-ILP was performed 56 months after the first. Owing to continued 
disease progression, the patient underwent above-knee amputation and radiotherapy 
of the stump, which resulted in disease stabilization. The patient developed yet another 
recurrence, which was treated with systemic therapy. This was the only patient with 
progressive disease at the end of follow-up.
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Toxicity and function
Local and systemic toxicity were modest. Wieberdink grade I was recorded after four 
procedures, grade II after 16 procedures and grade III after six procedures. More severe 
toxicity (Wieberdink grade IV) was seen after two TM-ILP treatments: one patient required 
fasciotomy and necrosectomy, and the other needed amputation as a result of rapid 
disease progression.
Leakage of perfusate to the systemic circulation was seen after one treatment. The leakage 
was managed conservatively and did not result in systemic toxicity.
Functional outcome was good. Sixteen patients had no limitations of physical function; six 
had some limitations of the limb, but without the need for medical aids. Amputation could 
not be prevented in three patients (Table2).
Recurrence and survival
Local recurrence or disease progression after initial disease control was documented 
following 11 of the 28 TM-ILP treatments. The median time for tumour recurrence or 
progression was 27 (17–44) months. No patient died during follow-up.
Discussion
This multicentre study indicates that treatment with TM-ILP may be a limb-saving strategy 
for aggressive fibromatosis in patients for whom previous therapy has failed or where 
surgical treatment might result in severe limb impairment. A tumour response was seen 
after 19 of 28 TM-ILP treatments, and amputation was avoided in all but three of the 
25 patients.
A limitation of this study is the absence of pain scores before treatment, as a result of the 
retrospective study design. Although details are lacking, the indication for TM-ILP for each 
patient was assessed carefully during a multidisciplinary board meeting, which included 
evaluation of pain due to tumour growth.
Tumour behaviour of aggressive fibromatosis varies greatly. At the time of diagnosis, a 
conservative approach with careful follow-up only is advocated, in agreement with a recent 
study6. Even minor tumour progression in the absence of patient complaints may justify 
a conservative approach. Aggressive local tumour growth or intolerable pain are reasons 
for active therapy. In these patients, surgery is the mainstay of treatment, but adequate 
surgical resection may lead to severe impairment of the limb or even amputation. In these 
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patients, treatment with TM-ILP might be successful and achieve an excellent limb salvage 
rate, as shown in the present series.
Chemotherapy, non-cytotoxic systemic treatment and radiotherapy are other options 
when the extent of disease excludes surgery as a primary treatment modality. Several 
different chemotherapy regimens have been proposed, with varied response rates16. In an 
overview by the French Sarcoma Group17, 62 patients were analysed after treatment with 
various regimens; the overall response rate was 21 per cent. The systemic side-effects 
of chemotherapy for a localized tumour disease warrant careful consideration before 
treatment.
Fig. 1 Patient with recurring aggressive fibromatosis of the right foot. 
a. Appearance before ILP c. Appearance 2 years after ILP
b. MRI before ILP d. MRI 2 years after ILP
a. Macroscopic appearance and b. axial view of contrast-enhanced, T1-weighted MRI before isolated limb perfusion 
(ILP); c. macroscopic appearance and d. axial view of contrast-enhanced, T1-weighted MRI 24 months after ILP.
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Less aggressive systemic treatment options are hormone therapy, non-steroid anti-
inflammatory drugs or the tyrosine kinase inhibitor imatinib. Response rates of 
approximately 50 per cent have been reported18,19, but only small groups of patients 
were studied and with limited follow-up time. Side-effects vary depending on the type 
of treatment, but often include gastrointestinal complaints and fatigue. Long-term side-
effects are unknown and follow-up protocols have yet to be established.
Most of the experience with radiotherapy has been acquired in the adjuvant setting. Few 
reports discuss radiotherapy as a single-modality treatment for aggressive fibromatosis. 
Ballo and colleagues20 showed a 5-year progression-free survival rate of 69 per cent.  
A review21 reported local tumour control rates of 78 per cent. The most compelling data are 
from a recent EORTC study22, which included 44 patients with inoperable or incompletely 
resected disease with a median follow-up of 4-8 years; all patients received a dose of 56 Gy 
in 28 fractions. The 3-year local control rate was 81.5 per cent. A further response with 
tumour regression was seen after 3 years in three patients; two patients had a CR and one 
had a PR.
Acute grade 3 side-effects were limited to the skin, mucosa and pain, whereas mild 
oedema was the late toxic effect in ten patients22.
In the present study, nine patients had received radiotherapy before TM-ILP, excluding 
radiotherapy as a treatment option. For patients without previous radiotherapy, the 
present authors advocate treatment with TM-ILP because of the potential for surgical 
resection, and radiotherapy, or even repeat TM-ILP, after the initial treatment. In areas 
that are not amenable to TM-ILP, such as the groin or buttocks, radiotherapy might be an 
attractive alternative for unresectable and limb-threatening tumours.
Local and systemic toxicity was limited in the present series. Toxicity in these patients was 
comparable to that reported in previous series9,10,12 of nearly 400 TM-ILP treatments of 
extremity sarcomas.
Patient selection is essential in the current era of tailored treatment strategies. TNF-
α-based ILP is an aggressive treatment for this relatively benign disease. Patients who 
are considered for TM-ILP have tumours with aggressive tumour biology and severe 
symptoms.
Aetiological studies23,24 have shown the importance of the Wnt pathway and β-catenin 
in the development of aggressive fibromatosis. Specific mutations of the CTNNB1 gene 
(which encodes β-catenin) have been associated with aggressive fibromatosis25–27. The 
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precise mechanism and the different effects exerted by the specific mutations are not well 
understood. Several studies28–31 have demonstrated a predictive value for the mutations 
on the risk of tumour recurrence after surgery. Whether the mutational status of the 
tumour has an effect on the outcome after TM-ILP is unknown.
TNF-α-based ILP is an effective limb-sparing technique for the treatment of aggressive 
fibromatosis in selected patients. It should be considered after failure of initial therapy 
and where surgery for recurrent or progressive disease would lead to functional loss or 
amputation.
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Outcome of non-surgical management of extra-abdominal, 
trunk and abdominal desmoid-type fibromatosis: a population-
based study in the Netherlands.
Abstract
Background
Non-surgical management of patients with desmoid-type fibromatosis (DF) is increasing. 
Aim of the present study is to provide insight on type, usage and outcome of first-line non-
surgical management strategies. 
Methods
From the Dutch Pathology Registry (PALGA) patients with extra-abdominal or trunk/
abdominal wall DF, diagnosed between 1993 and 2013, were identified. First-line treatment 
was analyzed. Best response using RECIST-criteria and time to progression (TTP) from start 
of treatment/surveillance until change of treatment or last documented follow-up visit.
Results
1134 patients were identified, 91 patients had first-line non-surgical management. During 
the study period, the percentage of patients treated non-surgically increased from 0.6% 
in 1993-1998 to 12.8% in 2009-2013. Best response (BR) for surveillance was complete 
response (CR) in 2/37, partial response (PR) in 4/37, stable disease (SD) in 21/37, progressive 
disease (PD) in 5/37 and unknown in 5/37 patients. During follow-up, 13 patients 
developed PD with median TTP of 7 months. BR for radiotherapy was CR in 4/35, PR in 
11/35, SD in 16/35 and unknown in 4/35. During follow-up, 2 patients developed PD after 
31 and 47 months. BR for systemic treatment was CR in 1/19, PR in 1/19, SD in 10/19, PD in 
2/19 and unknown in 5/19. During follow-up, 3 patients developed PD with median TTP of 7 
months (range 6-7 months). 
Conclusion
Over a 20-year period, the percentage of patients with primary non-surgical management 
for extra-abdominal and trunk/abdominal wall DF increased from 0.6% up to 12.8%. Given 
the low percentage of early PD, this policy deserves further exploration prospectively.
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Background
Desmoid-type fibromatosis (DF or aggressive fibromatosis) is an intermediate grade 
soft tissue tumor that does not metastasize, but can be locally aggressive1. For long, 
surgery has been the primary treatment for resectable tumors, with or without additional 
radiotherapy. Currently, a more conservative approach is applied based on reports of 
disease stabilization and spontaneous regression and on progression after surgery 
because complete resection is sometimes difficult to achieve2,3. An epidemiological study 
conducted in extra-abdominal and trunk/abdominal wall DF patients in the Netherlands 
reported an increase in the use of non-surgical modalities over the past decade4. 
An European consensus on the management of DF has recently been published, advocating 
active surveillance as the initial treatment modality, with systemic treatment, surgery 
or radiotherapy in case of tumor progression5. Despite a trend towards conservative 
treatment, knowledge on the outcome of different management modalities as first-line 
treatment is limited. We conducted this nationwide retrospective study to report on 
the prevalence of used treatment modalities, especially active surveillance, for extra-
abdominal and trunk/abdominal wall desmoid-type fibromatosis in the past 20 years. 
Moreover, we used this retrospective study to gain more insight in the application and 
outcome of all first-line treatment modalities in a cohort of DF patients during routine 
clinical care.
Studies on radiotherapy have described disease stabilization and tumor regression6-8. 
Literature on systemic treatment is limited, with a variety of treatment regimes, often 
applied at different stages of disease presentation. Active surveillance is currently 
being investigated in a prospective setting by three different groups; a French group 
(NCT01801176), an Italian group (NCT02547831) and a Dutch group (NTR4714)9. Non-
surgical management of patients with DF is increasing. Population-based studies are 
needed to gain insight into the actual implementation of non-surgical treatment in daily 
practice. Since these studies are lacking for patients with DF, the present study reports 
type and outcome of first-line non-surgical treatments in a nationwide population based 
study. Because this study is a retrospective study, it is not designed to compare the 
outcomes of the different non-surgical treatments. Moreover data regarding symptoms in 
relation to the disease status were not sublet to this analysis.
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Methods
From the Dutch national pathology database (PALGA) patients diagnosed between 1-1-
1993 and 31-12-2013 having extra-abdominal or trunk/abdominal wall DF were identified. 
The PALGA database contains encoded excerpts of all nationwide pathology examinations 
obtained by diagnostic procedure, including tissue biopsy or resection since 1971 in 
selected laboratories and expanded to nationwide inclusion in 199110. Due to incomplete 
data registration, patients with disease presentation before 1993 were excluded. 
Specialists from PALGA reviewed the study design before providing excerpts. Excerpts 
contained standardized information: an encrypted patient identification, date of pathology 
report, age and gender of the patient, and the conclusion of the pathology reports. 
Reports were scored as biopsy, resection or re-resection. Patients with diagnostic biopsy 
of DF, without excision specimens were selected. Exclusion criteria were intra-abdominal 
DF, recurrent disease at presentation, uncertain diagnosis and initial surgical treatment.
Hospitals with more than 10 patients were contacted for information. Data collection was 
performed in seven centers, as most patients were referred after diagnosis. In addition 
to the PALGA registration, center-based registrations were searched for patients. Medical 
records were retrieved for patient characteristics, tumor characteristics and details on 
treatment modalities. Only the first-line of treatment was documented. 
Tumor localization was categorized as: head/neck, trunk (including thoracic wall, breast 
and back), abdominal wall, extremity or groin. Type of systemic treatment was categorized 
as: non-steroidal anti-inflammatory drug (NSAID), anti-hormonal (HT), chemotherapy (ChT) 
or tyrosine kinase inhibitors (TKI).
Reports from all available imaging studies were reviewed. Best response to treatment 
was classified using RECIST 1.1 as complete response (CR), partial response (PR) in case 
of >30% decrease of the largest diameter, stable disease (SD) or progressive disease (PD) 
in case of >20% increase of largest diameter based on reported measurements11. Date 
for the start of treatment was defined as the date of visit with the physician, in which the 
treatment modality was initiated. In most patients, active surveillance was initiated within 
3 weeks after diagnosis. Results are shown as best response and time to progression (TTP). 
Time to progression was defined as the period from start of treatment to radiological 
progressive disease as classified by RECIST 1.1. Follow-up period for each treatment was 
documented as time of start treatment or active surveillance until change of treatment or 
last documented follow-up visit, whichever came first. 
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To evaluate the changes in the approach and choice of non-surgical management over 
time, the results are presented in 5-year cohorts. Late toxicity after radiotherapy was 
retrospectively scored using RTOG-EORTC criteria12.
Statistical analysis was performed using IBM SPSS Statistics 21. Continuous variables are 
shown as median with interquartile range (IQR), and categorical variables as numbers with 
percentages. Associations between clinicopathological variables were determined by Chi-
square analysis. For all analyses, two-sided P<0.05 was considered statistically significant. 
Results
The PALGA search covering the period between 1-1-1993 and 31-12-2013, identified 1134 
patients with extra-abdominal and trunk/abdominal wall DF. Patients were selected using 
in- and exclusion criteria (see Figure 1). Hospital records could be traced for 181 patients. 
Their files were reviewed for details on tumor characteristics and treatment modalities. 
Centre-based registrations provided data on additional patients (diagnosed in 2014). In 
total, 91 patients were included for further analysis. Baseline characteristics are listed in 
Table 1. Median follow-up was 37 months (IQR 20–62). Details on beta catenin (CTNNB1) 
and APC gene mutation status were reported sporadically. To our knowledge, 6 patients 
with APC gene mutation were included. Due to the scarce data, these factors were not 
included in further analyses. 
Based on initial management patients were divided in 3 groups: active surveillance, 
radiotherapy and systemic treatment. Outcome for each group is listed in Table 2. Median 
follow-up after active surveillance, radiotherapy and systemic treatment was 16 months 
(IQR 7-31), 44 months (IQR 24-62) and 5 months (IQR 2-12) respectively.
There is a clear increase in the use of non-surgical management over the years, from 0.6% 
in 1993-1998 up to 12.8% in 2009-2013 (Table 3). 
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Figure 1. CONSORT diagram of patient selection
PALGA database of patients with new 
diagnosis of extra-abdominal DF 
(n=1134)
Requested identification by PALGA to link excerpt 
number to pathology number and laboratory
All laboratories were contacted for further 
identification based on local pathology numbers.
Exclusion on patients with excision <6 months of 
diagnosis or patients with primary excision (n=857)
Centers with >10 pathology numbers were contacted 
for patient identification and file retrieval (n=186)
● 11 centers, 8 willing to cooperate. (n=152)
●  Own databases were available for additional 
inclusion of patients (29 additional patients 
identified)
Exclusion based on:
➔ 16x not traceble
➔ 4x no desmoid
➔ 3x recurrent disease, no data on primary
➔ 27x intra-abdominal disease (mostly pelvis)
➔ 40x primary surgery
Requested identification by PALGA
(n=277)
277 excerpts were linked to 
328 pathology numbers in 
50 laboratories (51 double 
identifications)
(n=328)
Response from 24 laboratories, 
responsible for 219 excerpts (including 
unknown number of doubles). 
(n=219)
181 patients identified and available 
for file review
91 patients for analysis
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Table1. Baseline characteristics 
All patients Active  
surveillance
Radiotherapy Systemic 
treatment
N % N % N % N %
Gender
Male
Female
30
61
33
67
9
28
24.3
75.7
12
23
34.3
65.7
9
10
47.4
52.6
Age
Median (IQR) 39 (33.1-52.2) 36 (31.2-51.6) 43,6 (39.4-52.4) 34.8 (23.3-46.3)
Localization
Head/Neck
Thorax/back
Abdominal wall
Extremity
Other* 
9
35
25
21
1
9.9
38.5
27.5
23.1
1.1
3
13
17
4
-
8.1
35.1
45.9
10.8
-
6
13
1
15
-
17.1
37.1
2.9
42.9
-
-
9
7
2
1
-
47.4
36.8
10.5
5.3
Size
<5 cm
5-10 cm
>10 cm
Missing data
25
48
15
3
27.5
52.7
16.5
3.3
16
18
2
1
43.2
48.6
5.4
2.7
7
19
8
1
20.0
54.3
22.9
2.9
2
11
5
1
10.5
57.9
26.3
5.3
Beta-catenin (nuclear)
Positive
Negative
Unknown
56
10
25
61.5
11
27.5
28
3
6
75.7
8.1
16.2
16
6
13
45.7
17.1
37.1
12
1
6
63.2
5.3
31.6
N=number of patients. Cm=centimeters. IQR=interquartile range. *groin.
Table 2. Outcome of non-surgical treatment, using best response according to RECIST
CR PR SD PD Unknown Total
N % N % N % N % N % N
Active surveillance 2 5.4% 4 10.8% 21 56.8% 5 13.5% 5 13.5% 37
Radiotherapy 4 11.4% 11 31.4% 16 45.7% 0 0% 4 11.4% 35
Systemic treatment 1 5.3% 1 5.3% 10 52.6% 2 10.5% 5 26.3% 19
N=number of patients. CR=complete response. PR=partial response. SD=stable disease. PD=progressive 
disease.
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Table 3. First-line non-surgical management per 5 year time period
1993-1998 1999 - 2003 2004 - 2008 2009 - 2013 2014 Total
N N N N N N
PALGA registration4 180 185 331 438 1134
First-line treatment 1 5 22 56 7 91
Stratified treatment
Active surveillance
Radiotherapy
Systemic treatment
0
0
1
0
1
4
5
13
4
26
20
10
6
1
0
37
35
19
Percentage* 0.6 % 2.7% 6.6% 12.8% 8.0%
N=number of patients. *Percentage of non-surgical treatment compared to overall diagnoses as documented 
in the PALGA registration
Active surveillance
Thirty-seven patients were directed to active surveillance after diagnosis. Tumor 
localization was as follows: 3 patients with head/neck tumors, 13 patients with truncal 
tumors, 17 patients with abdominal wall tumors and 4 patients with extremity tumors. 
Best response during that period was spontaneous CR for 2 patients (5%), PR for 4 patients 
(11%), SD for 21 patients (57%) and PD for 5 patients (14%). For 5 patients, images required 
for RECIST were not available. During the follow-up period, 13 patients had progressive 
disease with a median TTP of 7.3 months (IQR 4.1-11.9). In total, 22 patients (63%) were 
still under active surveillance at the date of last of follow-up after a median of 16 months, 
including all patients with CR or PR (median duration of active surveillance for patients 
with CR and PR was 22 months, IQR 13-46). Of the 21 patients with SD, 3 ended active 
surveillance due to complaints related to the tumor and 5 patient had tumor growth of 
which 1 patient with <20% increase. Of the 5 patients with PD, 4 patients remained under 
active surveillance.
Radiotherapy
Initial treatment was radiotherapy for 35 patients. Tumor localization was categorized as 
follows: 6 patients with head/neck tumors, 13 patients with truncal tumors, 1 patient with 
abdominal wall tumor and 15 patients with extremity tumors. 
Most patients (n=34) received 56 Gy in 28 fractions of 2 Gy or 25 fractions of 2 Gy and 
2 fractions with 3 Gy. One patient with a tumor on the head/neck received 54 Gy over 
30 sessions of 1.8 Gy. 
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Ten patients had no toxicity, 11 patients had grade 1, 10 patients had grade 2 and one patient 
had grade 3 toxicity. Data used for scoring was too limited in 3 patients. 
Best response to radiotherapy was CR in 4 patients (11%), PR in 11 patients (31%) and SD 
in 16 patients (46%). For 4 patients, no images were available to determine outcome using 
RECIST. During follow-up, 2 patients developed PD with TTP of 31 and 47 months. Median 
follow-up after radiotherapy was 44 months (IQR 24-62). 
Systemic treatment
A total of 19 patients received initial systemic treatment. Type of systemic treatment was 
non-steroid anti-inflammatory drugs (NSAID) in 10 patients, anti-hormonal therapy (HT) in 
5 patients, chemotherapy (ChT) in 1 patient, tyrosine kinase inhibitor (TKI) in 1 patient and 
a combination of HT and TKI in 1 patient. Details were missing for 1 patient. 
Tumor localization was categorized as follows: thoracic/back in 9 patients, abdominal wall 
in 7 patients, extremity in 2 patients and groin in 1 patient. 
Median duration of initial systemic treatment was 5 months (IQR 2-12). Best response 
during initial systemic treatment was CR for 1 patient (5%), PR for 1 patient (5%), SD for 
10 patients (53%), PD for 2 patients (11%) and unknown for 5 patients (26%). The female 
patient with CR received HT. The patient with PR received a NSAID. The 10 patients with SD 
had received NSAIDs (n=7), HT (n=2) and TKI (n=1). PD was seen after NSAID (n=1) and ChT 
(n=1). During follow-up, 3 patients developed PD with TTP of 6.3, 7.1 and 7.2 months.
After initial systemic treatment, multiple regimes of systemic treatments were given to 
10 patients. Overall, NSAIDs were given in 14 regimes, HT was given in 7 regimes, ChT was 
given in 7 regimes, TKIs were given in 1 regime, a combination of TKI with HT was given in 
1 regime and a combination of NSAIDs and HT was given in 4 regimes. 
Discussion
The change in treatment strategies from initial surgery with or without radiotherapy to 
initial non-surgical treatment has been fueled by several studies and increasing expertise 
about this disease with its unpredictable behavior. Reports on outcome of initial non-
surgical treatment are limited. The Dutch PALGA registration provided data to analyze 
treatment strategies in the Netherlands over the last 20 years. Overall trends have been 
recently described, reporting a decrease in surgery as initial treatment4. The present 
study describes the first-line non-surgical management modalities, including 37 patients 
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receiving surveillance (41%), 35 patients receiving radiotherapy (38%) and 19 patients 
receiving systemic treatment (21%). Overall, patients had a 25% response rate and 52% 
stable disease rate. This study was not designed to compare the outcome of the different 
treatment modalities, merely to report common practice over the years. 
Over the past 20 years, first-line non-surgical management has increased to up to 12.8%. 
Although the ratio between the time periods might be biased by several factors (such as 
limited numbers and registration), the trend towards non-surgical management is evident 
and is expected to increase, as more specialists adhere to the current guidelines. 
Literature on first-line non-surgical management is limited. Moreover, all studies are 
reports from specialized centers. Retrospective studies with combined data from the 
French and Italian research groups reported promising results for all tumor localizations. 
Even a predictive value to switch to non-surgical management was found: tumor size13,14. 
The present study was designed to provide more insight in common practice for this 
rare disease on a population based level. Using a national database of 1134 patients, the 
number of patients treated non-surgically, is still very small, but increasing. This indicates 
that surgery remained the first-line treatment over the last 20 years. The paradigm shift 
towards active surveillance could be observed in the present study, as these patients 
represent the largest group among non-surgical management. Radiotherapy comes 
second, possibly due to available knowledge on efficacy, a study that has run within 
participating centers in this analysis and the often irresectable cases where radiotherapy is 
the only treatment of choice. The small numbers of systemic treatment reflect the limited 
evidence for any of those and lack of clinical studies in the Netherlands. 
Overall, outcome of first-line non-surgical treatment was good. Among patients under 
active surveillance, 16% showed spontaneous regression and 57% disease stabilization. 
These results might be biased because in many cases choice for first-line treatment was 
made after referring the patient to a tertiary referral center which enabled the physicians 
to observe the natural behavior of the tumor, thereby selecting patients for active 
surveillance or more aggressive treatments. For radiotherapy, the patients in the present 
study received radiotherapy at the recommended dose of 50-56 Gy6-8,15. Results showed 
response in 43% and SD in 46% of the patients. During the follow-up period (median 
of 44 months (IQR 24-62) only 2 patients had disease progression with long TTPs of 31 
and 47 months. These results are promising and might seem to advocate radiotherapy. 
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However, radiotherapy might be considered an aggressive treatment for this intermediate 
grade tumor, usually reserved for patients with advanced disease. Especially in younger 
patients, given the low, but present long term risk on irradiation induced sarcomas 
radiotherapy is not deemed as first line treatment. When systemic treatment is chosen, 
a large variety of possible agents and regimes are available, such as hormonal agents, 
NSAIDS, chemotherapy and angiogenesis inhibitors, making comparison impossible. 
Although the group in the present study was small and diverse, results show stabilization 
and response in 63% of patients. Again, due to the large variety, no conclusions can be 
made for on preference of specific agents or regimes.
For each type of active treatment, the possible results should be weighed against adverse 
events. In particular, the small risk of secondary tumors should be taken into account for 
this relatively young patient group. Treatment decisions should therefore always be made 
during multidisciplinary expert meetings. 
The optimal first-line non-surgical management of DF has been discussed by many groups, 
predominantly based on expert opinions and specific treatment modalities. The European 
consensus, reported by Kasper et al.5 advises to start with active surveillance and switch 
to active treatment in case of 3 subsequent reports of progression, and that treatment 
should be guided by tumor localization. This advice is consensus-based. There is no 
staging system available to predict outcome at the time of diagnosis. Predictive factors 
have been described, such as age, tumor localization and CTNNB1 mutations16-21. Recent 
data on CTNNB1 mutations show different behavior for tumors with different mutations. 
In the future, these mutations could play an important role when deciding to initiate 
specific treatment modalities. Moreover, it is increasingly important to recognize the lack 
of correlation between radiological volume and symptoms. Given the chronic condition 
and the spontaneous fluctuations of the disease this should be taken into account in any 
decision that will be taken.
By the use of PALGA, the Dutch pathology registry, and the long study period, we have 
tried to be as inclusive as possible. Because referral for a desmoid-type fibromatosis to 
one of the sarcoma referral centers is standard practice in the Netherlands, the study is 
unbiased by clinical behavior.
Finally, a limitation of the study is it retrospective nature. As a result, details on symptoms 
during or after treatment are lacking, which could have provided insight in the way 
decisions to either management had been taken. Therefore, no comparisons can be made 
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between the different strategies. The natural behavior of these tumors is variable, varying 
from spontaneous regression to long-term disease stabilization and rapid progression. 
In the absence of randomization, no clear recommendations can be given. Desmoid-type 
fibromatosis remains a rare disease, for which several treatment modalities are available. 
Active surveillance is a good and safe initial treatment, with options for adjuvant treatment 
in case of progression. Importantly, expected benefits from therapy should be well 
balanced against potential treatment-induced untoward effects.
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Abstract
 
Background
Aggressive fibromatosis (AF) comprises tumors with a varying biological behavior. 
Genetic tumor characteristics may be predictive of recurrence; hence the prognostic 
value of three specific mutations on the CTNNB1 gene was evaluated in relation to known 
clinicopathological risk factors in patients with primary, sporadic AF.
Methods
In a multi-institutional retrospective cohort study of patients with primary extra-
abdominal and abdominal wall AF who underwent surgical treatment, the original 
pathology specimens were reviewed for the presence of a T41A, S45F and 45P mutations 
on the CTNNB1 gene. For these mutations the risk of recurrence was analyzed using the 
Kaplan-Meier method with log-rank test. Univariable and multivariable Cox-regression was 
performed to calculate hazard ratio’s.
Results
A total of 101 patients were analyzed. During a median follow-up of 41 months, 
17 recurrences were detected; the cumulative 5-year recurrence rate was 22.8%. A specific 
CTNNB1 mutation was found in 76 patients, the majority of patients having a T41A mutation 
(n=49). CTNNB1 mutations were associated with the risk of recurrence: the presence of a 
S45F mutation was associated with a 5-year cumulative risk of recurrence of 63.8% (P<0.001). 
Multivariable analysis showed that young age and S45F mutation were independent risk 
factors (P=0.011 and P<0.001). 
Conclusion
The presence of specific CTNNB1 mutations was predictive for recurrence in patients after 
surgical treatment for primary, sporadic extra-abdominal and abdominal AF.  
A S45F mutation increased the risk of recurrence significantly.
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Introduction
Aggressive fibromatosis (AF) is a soft tissue tumor that does not metastasize, but 
frequently recurs following surgical excision1,2. On the other hand, the growth of these 
tumors may halt spontaneously in a substantial proportion of patients2,3. Because of this 
heterogeneity of biological behavior, the course of the disease is difficult to predict and 
the benefit of aggressive treatment modalities is unclear. On a cellular level the beta-
catenin protein level is elevated in these tumors, and the demonstration of mutations in 
two mediators in the Wnt-APC-beta-catenin pathway implicates beta-catenin stabilization 
as the key factor in the pathogenesis of AF4,5. The CTNNB1 gene encodes for β-catenin and 
literature suggests the involvement of CTNNB1 gene mutations in sporadic AF6,7. 
Three particular mutations on the CTNNB1 gene have been associated with AF, namely 
T41A, S45F and 45P5,8. Although it remains unclear how these mutations precisely affect the 
aforementioned pathway in these tumors, the presence or absence of a specific mutation 
appears to be predictive of recurrence. A number of studies observed a prognostic impact 
of CTNNB1 mutations; in particular S45F mutations were associated with a high risk of 
recurrence following surgical excision9-11. Others, however, have failed to demonstrate this 
increased risk12.
We recently analyzed clinicopathological factors for their prognostic significance in a multi-
institutional cohort of patients who underwent surgery for primary, sporadic AF13. The 
original pathology specimens of the patients in this cohort were collected and reexamined 
for the presence of the specific CTNNB1 gene mutations. The association with other 
clinicopathological factors was evaluated in an attempt to use mutation status in addition 
to clinical factors to stratify the risk of recurrence in patients with AF.
Methods
Data collection
The institutional databases of patients with soft tissue tumors at the University Medical 
Center Utrecht, the affiliated Diakonessenhuis in Utrecht and the Erasmus MC Cancer 
Institute in Rotterdam were searched. Patients diagnosed between November 1989 and 
October 2013 as having a a first manifastation of sporadic extra-abdominal or abdominal 
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wall AF were included if original pathology specimens were available for mutation 
analysis14. Patients who underwent incomplete (R2) tumor resection were excluded. None 
of the patients had undergone previous surgery for AF.
Mutation Analysis
The soft tissue pathology boards at the University Medical Center Utrecht or the Erasmus 
MC Cancer Institute reviewed the histopathological diagnosis for all patients at the time of 
treatment. The available pathology specimens of the patients were collected and analyzed 
in one laboratory. Tumor areas as identified on serial H&E sections were harvested from 
4 µm thick formalin fixed paraffin embedded sections (corresponding to approximately 
1 square cm tumor tissue) with a scalpel. Tumor percentages of all samples were estimated 
before DNA isolation and only samples with tumor percentages of at least 10% were used. 
DNA was isolated from these tissue fragments with the Cobas® DNA Sample Preparation 
kit (Roche Diagnostics). 
For the detection of CTNNB1 mutations, 1 µl of DNA (10-50 ng/µl) was amplified with 
primers positioned in exon 4, flanking codons 41 and 45 (forward PCR primer: 5` AAA-
GCG-GCT-GTT-AGT-CAC 3 ,` reverse PCR primer: 5` TCC-CTG-TTC-CCA-CTC-ATA 3 ,` 35 cycles, 
annealing temperature 55 ºC). After subjecting to agarose gel electrophoresis, 1-2 µl of 
viable PCR product was sequenced (forward sequence primer: 5` ACT-GGC-AGC-AAC-AGT-
CTT 3 ,` reverse sequence primer: 5` ACA-GGA-CTT-GGG-AGG-TAT-C-3 ,` 25 cycles, annealing 
temperature 50 ºC ) in both sense and antisense directions, using the BigDye Terminator 
v1.1 sequencing kit on an ABI 3730 capillary sequencer (Life technologies) according to the 
manufacturer’s instructions. Only mutations that could be confirmed in both sequencing 
directions were taken into account.
Patient and tumor characteristics
Age was categorized into quartiles. Tumor localization was categorized as extra-abdominal 
(head/neck, extremity, chest wall/back, other) and abdominal (abdominal wall) in accordance 
with the WHO Classification of Tumours14. Tumor depth was categorized as superficial or 
deep, in relation to the fascia. The result of surgery was categorized based on the histological 
examination of surgical margins and the operative report, using the classification of the 
International Union Against Cancer (UICC), as R0 (microscopic negative resection) or R1 
(microscopic tumor positive margins). In case of more than one operation on the primary 
tumor, surgical margin status was classified based on the histopathological findings after 
the last operation. The type of CTNNB1 gene mutation was categorized based on the three 
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known mutations related with aggressive fibromatosis: T41A, S45F and 45P mutation. Other 
deletions or mutations on the CTNNB1 gene were categorized as “other”. Specimens without 
a mutation were considered to be ‘wild type’ and were categorized as such. 
Local recurrence was the main endpoint, defined as radiological and/or pathological 
evidence of tumor recurrence established during follow-up after resection. The end of 
follow-up was marked by local recurrence, the last registered contact between surgeon 
and patient or death. The follow-up protocol was not identical in the different institutions. 
The Erasmus MC Cancer Institute performed physical examination of patients every three 
months in the first year, every six months during the second year and then yearly until a 
five year follow-up. In addition to physical examination, magnetic resonance imaging (MRI) 
was performed routinely six months postoperatively and from then on indication only. At 
the University Medical Center Utrecht and the Diakonessenhuis, patients were evaluated at 
the same intervals postoperatively. In addition, MRI was performed routinely on an annual 
basis. Regular follow-up was ended after five years. Patients were encouraged to contact 
the hospital if symptoms occurred. 
Statistical analysis 
Categorical variables are shown as numbers and percentages, continuous variables as 
median and interquartile range (IQR). Associations between variables were explored by 
Chi-square analysis. The Kaplan-Meier method was used to estimate the 5-year cumulative 
risk of recurrence and differences in the risk of recurrence between the CTNNB1 mutations 
as well as for the other clinicopathological variables were analyzed with the log-rank test. 
To support these analyses, univariable Cox regression analysis was used, and results are 
presented as hazard ratios (HR) compared to a reference category and with 95% confidence 
interval. Multivariable Cox regression was performed using variables that were statistically 
significant in univariable analysis. The association between the CTNNB1 mutation that was 
most predictive for recurrence and the other clinicopathological factors was explored by Chi-
square analysis. For all analyses, two-sided P < 0.050 was considered statistically significant. 
Results
There were 101 patients who were surgically treated for primary, sporadic extra-abdominal 
and abdominal AF and for whom pathology specimens were available for CTNNB1 mutation 
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analysis. Median age at the time of treatment was 36 years (IQR 28-44). The majority of 
patients were female (65.3 percent; see Table 1).
Table 1. Baseline characteristics of patients with primary sporadic aggressive 
fibromatosis. 
No. of patients
Sex ratio (M : F) 35:66
Median age (years) 36
Age (years)
0-27
28-35
36-44
45-80
24
25
27
25
Extra-abdominal localization
Head/Neck
Chest wall/back
Extremity
Other*
10
23
26
7
Abdominal localization
Abdominal wall 35
Size (mm)
0-50 
51-100 
>100 
61
32
8
Depth
Superficial
Deep
21
80
CTNNB1 mutation
Wild type
T41A
S45F
Other
25
49
18
9
* Groin (n=4), retroperitoneal (n=3) 
Treatment
R0 resection was achieved in 64 patients, 17 of these patients underwent a second 
operation to obtain this result. A total of 32 patients underwent R1 resection as a definitive 
operative treatment (including 3 patients who underwent a re-excision). In 5 patients, 
the tumor was completely removed according to the operative report but information 
regarding resection margins was lacking in the histopathological report. Medical therapy 
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was provided to five patients (chemotherapy n=4; sulindac n=1) as induction treatment 
in order to improve the feasibility of a complete tumor resection. One patient had a 
partial response. Forty patients received postoperative radiotherapy, twenty-six of them 
after microscopically radical surgery (R0), fourteen following an R1 resection. No patient 
received adjuvant medical therapy.
CTNNB1 gene analysis
A specific CTNNB1 gene mutation was found in 76 patients (75%): a T41A mutation was 
most common (n=49), an S45F mutation was present in 18 patients and a 45P mutation 
was seen in three patients. A mutation or deletion on the CTNNB1 gene other than 
T41A, S45F or 45P was found in 6 patients. Due to the limited number of patients with a 
45P mutation, these patients were categorized in the group “other” for the analyses. Wild 
type was documented for 25 patients.
Recurrences
After a median follow-up period of 41 months (IQR 18-71), 17 patients developed recurrent 
disease. Median time till recurrence was 20 months (IQR 13-45). The 5-year cumulative 
risk of recurrence was 22.8%. Three patients died during follow-up, in two cases due to 
unrelated causes. One patient died at the age of 4 after extensive treatment of a tumor 
located in the head and neck. 
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Table 2. Univariate analysis of factors predictive of recurrence after R0/R1 resection of AF. 
 No. of 
recurrence
Kaplan-Meier 
5-year risk of recurrence %
P (log-rank) Cox HR (95% CI) P (Wald)
Age
0-27
28-35
36-44
45-80
10/24
2/25
3/27
2/25
60.5
10.3
11.2
11.8
0.001
Reference
0.16 (0.04-0.74)
0.20 (0.05-0.73)
0.15 (0.03-0.69)
0.019
0.015
0.015
Localizationa 
Extra-abdominal
Abdominal
17/66
0/35
31.0
0
0.006
Extra-abdominal
Head/Neck
Chest wall/Back
Extremity
Other
4/10
4/23
7/26
2/7
40.0
22.5
33.6
40.0
0.463
Reference
0.33 (0.08-1.34)
0.56 (0.16-1.92)
0.52 (0.09-2.84)
0.122
0.357
0.449
Size
0-50 mm
51-100 mm
>100 mm
7/61
8/32
2/8
19.1
26.5
37.5
0.323
Reference
1.68 (0.61-4.64)
3.04 (0.63-14.68)
0.318
0.167
Depth
Superficial
Deep
1/21
16/80
9.1
26.3
0.109
Reference
4.51 (0.60-34.07) 0.144
Resection margin
R0
R1
Rxb
9/64
6/32
2/5
16.9
31.2
50.0
0.219
Reference
1.85 (0.65-5.26)
3.22 (0.69-14.95)
0.248
0.136
Adjuvant radiotherapy
No
Yes
11/61
6/40
29.7
15.7
0.213
Reference
0.53 (0.20-1.46) 0.220
Mutation 
Negative
Positive
2/25
15/76
13.4
25.6
0.248
Reference
2.33 (0.53-10.18) 0.262
Mutation
Wild Type
T41A
S45F
Other/45P
2/25
4/49
10/18
1/9
13.4
12.2
63.8
16.7
<0.001
Reference
0.86 (0.16-4.73)
8.50 (1.85-39.00)
1.47 (0.13-16.26)
0.866
0.006
0.751
a Cox regression was not possible due to no events in the abdominal group. b Missing data on resection 
margin, operative report states macroscopic radical resection. No=number, KM=Kaplan Meier, Cox=Cox 
regression, HR=Hazard Ratio, CI=confidence interval
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Factors affecting recurrence
Univariable analysis of factors affecting the risk of recurrence showed a statistically 
significant effect of age (P=0.001), tumor localization (P=0.006) and the presence of a 
CTNNB1 mutation (P<0.001), see Table 2. Young age (< 28 years) and the presence of  
a S45F mutation were associated with an increased risk of recurrence. Tumor localization 
in the abdominal wall was associated with a decreased risk of recurrence. The highest risk 
of local recurrence was observed in patients with a S45F mutation. These patients had a 
5-year recurrence risk of 63.8% and a 8.5 fold higher risk of recurrence (95% CI 1.85-39.00; 
P=0.006) than patients with tumors that were wild type. The 5-year risk of recurrence for 
wild type, T41A- or other mutations was 13.4%, 12.2% and 16.7% respectively (Figure 1). 
Multivariable analysis was performed using age and CTNNB1 mutations (Table 3). Both the 
presence of S45F mutation and young age (under 28 years) proved to be independent risk 
factors (P<0.001 and P=0.011 respectively). The association between the presence of a 
S45F mutation and the conventional clinicopathological factors is presented in Table 4.  
A significant association with tumor depth was observed (P=0.021) as S45F mutations did 
not occur in superficial tumors. 
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Table 3. Multivariate analysis of factors predictive for recurrence following R0/R1 
resection of AF. 
Cox HR (95% CI) P (Wald)
Age: 0-27 year vs other age groups* 3.70 (1.34-10.19) 0.011
Mutation: S45F vs no S45F* 6.20 (2.24-17.15) <0.001
*Reference. Localization was not included due to the statistical limitation of Cox regression when no events 
occur in a group. Cox=Cox regression, HR=hazard ratio, CI=confidence interval
Figure 1. Recurrence- free survival of the specific CTNNB1 mutations 
Follow-up period
No. at risk
Wild type 25 20 17 11 10 8
T41A 49 40 34 30 28 20
S45F 18 15 11 8 3 3
Other 9 8 5 4 4 2
Other
S45F
T41A
Wild type
60483624120
Re
cu
rr
en
ce
-f
re
e 
su
rv
iv
al
1,0
0,8
0,6
0,4
0,2
0,0
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Table 4. Association between S45F mutation and other clinicopathological factors by  
Chi-square analysis.
S45F mutation (n=18) No S45F mutation (n=83) P (Pearson)
Sex ratio (M : F) 9:9 26:57 0.109
Median age (years) 35 36
Age (years)
0-27
28-35
36-44
45-80
7
3
4
4
17
22
23
21
0.407
Localization
Extra-abdominal
Abdominal 
15
3
51
32
0.103
Extra-abdominal
Head/Neck
Chest wall/Back
Extremity
Other
3
3
8
1
7
20
18
6
0.440
Size (mm)
0-50
51-100 
>100 
8
8
2
53
24
6
0.366
Depth
Superficial
Deep
0
18
21
62
0.021
Resection margin
R0
R1
Rx*
8
9
1
56
23
4
0.161
Postoperative radiotherapy
No
Yes
12
6
49
34
0.605
*missing data on resection margin; operative report states macroscopic radical resection 
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Discussion
In patients with primary, sporadic extra-abdominal and abdominal AF, the 5-year 
cumulative risk for recurrence was 22.8%. The presence of a S45F mutation and age 
<28 years were independent predictors of recurrence. Both were associated with a 60% 
risk of developing recurrence within five years.
The present study evaluated the prognostic value of specific CTNNB1 gene mutations in 
a uniform cohort of patients with primary, sporadic AF who underwent a macroscopic 
complete tumor resection. A strength of the present study is the verification of pathology 
specimens by experts on soft tissue tumors and the central pathologic analysis of the 
CTNNB1 mutations and the homogeneous inclusion of primary, sporadic extra-abdominal 
and abdominal tumors. Because intra-abdominal AF is considered a different biological 
entity with a deviating treatment protocol, this category of patients was excluded from the 
study. All patients were treated in specialized centers. 
This study has some limitations too, mostly inherent to the retrospective study design, 
such as the small sample size and the different follow-up schemes in the respective 
institutions. Information on postoperative radiotherapy (indications, precise doses and 
effects) was limited. In addition, the median follow-up period of 41 months may cause 
underreporting of recurrences for a disease which can recur after several years. However, 
the observed difference in recurrence rates between mutations is evident with this modest 
follow-up. 
The impact of clinicopathological factors on recurrence has recently been used to 
construct a nomogram for predicting recurrence15. In this nomogram, age, localization 
and tumor size are important predictive factors. The present data confirms the high risk 
associated with young age, while the predictive value of tumor size was not. The low 
risk associated with abdominal wall localization was confirmed by the present study: no 
recurrences were observed in the abdominal wall group (n=35). 
In the present study, desmoid-specific CTNNB1 mutations significantly influenced the 
risk of recurrence. A study by Lazar et al. also reported a significantly increased risk of 
recurrence associated with a S45F mutation with a relative risk of 3.59. Colombo et al. 
observed comparable results with a S45F mutation as a significant predictor for recurrence 
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in a multivariable analysis11. In these studies the 5-year risk of recurrence was 77% and 
54% respectively for patients with an S45F mutation, underscoring the overall high risk of 
recurrence after surgery in this group. In addition, Bo et al. found a predominance of S45F 
mutations in the group of patients with recurrent disease, whereas T41A mutation was 
observed more often in primary disease, also suggesting an increased recurrence risk in 
the former mutation16. Discordant findings have been reported by Mullen et al12. In their 
analysis on 115 patients with primary and recurrent AF the difference in recurrent free 
survival (RFS) for patients with CTNNB1 mutations was modest (58,0% vs 73.6% for wild 
type) and did not reach statistical significance. The frequency of S45F mutations varied 
between the studies and was 28%, 22%, 22% and 25% in the studies by Lazar, Colombo, Bo 
and Mullen respectively9,11,12,16 compared to 18% in the present study. Differences between 
these studies and the present study are mainly explained by inclusion criteria. We applied 
a strict selection of primary sporadic (extra-abdominal and abdominal) tumors to present 
a uniform cohort. The exclusion of recurrent disease will lower the frequency of S45F, as 
this mutation has a predominance in recurrent tumors16.
Other than the knowledge that CTNNB1 mutations can lead to increased beta-catenin 
levels, the exact mechanism and the different effects exerted by the specific mutations on 
the same gene are not well understood. Other enzymes within the Wingless/Wnt-pathway 
can have the same effect, whereas mutations in the APC gene can cause increased beta-
catenin levels too, as is most often seen in intra-abdominal aggressive fibromatoses6,7. On 
the other hand CTNNB1 mutations have been found in beta-catenin negative tumors also, 
suggesting a more elaborate role of mutational status over beta-catenin levels17. 
The effect of mutation status on the risk of recurrence fuels the discussion about the 
indications for surgery and other treatment options. In this context we would like to 
emphasize that the presented results are based on a modest number of eighteen 
S45F patients. Yet when confirmed by larger studies, the extra information gained by 
determination of CTNNB1 gene mutation, will play a valuable role in treatment choices. 
Patients with a low risk of recurrence are likely to benefit most from primary surgical 
treatment. As such, patients with abdominal tumors, superficial tumors and S45F-negative 
tumors appear to be good candidates for an upfront surgical approach. Given the high risk 
of recurrence after surgery in young patients (<28 years) and in patients with S45F-positive 
tumors, upfront surgical treatment is disputable in these patients. Aggressive treatment by 
repeated surgery and postoperative radiotherapy has been standard of care until recently. 
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Therefore, in the latter high risk categories other treatment options should be taken into 
consideration. 
Currently there is a trend towards a more conservative treatment strategy in patients with 
AF18. The high risk of recurrence associated with a particular mutation suggests a more 
aggressive behavior of the primary tumor. Although conceivable that this is associated 
with a higher progression rate in untreated AF, this remains to be established. It is too early 
to advise a watchful waiting approach based on a particular mutation. Still, patients with 
S45F mutations and young patients have such a high absolute risk of recurrence following 
radical surgery that they still may be considered eligible for other treatment modalities 
than surgery. Radiotherapy as a single treatment modality has shown promising results 
in patients with AF with an objectified response or stabilization in up to 80% of patients 
after three years19. It appears to work better as an upfront approach than as an adjunct to 
surgery13,20,21. Although no information exists about the effect of radiotherapy in relation 
to mutation status, it appears an attractive treatment option in a category of tumors 
that, more likely than not, will recur after surgery. Various regimes of chemotherapy have 
shown an overall response rate of 21% in an unselected group of patients22,23. It would be 
worthwhile to conduct studies analyzing the effect of systemic therapy and radiotherapy in 
relation to the CTNNB1 mutation. 
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Abstract
Background
The efficacy of the classical treatment modalities surgery and radiotherapy in the 
treatment of aggressive fibromatosis is presently disputed and there is a shift towards a 
more conservative approach. The aim of the present study is to objectify tumor growth in 
patients with extra-abdominal or abdominal wall aggressive fibromatosis, while adhering 
to a “watchful waiting” policy. Other objectives are to investigate quality of life and to 
identify factors associated with tumor growth, in particular the relation with the presence 
of a CTNNB1 gene mutation in the tumor.
Design and methods
GRAFITI is a nationwide, multicenter, prospective registration trial. All patients with 
extra-abdominal or abdominal wall aggressive fibromatosis are eligible for inclusion in 
the study. Main exclusion criteria are: history of familiar adenomatous polyposis, severe 
pain, functional impairment, life/limb threating situations in case of progressive disease. 
Patients included in the study will be treated with a watchful waiting policy during a period 
of 5 years. Imaging studies with ultrasound and magnetic resonance imaging scan will be 
performed during follow-up to monitor possible growth: the first years every 3 months, 
the second year twice and then yearly. In addition, patients will be asked to complete a 
quality of life questionnaire on specific follow-up moments. The primary endpoint is the 
rate of progression per year, defined by the Response Evaluation Criteria In Solid Tumors 
(RECIST). Secondary endpoints are quality of life and the rate of influence on tumor 
progression for several factors, such as CTNNB1 mutations, age and localization. 
Discussion
This study will provide insight in tumor behavior, the effect on quality of life and 
clinicopathological factors predictive of tumor progression. 
Trial registration
The GRAFITI trial is registered in the Netherlands National Trial Register (NTR), number 
4714.
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Background
Biological behavior
Desmoid-type fibromatoses are rare, non-metastasizing, locally aggressive soft tissue 
tumors. Aggressive fibromatoses can be located in every part of the body and are 
classified as extra-abdominal, abdominal wall or intra-abdominal1,2. The abdominal wall is 
a predilection site in women of reproductive age3. Sporadic onset of the tumor is common, 
but an association with familiar adenomatous polyposis (FAP) has been documented, 
in particular in intra-abdominally localized aggressive fibromatoses4. The course of the 
disease is unpredictable and varies between relatively indolent, i.e. stabilization of the 
tumor, and progressive growth, which may halt spontaneously5. The reported frequency of 
recurrence following local treatment ranges from 5 to 63%6. 
Genetic markers in tumor tissue have been analyzed, in particular the CTNNB1 gene. 
CTNNB1 gene encodes beta-catenin, a proto-oncogene involved in cell adhesion and cell 
transcription. Beta-catenin is a key factor in the Wnt-APC-beta-catenin pathway. On a 
cellular level the beta-catenin protein level is elevated in these tumors, implicating beta-
catenin stabilization as a key factor in the pathogenesis of aggressive fibromatosis7,8. 
Nuclear overexpression of beta-catenin is a histological condition used in a diagnostic 
setting. The diagnostic value is sensitive, but not specific8-10. Research on the CTNNB1 gene 
revealed 3 specific mutations, namely T41A, S45F and 45P8,10. While it is yet unclear how 
these mutations precisely affect the aforementioned pathway in these tumors, a role in 
biologic behavior seems natural according to their role in pathogenesis. Several groups 
have analyzed CTNNB1 mutation and these mutations appear to have a prognostic value in 
determining the risk of recurrence in retrospective series of surgically treated patients11-15. 
Although Mullen et al. did not find a statistical significant prognostic15, several other 
groups reported a higher risk of recurrence for patients with an S45F mutation11-13, even in 
multivariate analysis12. In addition, (surgical) trauma and hormones presumably play a role 
in the genesis of this tumor, as aggressive fibromatosis is known to arise in scars and in 
fertile females16 .
Treatment 
Treatment of aggressive fibromatosis classically involves surgery, combined with 
radiotherapy on indication. Literature on the effects of surgery and radiotherapy on 
the rate of recurrence is conflicting17-19. While these effects are still being questioned, 
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treatment policies have recently turned towards a more conservative approach. Nowadays, 
a watchful waiting approach is being advocated by various authors and is currently the 
standard in European care20-25. Retrospective studies showed that progression usually 
occurs within 2 years of diagnosis. Fiore et al.22 reported a median time till progression of 
14 months, with 89% of progression observed within 2 years, while Salas et al.18 described 
a median time till progression of 20 months. In addition, these studies have also reported 
spontaneous regression in up to 18.5% of the patients18,22. 
The ability to predict tumor behavior would enable tailoring individual patient treatment. 
Little is known about tumor growth. Available literature is dated and descriptive, without 
objective measurements16.
Study aim 
The GRAFITI study will evaluate a watchful waiting approach as an initial treatment for 
patients with extra-abdominal or abdominal wall aggressive fibromatosis. The primary 
objective is to assess tumor progression using the Response Evaluation Criteria In Solid 
Tumors (RECIST)26. We will attempt to identify patient and tumor characteristics related to 
growth. A twin study is ongoing in Milan, Italy (NCT02547831). The present study proposal 
was designed in collaboration with the Italian study group, to facilitate a possible future 
merger of data. 
Design and methods
Study design
GRAFITI was designed in collaboration with experts in sarcoma care throughout the 
Netherlands as a nationwide prospective observational study. All patients with extra-
abdominal or abdominal wall aggressive fibromatosis are eligible for participation. 
Inclusion and exclusion criteria are discussed below. If not included, treatment options will 
be discussed by the local multidisciplinary teams. Treatment modalities include systemic 
treatment, surgery and radiotherapy, and individualized treatment will be chosen based on 
patient characteristics, tumor localization and predicted outcome. 
Patients will be treated by a watchful waiting policy and asked to complete quality of life 
questionnaires. During follow-up, imaging studies will be performed to monitor tumor 
growth. In case of growth, all treatment options will be evaluated, including continuation 
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of watchful waiting. A switch in treatment strategy will be monitored and reasons for this 
switch documented (see Figure 1). 
Figure 1. Flowchart 
Aggressive fibromatosis
Eligible for watchful waiting
Eligible for 
watchful waiting
NO
NO
Routine treatment, locally or systemic.
In case of previous study inclusion: 
Registration of considerations not  
to continue in the study
Not willing to  
participate
Willing to  
participate
1. Register required data 
2.  Perform additional 
radiological measurements 
YES
YES
Discuss study inclusion
Progression Follow-up
No progression
Continue follow-up
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Primary objective
The primary objective is to assess tumor progression in terms of objectifying and 
monitoring growth during watchful waiting policy as an initial treatment. Ultrasound and 
MRI imaging will be used to determine tumor size. Tumor behavior will be scored using 
RECIST. Primary endpoint is the rate of progression per year, which will be measured after 
5 years of follow-up. 
Secondary objectives
The secondary objective is to investigate the effect of treatment on the quality of 
life. During the study period, patients will be asked to complete the EORTC QLQ-C30 
questionnaire five times: at inclusion and after 6, 12, 24 and 60 months. After a switch to 
active treatment, patients will remain on-study for the questionnaires. The scores will be 
evaluated and related to treatment policy. 
Other objectives are to analyze the value of clinicopathological factors, including CTNNB1 
gene mutation, in predicting progression. The reasons and considerations for active 
treatment will be analyzed in relation to the applicability of a watchful waiting policy. 
Study population
The study will take place in the Netherlands. All patients with extra-abdominal or 
abdominal wall aggressive fibromatosis are eligible for inclusion in the study. Primary and 
recurrent disease will be included, stratification will be done for analyses. 
Inclusion criteria
Histological evidence of aggressive fibromatosis. Capable to undergo MRI-scans and 
ultrasounds. Capable to understand and sign informed consent. 
Exclusion criteria 
Age <18 years. Personal or family history of FAP. Intra-abdominal tumor localization. 
Previous treatment for the current manifestation (recurrent lesions without previous 
treatment are included). Severe pain or functional impairment due to the tumor (as 
indicated by the patient. The use of painkillers is not an exclusion criterion). Tumor 
progression leading to mutilation or life/limb-threatening situations, as assessed by the 
attending physician. 
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Sample size
Based on the incidence of sporadic aggressive fibromatosis and tumor localization, we 
expect to include 20 patients annually, we aim to include 100 patients in 5 years. Loss to 
follow-up or death is not to be expected. Under the most adverse conditions, a progression 
rate of 50% would result in a 95% confidence interval (95% CI) of 40-60%. A progression 
rate of 25% would result in a 95% CI of 18%-34%. We consider the presented 95% CI to be 
acceptable for the study.
Methods 
Participation in the study implies that the work-up does not deviate from present common 
practice. A contrast enhanced MRI-scan (T1 and T2 weighted) is used to determine the 
precise localization, size and involved structures. Subsequently, and also in line with 
national guidelines, the patient will undergo an ultrasound-guided, histological needle-
biopsy of the soft tissue tumor, with a 14 G needle. Preferably 3 biopsies will be obtained. 
During the ultrasound, tumor size will be measured in three dimensions. In addition, as 
part of this study a quality of life questionnaire is completed by the patient. 
Table 1. Follow-up schedule
Assessment Enrollment Year 1 Year 2 Year 3-5
Month 3 6 9 12 18 24 36 48 60
History and Physical examination x x x x x x x x x x
MRI-scan x x x x x
Ultrasound x x x x x x
QoL questionnaire x x x x x
Qol=Quality of life
The follow-up schedule is set for 9 outpatient-clinic visits (see Table 1).
During each visit imaging studies will be performed to monitor possible growth. In 
addition, patients will be asked to complete a questionnaire during 5 follow-up visits. 
The radiology report of the ultrasound or MRI-scan will specify the maximum diameter 
in all 3 dimensions and the growth in relation to previous radiological examinations. 
When ultrasonography suggests tumor progression, an MRI-scan is additionally made as 
standard care and considered as the golden standard for detecting changes within the 
tumor. 
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In case of tumor progression, the patient will be re-evaluated. If the patient is still eligible, 
watchful waiting policy will be continued. If not, local or systemic treatment will be started 
and considerations to switch treatment strategies will be documented. 
After inclusion of all patients, pathology specimens will be collected by one pathology 
laboratory and CTNNB1 gene analysis will be performed for all patients. If CTNNB1 
mutation status is already known, this procedure will not be repeated. 
Statistical considerations 
Statistical analysis will be carried out using IBM SPSS Statistics 21. Radiological 
measurements will be registered as a continuous variable at ratio. The average progression 
rate per year will be analyzed using data of all patients. The progression rate per year, 
defined as increase in size per tumor, using RECIST criteria, with the associated range and 
confidence interval, will be registered as the primary outcome. The QLQ-C30 questionnaire 
results in a score to classify the quality of life. This score will be registered as discrete 
data at ratio scale. If a score cannot be rewarded, the data of the questionnaire will be 
regarded as missing data. If a score is missing, but later registered scores are available, the 
later scores will be used in assessment of the quality of life. The overall quality of life will 
be calculated using data of all patients at the end of follow-up. The median value will be 
extracted with the associated range.
The possible influence of patient and tumor related factors on the progression rate and the 
quality of life are analyzed using the Kaplan-Meier method and univariable Cox regression. 
Associations between variables will be explored by Chi-square analysis. Multivariate 
analysis will be performed if possible by means of Cox regression. Those factors which 
prove to have statistical significance in univariate analyses, will be included in the 
multivariate analysis. The considerations for treatment will be categorized and analysis will 
show the occurrence of specific considerations. 
The interim analysis of both primary and secondary parameters will be done after one year 
of follow-up on 20 patients. The analyses will be the same as described above and will be 
performed by the principal investigator. For all analyses, two-sided P < 0.050 is considered 
statistically significant. 
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Discussion
During the last decade, there has been a shift in treatment strategy for aggressive 
fibromatosis from aggressive to conservative modalities. A watchful waiting policy is 
currently advised for extra-abdominal and abdominal wall aggressive fibromatosis25. 
Research validating the efficacy and applicability of a watchful waiting policy is limited. 
Mitchell et al. were the first to describe a stable phase for aggressive fibromatosis5. In a 
retrospective study of 17 patients under medical observation, all experienced at least 
one period of stable disease for over 6 months. A larger study by Fiore et al. evaluated 
142 patients with primary and recurrent aggressive fibromatosis, treated with initial 
conservative treatment retrospectively22. Approximately 50% of the patients did not have 
tumor progression after 1 year. Spontaneous regression has been reported by Salas et al18. 
In a retrospective study analyzing 426 patients with aggressive fibromatosis, 27 patients 
were treated with a watchful waiting policy. Five of these patients had spontaneous 
remission, 16 patients stable disease and 6 patients had progressive disease. The median 
time to progression was 19.7 months. A recent study by Colombo et al. reported 216 
patients with primary extra-abdominal (n=188) and intra-abdominal (n=28) disease 
undergoing a diversity of treatments24. Initial wait-and-see policy was applied in 70 
patients (60 extra-abdominal) and continued till the end of follow-up in 60%. Progression 
occurred in 16 of the 70 patients, mostly treated with systemic modalities. These results 
demonstrate the potential safety of a watchful waiting policy. 
Current knowledge on predictive factors is mostly based on surgical cohorts. Age, tumor 
localization and tumor size have been reported as predictive factors for the risk of 
recurrence following surgery. A nomogram was proposed by Crago et al.27 using all these 
factors in a postoperative setting. 
In addition, CTNNB1 mutations are found to be a predictive factor for the risk of recurrence 
following surgery12-14,16. The value of these factors in a postoperative setting cannot be 
extrapolated to a watchful waiting setting. The present study was designed to evaluate 
the role of these factors in relation to the progression rate in a watchful waiting setting. 
This information would help in determining which patients can safely undergo a watchful 
waiting policy, and which patients would benefit most from active treatment. The ability 
to predict tumor behavior would enable tailoring individual patient treatment and prevent 
over- or undertreatment. 
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The low incidence of aggressive fibromatosis presents a challenge for quality research. 
Collaborations between specialized institutions is essential. The prospective evaluation 
of predictive factors in a watchful waiting setting has been initiated by two other research 
groups. In France, Bonvalot et al. are conducting a similar study (ClinicalTrials.gov identifier 
NCT01801176). They have finished the inclusion process and are now conducting the 
final follow-up. In Italy, a similar study is coordinated by Colombo et al. (ClinicalTrials.gov 
identifier NCT02547831). This study is still open and we encourage inclusion. The present 
study was designed to resemble the French and Italian study, to facilitate a possible 
merging of the data if the inclusion rate in the studies would be disappointing. Main 
inclusion and exclusion criteria match for all three studies, though our study also includes 
patients presenting with recurrent disease. 
The occurrence of aggressive fibromatosis has been related to hormonal influences and 
pregnancy by Häyry and Reitamo et al.16,28. Although hormonal levels and receptors on the 
tumor have not been investigated, the occurrence of disease among fertile females is very 
suggestive. A recent study by van Broekhoven et al. evaluated time trends in the Dutch 
population29. Their analysis between incidence and hormonal influences did not show a 
positive correlation. In an attempt to evaluate the hormonal influence, data on the use of 
hormonal medication and history of pregnancy will be collected during the present study. 
Intra-abdominal tumor depositions and personal or family history of FAP are among the 
exclusion criteria for the presented study. Intra-abdominal desmoid tumors are associated 
with FAP30. This association is suggestive of a different tumor biology compared to  
sporadic disease. In addition, intra-abdominal disease is related to a high mortality among 
FAP-patients and as such treated differently. To limit the risks associated with the present 
study, these patients are excluded from participation.
The occurrence of progression does not necessitate a switch to active treatment. In 
case the safety of the patient is compromised, for example due to organ involvement 
or increased pressure, a switch to active treatment will be recommended. In order to 
minimize the risk of compromised abilities due to tumor growth, the follow-up schedule 
allows for timely detection of tumor progression and patients with vital structures at risk 
will not be included in the study. The exclusion criteria prevent life threaten of functional 
impairment in case of tumor growth. Severe pain is considered to require continuous 
pain medication. Active treatment does not guarantee pain relief. As such, a watchful 
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waiting policy should be considered and discussed in patients experiencing degrees of 
pain. During the study period, we will monitor the considerations in switching treatment 
strategies.
An interim analysis will be performed after 1 year follow-up from the first 20 patients. This 
analysis is designed to validate the safety of the study. If too many patients deviate from 
the watchful waiting policy, this policy should be questioned. Due to the benign nature 
of this disease, we consider it safe if over 50% of the patients is still undergoing watchful 
waiting after 1 year of follow-up. 
This study will provide insight in tumor behavior and clinicopathological factors predictive 
of tumor progression. The ability to predict tumor behavior would enable tailoring 
individual patient treatment. 
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General discussion 
(adjusted from “Abdominal Desmoid Tumors: Hands Off?”)
Epidemiology
Desmoid-type fibromatosis (DF) is a challenging disease. Insight in biology and 
understanding of epidemiology, incidence and treatments started over 30 years ago, when 
Finnish studies provided a foundation1-3. This foundation was dated and more insight in 
current epidemiologic trends and treatment related trends was imperative. Analysis of 
the Dutch population (reported in chapter 2) showed an increase from about two cases 
per million people in 1993 to about five cases per million people in 2013. Explanations for 
the rising incidence are not evident. Improved diagnostic modalities, better registration, 
awareness and screening programs are likely to influence these numbers. The possibility 
of a true rise in the incidence is made more likely by the observed changes of increased 
median age and female predominance, with a shift in tumor distribution. The driving factor 
for these observed changes is unclear. Direct correlations for etiological factors could not 
be explored and possible biases should be taken into consideration. 
Treatment modalities
Treatment strategies for DF were similar to (malignant) soft tissue tumors. Radical surgery 
used to be the standard treatment, often combined with radiotherapy. The evidence for 
these aggressive treatment modalities is ambiguous. Reports of disease stabilization and 
spontaneous regression has tempered the use of surgery and radiotherapy. In addition, 
it underscores the poor understanding of the natural history of DF4-6. These reports have 
fueled the trend for primary conservative management, that is, an active surveillance 
approach. No established or evidence-based approach for the management of this 
neoplasm is available as of today. In order to interpret results of active surveillance in DF, 
the context of all treatment modalities is important. 
Surgery has been the cornerstone in treatment of DF. The reported recurrence rate following 
resection varies greatly from 5 to 63 per cent 5,7, with most studies reporting recurrence 
rates around 20-25% 8-11. In an attempt to predict the risk of recurrence, several study 
groups have analyzed patient and tumor characteristics for prognostic value. The reported 
results about importance of age, location, resection margins and adjuvant radiotherapy are 
conflicting7,10,12-14. In chapter 3, we report our results from a large Dutch cohort. The patients 
in the cohort were treated in a period of time when aggressive local treatment was routinely 
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performed. The 5-year risk of local recurrence was 18%. This relatively low percentage is 
partially explained by the uniform cohort of patients with primary disease, located in the 
abdominal wall or extra-abdominal structures. Many studies analyze primary and recurrent 
disease combined, or evaluate intra-abdominal DF as part of the cohort. Results should be 
stratified for these subgroups. Primary and recurrent disease are two different subtypes, 
as recurrent disease has already shown its nature to recur. Intra-abdominal disease has a 
different tumor biology and behavior, with a high mortality rate and should therefore be 
analyzed apart from extra-abdominal or abdominal wall disease. 
Our results showed resection margin did not have an significant influence on the risk of 
recurrence, whereas age and localization did have a significant influence. These results 
underscore the nomogram drafted by Crago et al.14. 
The ambivalent results in several studies fuel the discussion on adjuvant treatment 
following microscopically irradical resection (R1). Radical resection (R0) is always strived 
for by the surgeon, sometimes by performing several surgeries to achieve radical resection 
margins. Our data provides an argument not to pursue microscopically tumor free 
resection margins (R0) at all (functional) costs. 
Radiotherapy has been widely applied for desmoid tumors, both in primary and adjuvant 
settings. Results have been ambiguous, especially for adjuvant radiotherapy7,11,13,15. A 
comparative review by Nuyttens et al. showed significantly better local control rates 
with adjuvant radiotherapy, irrespective of resection margin width, in both primary and 
recurrent disease16. Despite these convincing results, the therapeutic benefits should be 
weighed against long term side effects of radiotherapy. In an attempt to provide more 
guidance, we performed a systematic review as described in chapter 4. Results showed 
improved local control rates for adjuvant radiotherapy in patients with microscopically 
irradicale resection (R1) in both primary and recurrent disease. These results support 
the use of adjuvant radiotherapy for local control after incomplete resection, with the 
nuances that in case of R1-resection, patients must be discussed in a multidisciplinary 
setting. Several adjuvant treatment strategies are possible, including the preferred active 
surveillance instead of radiotherapy. 
A study by Keus et al. addressed the role of radiotherapy in a primary setting17. They 
reported partial and complete response in 50% of patients and stable disease in 41% 
of patients, with ongoing effect of radiotherapy after 3 years of follow-up. In chapter 6, 
we addressed the use of radiotherapy in the primary setting for patients with extra-
abdominal DF. Complete or partial response was documented in 43% and stable disease 
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in 46% of patients. Progression of disease did not occur in the first 30 months of follow-up. 
Again, these results are promising for the effect of radiotherapy on DF and underscore its 
potential value. However, the possible long term effects should not be taken lightly in this 
intermediate grade disease. 
Isolated limb perfusion (ILP) is reserved for patients with advanced disease in which 
surgery would lead to severe loss of function. This procedure is only performed in 
specialized centers. ILP is mostly applied in patients with sarcoma or melanoma and 
rarely used for DF. We combined data from three European sarcoma centers to evaluate 
the effect in DF, as described in chapter 5. Limb preservation was achieved in up to 88% 
of patients. The small number of patients (N=25) underscores the limited use of ILP in 
DF. Besides the needed experience to perform the procedure, it is also an indication 
that most patients do not have disease as advanced that they qualify. The aim of ILP is 
limb preservation with adequate function. Toxicity is often accepted to some degree, as 
amputation remains an option after ILP. 
Literature on systemic treatment for DF is heterogeneous and limited. Anti-hormonal 
drugs, non-steroid anti-inflammatory drugs (NSAID’s), chemotherapy and tyrosine kinase 
inhibitors have been applied in different regimes. Most studies consist of small cohorts, 
with a variation of systemic regimes. Randomised controlled trials are currently running 
with sorafenib (NCT 02066181) and pazopanib (NCT01876082). 
With increasing knowledge on biology in DF and involved pathways, systemic treatment 
gains interest. As described in chapter 6, the use in common practice is very limited, thus 
hampering research. Selection bias should be taken into consideration when interpreting 
results. As first-line management, good results for systemic treatment were achieved 
with overall response and stabilization in 63% of patients. Patients in our cohort mostly 
received anti-hormonal drugs and NSAID’s. Again, similar to radiotherapy, possible side 
effects and toxicity must be taken into account when considering systemic treatment. 
Predicting behavior 
The WHO is very clear in discriminating 3 subtypes of DF: extra-abdominal, abdominal 
(or abdominal wall) and intra-abdominal18. The biology and natural behavior for each 
subtype is different and thus requires different treatment. In addition, discrimination 
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between primary and recurrent disease is essential as recurrent disease has already 
proved to be more aggressive by recurring. Most studies in existing literature have mingled 
intra- abdominal tumors, tumors on the trunk, extremities and head/neck as well as 
primary and recurrent lesions and familial adenomatous polyposis (FAP) and non- FAP 
related. These heterogeneous reports lead to conflicting results regarding the biology and 
recommendations regarding management of these tumors.
Since the European consensus, an increasing number of centers have implemented active 
surveillance as primary treatment19. A recent article by Burtenshaw et al describes the 
effect of active surveillance on intra-abdominal and abdominal disease20. While they do 
stratify for primary and recurrent disease, intra-abdominal and abdominal DF, with or 
without FAP or pregnancy, were analyzed as one entity. 
Literature consistently reports that patients with abdominal tumors have ideal outcomes 
regardless of treatment strategy. Intra-abdominal and abdominal DF likely have different 
inherent biology and distinction between these two subsets of patients is evolving in 
the literature. It is very likely that this is not one entity to treat; intra-abdominal DF need 
another approach. A recent study by Huss et al. investigated clinico-pathological and 
genetic features of intra-abdominal DF21. They found a difference in biology, as intra-
abdominal tumors were solid, bulky, localized and originated from mesentery, whereas 
extra-abdominal and abdominal wall tumors were flat and growing in an infiltrating manner. 
Patient characteristics were different, as intra-abdominal tumors presented mostly in men, 
with a median age of 50. Abdominal tumors occur predominantly in fertile women. 
Within the intra-abdominal disease, there is a difference between FAP and non-FAP related 
DF. In several publications of FAP associated intra-abdominal DF, surgical resection is 
associated with morbidity rates of 22–60%, perioperative mortality rates of up to 36% and 
recurrence rates of 65–88% 22-24. Non-FAP-associated intra-abdominal DF can be resected 
with low morbidity and mortality rates in specialist centers, and is associated with low 
rates of local recurrence25. 
In non-FAP related DF, mutations in the CTNNB1 gene are mostly present. 
This distinction in subtypes might be applicable for more types of DF, such as pregnancy 
and non-pregnancy related DF26. 
Knowledge on genetic aspects of DF have increased our understanding of this disease. 
Patients with FAP have a genetic mutation in the APC gene. This gene is also involved in 
bowel cancer. FAP related DF harbor more genetic changes compared to sporadic DF, which 
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predominantly present CTNNB1 mutations27. Three disease-specific CTNNB1 mutations are 
recognized (T41A, S45F, 45P), each with their own characteristics and recurrence risks28,29. 
As such, genetics have become essential in predicting outcome of treatment. In chapter 7 
we reported results on the predictive value of CTNNB1 mutations for recurrence after 
surgery. The differences in recurrence rates is remarkable and underlines the different 
behavior based on biology. Tumors with an S45F mutation have a higher risk of recurrence, 
which could be a sign of generally more aggressive behavior. The exact mechanism of 
different pathways in the pathogenesis of DF are not well understood. CTNNB1 mutations 
can lead to increased beta-catenin levels, though these mutations have also been found 
in beta-catenin negative tumors. Perhaps the mutational status has a more elaborate role 
over beta-catenin levels21. 
Biological behavior remains a subject for future studies. Several study groups are 
investigating the behavior under active surveillance in a prospective manner [NCT01801176, 
NCT02547831]. In chapter 8, the Dutch study protocol is presented [NTR4714]. All 
specialized centers in the Netherlands are participating in this project. The protocol was 
drafted in collaboration with the Italian study group [NCT02547831]. The information 
from the studies will provide guidance to an individualized treatment strategy. The recent 
European consensus is the result of such collaboration and is now the guideline for treating 
desmoid tumors19. All types and locations are included. Different treatments are advised 
based on tumor location. In the European consensus, intra-abdominal tumors are included 
and regarded as different from all other types of locations, in line with WHO classification18.
Knowledge on biology, epidemiology and treatment modalities for DF has greatly increased. 
Guidelines have been formed, weighing the prognostic value of several characteristics to 
assist decision making in disease management. A staging system that can stratify patients 
according to the severity of disease, is a prerequisite to understand the natural history, 
compare treatments, and delineate guidelines for a specific disease as DF. An attempt has 
been done by the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-
ICC) in 2005 for the management of patients with intra-abdominal DF30. There are additional 
variables that may interact with outcome (FAP, pregnancy associated, beta-catenin status, 
etc.). Larger multi-institutional experience must be gathered in the future for desmoid 
patients, which would be able to provide a more accurate assessment of different sites and 
clinico-pathological features as it pertains to outcome. 
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Future perspectives
Knowledge on DF is improving, and improved knowledge is accompanied by more 
questions. The reasons for the rising incidence remain unclear. Diagnostic modalities 
will certainly improve and screening programs are likely to find more asymptomatic 
lesions. Along with the shift in tumor distribution, this will effect treatment strategies. In 
a young population, curative treatment with low toxicity is pursued. An older population 
might have a different interpretation of quality of life. As management of DF is changing, 
discrimination for age groups should be taken into account. Factors such as cosmetic 
results, duration of treatment and possible long term effects might be weighed differently 
by patients in different age groups. Although research is hampered by the low incidence, 
international collaborations will aid to improve high quality research and enrich 
knowledge. 
Surgery has a risk of recurrence, which might be minimal in selected patients. As such, it 
could be an early and definite treatment, without extensive follow-up. 
Radiotherapy has added value but the long term effects prevent physicians from using 
it frequently. Prediction tools are needed to predict the effect of radiotherapy in an 
individual. As CTNNB1 mutations are a predictive tool for the effect of surgery, so might 
they be for radiotherapy or systemic treatment. In addition, tumor growth might be a 
predictor. More aggressive tumors are more likely to respond to radiotherapy or systemic 
treatment. 
Insight on involved pathways in the pathogenesis of DF is increasing. Untouched subjects, 
such as mRNA, might be the key to understanding the mechanisms of systemic treatment. 
For now, it is a good option for patients with progressive disease who are not eligible 
for radiotherapy. The preferable duration of treatment remains unclear, though it is an 
important factor in the young population. As such, radiotherapy might be more appealing. 
ILP should be reserved for patients with advanced disease. As this option should be 
evaluated, it is important patients should be treated in specialized centers. Current trends 
show a better concentration for care within specialized centers. In the future this will only 
increase, improving quality of care and facilitating high quality research.
Active surveillance is currently advised for all patients. This is generally a safe option, 
considering the intermediate nature of DF and generally slow growth. In addition, it helps 
the physician to select patients for further treatment and buys time for multidisciplinary 
evaluations. 
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Key questions in managing DF are when and how to treat. Importantly, expected benefits 
from therapy should be well balanced against potential treatment-induced untoward 
effects. The GRAFITI study is designed to better understand tumor behavior and to find 
factors which influence this behavior. If we are able to discriminate between aggressive 
and indolent behaving tumors at diagnosis, appropriate treatment strategies can be 
selected for the best result with minimal untoward effects. 
A better understanding of tumor behavior leads to different goals of treatment. As DF 
behaves non-malignant in most patients, it is not essential to aggressively pursue total 
tumour irradication. Preservation of function and quality of life become the real goals of 
treatment and should be a key outcome in future studies. A possible framework could be 
provided by the PROFILES registry, which is a registry for the study of the physical and 
psychosocial impact of cancer and its treatment from population-based cohort of cancer 
survivors1. 
Treatment of DF has been and will remain a focus point for future research. The paradigm 
shift from surgery to conservative treatment was radical, but will balance itself out. Toxicity 
is a driving factor for current guidelines. In the future, guidelines will be more focused on 
the expected effect of treatment and quality of life. When analyzing common practice, it 
is noted that the paradigm shift is not as visible as advocated in the literature. Over the 
past 20 years, first-line non-surgical management has increased to up to 12.8% of Dutch DF 
patients. This indicates that until recently, surgery was considered the first-line treatment. 
Awareness of the paradigm shift in treating DF is indispensable, so centralization of these 
patients is mandatory.
Experience is essential in treating patients with DF. The years of experience with surgery 
and radiotherapy are not lightly put aside. Specialized centers are gaining experience by 
applying different treatment modalities and investigating clinico-pathogenetic factors. 
Combined, this will lead to a staging system that can stratify patients according to the 
severity of disease and thus create an individualized treatment strategy for each patient. 
1.  van de Poll-Franse LV et al. The Patient Reported Outcomes Following Initial treatment and Long term 
Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of 
physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 2011 Sep;47(14):2188-94
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Nederlandse samenvatting
Epidemiologie
Desmoid-type fibromatose (DF) is een gecompliceerde en uitdagende ziekte. Inzicht in 
biologie en begrip van de epidemiologie, incidentie en behandelingen begon ruim 30 
jaar geleden, toen Finse studies de fundamenten hebben gelegd1-3. Dit fundament was 
gedateerd en meer inzicht in de hedendaagse trends van epidemiologie en soorten 
behandelingen was noodzakelijk. In hoofdstuk 2 beschrijven we een analyse van de 
Nederlandse bevolking. Er is een stijging van incidentie van circa 2 patiënten per miljoen 
mensen in 1993 naar circa 5 patiënten per miljoen mensen. Verklaring voor deze stijging is 
niet evident. Verbeterde diagnostische technieken, betere registratie, betere bekendheid 
van ziekte en diverse screening programma’s dragen hoogstwaarschijnlijk bij aan deze 
stijging. De mogelijkheid van een ware incidentie stijging wordt meer aannemelijk gemaakt 
door de veranderingen in gemiddelde leeftijd, man-vrouw verhouding en de verandering 
in distributie van ziekte. De drijvende factor achter deze veranderingen is niet duidelijk. 
Directe correlaties tussen etiologische factoren konden niet worden uitgezocht en er moet 
rekening worden gehouden met mogelijke vertekeningen. 
Behandelmodaliteiten
Behandelstrategieën voor DF waren gelijk met (kwaadaardige) weke delen tumoren. 
Radicale chirurgie was de standaard behandeling, vaak gecombineerd met radiotherapie. 
Het bewijs voor deze agressieve behandelingen is niet eenduidig. Berichten van stabilisatie 
van ziekte en spontane regressie hebben het gebruik van chirurgie en radiotherapie 
verminderd. Tevens onderschrijven deze berichten het slechte begrip van het natuurlijk 
beloop van DF4-6. Deze onderzoeken voeden de trend voor een primair conservatieve 
behandeling, namelijk actieve observatie4-6. Er is momenteel geen bewezen of 
wetenschappelijk onderbouwde benadering beschikbaar. Om de resultaten van de actieve 
observatie goed te interpreteren, is begrip en context van alle behandelmodaliteiten 
belangrijk. 
Chirurgie is de hoeksteen in de behandeling van DF geweest. Het aantal recidieven na 
resectie varieert enorm, van 5 tot 63% 5,7, waarbij de meeste studies een recidiefpercentage 
van circa 20% beschrijven8-11. De prognostische waarde in de voorspelling van recidieven 
is onderzocht voor diverse factoren. Uitkomsten met betrekking tot leeftijd, locatie, 
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snijmarges en adjuvante radiotherapie zijn tegenstrijdig7,10,12-14. In hoofdstuk 3 beschrijven 
we de resultaten van een Nederlands cohort. De patiënten werden behandeld in een tijd 
waar chirurgie de eerste keuze was in de behandeling. De kans op een recidief na 5 jaar 
was 18%. Dit relatief lage percentage is deels verklaarbaar door het uniforme cohort 
van patiënten met primaire ziekte, gelokaliseerd in de buikwand of extra-abdominale 
structuren. Andere studies beschrijven vaak een combinatie van primaire en recidiverende 
ziekte, of includeren patiënten met intra-abdominale ziekte. De resultaten moeten 
worden gestratificeerd voor deze subgroepen. Primaire en recidiverende ziekte zijn twee 
verschillende subgroepen, aangezien recidiverende ziekte al een agressiever gedrag 
vertoont door te recidiveren. Intra-abdominale ziekte heeft een afwijkende tumor biologie 
en gedrag, met een hoge mortaliteit en moet daarom apart worden geanalyseerd. 
Onze resultaten toonden dat een radicale snijmarge geen significant effect had op het 
recidiefpercentage. Leeftijd en lokalisatie waren in univariate analyse wel van invloed, wat 
het nomogram opgesteld door Crago et al. onderstreept14.
De tegenstrijdige resultaten voeden de discussie van adjuvante behandeling na irradicale 
resectie (R1). Een chirurg zal altijd streven naar een radicale resectie (R0), soms door 
meerdere operaties uit te voeren. Onze data bieden een argument om de radiale resectie 
niet ten koste van alles na te streven. 
Radiotherapie wordt vaak gebruikt in de behandeling van DF, zowel in primaire als 
adjuvante setting. Ook hierin zijn de resultaten tegenstrijdig, met name voor adjuvante 
radiotherapie7,11,13,15. Een vergelijkende studie van Nuyttens et al. toonde een significant 
betere lokale controle met de toepassing van adjuvante radiotherapie, voor alle snijmarges 
en in zowel primaire en recidiverende ziekte16. Ondanks deze overtuigende resultaten 
moeten de therapeutische voordelen worden afgewogen tegen de lange termijneffecten 
van radiotherapie. In een poging om meer duidelijkheid hierin te krijgen, hebben we een 
systematische review gedaan van de recente literatuur, zoals beschreven in hoofdstuk 4. 
De resultaten lieten verbeterde lokale controle zien bij gebruik van adjuvante radiotherapie 
in patiënten met een irradicale resectie (R1), zowel bij primaire als recidiverende ziekte. 
Deze resultaten ondersteunen het gebruik van adjuvante radiotherapie na incomplete 
resectie, met de nuance dat patiënten met een irradicale resectie moeten worden 
besproken in een multidisciplinaire setting. Verschillende adjuvante behandelingen zijn 
mogelijk, inclusief actieve monitoring in plaats van radiotherapie. 
De rol van radiotherapie als primaire behandeling werd onderzocht door Keus et al.17. Zij 
rapporteren een partiële en complete respons in 50% van patiënten, en stabilisatie van 
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ziekte in 41%, met tevens een continuerend effect van de radiotherapie na 3 jaar controle. 
In hoofdstuk 6 beschrijven we het gebruik van radiotherapie in de primaire setting voor 
patiënten met extra-abdominale DF. Complete of partiële respons werd gezien in 43% 
en stabilisatie in 46% van patiënten. Progressie van ziekte werd niet gezien in de eerste 
30 maanden na bestraling. Opnieuw zijn deze resultaten veelbelovend en bevestigen het 
effect van radiotherapie. Echter moeten de lange termijneffecten niet worden onderschat 
bij deze niet-maligne ziekte. 
Geïsoleerde ledemaat perfusie (ILP) is een behandeling welke enkel wordt toegepast in 
patiënten met vergevorderde ziekte, die kandidaat zijn voor amputatie. Deze behandeling 
wordt alleen toegepast in gespecialiseerde centra. ILP wordt vaker gebruikt in patiënten 
met sarcomen of melanomen, maar zelden voor DF. We hebben data gecombineerd van 
3 gespecialiseerde, Europese centra en de resultaten beschreven in hoofdstuk 5. Het 
ledemaat kon behouden worden in 88% van de patiënten. De kleine groep patiënten 
(N=25) bevestigt het beperkte gebruik van ILP voor DF. Naast de benodigde ervaring om 
de behandeling uit te voeren, is dit ook een indicatie dat de ziekte vaak niet dusdanig 
vergevorderd is om patiënten in aanmerking te laten komen. Het doel van ILP is 
ledemaat behoud met een acceptabele functie. Toxiciteit wordt veelal in bepaalde mate 
geaccepteerd, omdat amputatie de enige andere optie is. 
Literatuur betreffende de systemische behandeling is wisselend en beperkt. Anti-
hormonale medicatie, niet-steroïde anti-inflammatoire medicatie (NSAID’s), chemotherapie 
en tyrosine kinase remmers zijn beschreven in diverse combinaties. De meeste studies 
beschrijven kleine patiënt cohorten, met een variatie aan medicatie. Momenteel lopen er 
2 gerandomiseerde studies naar het gebruik van sorafenib (NCT 02066181) en pazopanib 
(NCT01876082). Door toename van kennis op het gebied van biologie en pathogenese van 
DF, neemt de interesse in systemische behandelingen toe. Het gebruik van deze medicatie 
in de primaire setting is zeer beperkt. In hoofdstuk 6 wordt het gebruik binnen Nederland 
beschreven. Het beperkte gebruik bemoeilijkt onderzoek. Vertekeningen in de selectie 
van patiënten moet worden meegewogen bij het interpreteren van de resultaten. Onze 
resultaten in de primaire setting waren goed, met respons en stabilisatie in 63% van de 
patiënten. Er werd meestal gebruik gemaakt van anti-hormonale medicatie en NSAID’s. 
Echter moet ook hier worden gekeken naar de mogelijke bijwerkingen en toxiciteit van de 
middelen, wanneer deze behandeling wordt overwogen. 
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Gedrag voorspellen
De WHO is zeer duidelijk in het onderscheiden van 3 subtypes van DF: extra-abdominaal, 
abdominaal (buikwand) en intra-abdoinaal18. De biologie en het natuurlijk gedrag van elk 
subtype is anders en daarom is er een andere behandeling nodig. Daarnaast is onderscheid 
tussen primaire en recidiverende ziekte essentieel omdat recidiverende ziekte al bewezen 
agressiever is door te recidiveren. De meeste studies in de huidige literatuur combineren 
intra-abdominale tumoren, tumoren op de romp, ledematen en het hoofd/hals gebied, net 
als primaire en recidiverende laesies en familiaire adenomateuze polyposis (FAP) en niet-
FAP gerelateerde ziekte. Deze heterogene verslagen leiden tot tegenstrijdige resultaten met 
betrekking tot de biologie en aanbevelingen voor de behandelingen van deze tumoren. 
Met het vormen van een Europese consensus is er een stijgend aantal centra welke 
de actieve monitoring gebruiken als primaire behandeling19. Een recent artikel van 
Burtenshaw et al. beschrijft het effect van actieve monitoring op intra-abdominale en 
abdominale tumoren. Hoewel zij wel onderscheid maken tussen primaire en recidiverende 
ziekte, worden intra-abdominale en abdominale ziekte als 1 entiteit geanalyseerd, 
ongeacht FAP. 
De literatuur beschrijft herhaaldelijk dat patiënten met abdominale tumoren een ideale 
uitkomst hebben, ongeacht de behandeling. Intra-abdominale en abdominale DF hebben 
zeer waarschijnlijk een andere biologie en onderscheid tussen deze subtypes van 
patiënten ontwikkelt zich in de literatuur. Het is zeer waarschijnlijk niet één entiteit om 
te behandelen: intra-abdominale DF heeft een andere benadering nodig. Een recente 
studie door Huss et al. onderzocht de clinicopathologische en genetische kenmerken van 
intra-abdominale DF21. Zij vonden een verschil in biologie; intra-abdominale tumoren 
waren solide, omvangrijk en mesenteriaal gelokaliseerd en ontstaan, terwijl extra-
abdominale en abdominale tumoren plat waren en groeiden op een infiltratieve manier. 
Patiënt karakteristieken waren ook anders; intra-abdominale tumoren kwamen het meest 
voor in mannen, met een gemiddelde leeftijd van 50 jaar, terwijl abdominale tumoren 
voornamelijk ontstaan in vruchtbare vrouwen. 
Binnen de intra-abdominale ziekte is er een onderscheid te maken tussen FAP en niet-FAP 
gerelateerde DF. Meerdere publicaties beschrijven een morbiditeitskans van 22-60% bij 
chirurgie, een kans op perioperatieve mortaliteit tot 36% en een recidiefkans van 65-88% 
voor FAP-gerelateerde intra-abdominale DF22-24. Niet-FAP gerelateerde intra-abdominale DF 
kan worden geopereerd met een lage morbiditeit- en mortaliteitkans in gespecialiseerde 
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centra, en is geassocieerd met een lagere recidiefkans25. 
In niet-FAP-gerelateerde DF komen vaak mutaties in het CTNNB1-gen voor. 
Dit onderscheid in subtypes is mogelijk toepasbaar voor meerdere types van DF, zoals 
zwangerschap of niet-zwangerschap gerelateerde DF. 
Kennis van de genetische aspecten van DF hebben ons begrip van deze ziekte vergroot. 
Patiënten met FAP hebben een genetische mutatie in het APC-gen. Dit gen is ook betrokken 
bij darmkanker. FAP-gerelateerde DF heeft meer genetische afwijkingen vergeleken met DF 
welke spontaan is ontstaan. Bij deze laatste groep is er vaak sprake van een mutatie in het 
CTNNB1-gen27. Er zijn drie CTNNB1-mutaties welke specifiek zijn voor DF (T41A, S45F, 45P), 
elk met eigen karakteristieken en recidiefkansen28,29. Deze genetische afwijken zijn een 
belangrijk onderdeel geworden in het voorspellen van de uitkomsten van behandelingen. 
In hoofdstuk 7 beschrijven we de voorspellende waarde van CTNNB1-mutaties op de 
recidiefkans na chirurgie. De verschillen in recidiefkansen zijn opvallend en onderschrijven 
het verschil in gedrag gebaseerd op biologie. Tumoren met een S45F-mutatie hebben 
een hogere kans op recidieven. Dit kan een aanwijzing zijn voor een algeheel agressiever 
gedrag. Het exacte mechanisme van diverse wegen binnen de pathogenese van DF wordt 
nog niet goed begrepen. CTNNB1-mutaties kunnen leiden tot verhoogde beta-catenine 
spiegels, terwijl deze mutaties ook worden gezien in tumoren met lage beta-catenine 
spiegels. Wellicht heeft de mutatie een belangrijkere rol vergeleken met de beta-catenine 
spiegel21. 
Het biologisch gedrag blijft een belangrijk onderwerp voor toekomstige studies. Enkele 
studiegroepen onderzoeken momenteel het natuurlijke gedrag van DF tijdens actieve 
monitoring in een prospectieve setting [NCT01801176, NCT02547831]. In hoofdstuk 8 
is het Nederlandse studieprotocol beschreven [NTR4714]. Alle gespecialiseerde centra 
binnen Nederland doen mee aan dit onderzoek. Het protocol is opgesteld in samenwerking 
met de Italiaanse studiegroep [NCT02547831]. De informatie uit deze studies zal richting 
geven aan patiënt-specifiek behandelplannen. De Europese consensus is ook de uitkomst 
van een dergelijke samenwerking, en is nu de richtlijn voor de behandeling van DF19. 
Alle types en lokalisaties van DF worden geïncludeerd. Verschillende behandelingen 
worden geadviseerd, afhankelijk van tumor lokalisatie. In deze consensus worden intra-
abdominale tumoren ook meegenomen, maar worden beschouwd als anders ten opzichte 
van de andere lokalisaties, in overeenstemming met de WHO classificatie18. 
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Kennis van biologie, epidemiologie en behandelmodaliteiten is aanzienlijk toegenomen. 
Er zijn richtlijnen gevormd, waarbij de prognostische waarde van diverse karakteristieken 
wordt meegenomen in het maken van beslissingen over de behandelstrategie. Een 
stadiëringssysteem wat patiënten kan verdelen op basis van ernst van de ziekte, is een 
voorwaarde om het natuurlijk beloop te begrijpen, behandelingen te vergelijken en 
richtlijnen op te stellen voor een zeldzame ziekte als DF. Een opzet hiervoor is gemaakt 
voor intra-abdominale DF in 2005 door de Samenwerkende Groep van de Amerikanen voor 
Erfelijke Colorectaal Kanker (Collaborative Group of the Americas on Inherited Colorectal 
Cancer; CGA-ICC)30. Er zijn aanvullende waarden die mogelijk invloed hebben op de 
uitkomst (FAP, zwangerschap, beta-catenine status, et cetera). Grote multi-institutionele 
onderzoeken moeten worden uitgevoerd waarbij de ervaring moet worden verzameld 
voor DF patiënten. Daarmee zijn we in staat om een meer nauwkeurige evaluatie van de 
verschillende lokalisaties en clinicopathologische kenmerken uit te voeren, welke van 
invloed zijn op de uitkomst van behandelingen. 
Toekomst perspectieven
De kennis over DF neemt toe, en hiermee nemen ook de vragen toe. De oorzaken van 
de toegenomen incidentie zijn onduidelijk. Diagnostische modaliteiten zullen zeker 
verbeteren en screening programma’s zullen waarschijnlijk meer asymptomatische 
laesies vinden. Samen met de verandering van ziektedistributie tussen de leeftijds-
groepen, zal dit effect hebben op de behandelstrategieën. In een jonge populatie 
wordt een curatieve behandeling met lage toxiciteit nagestreefd. Een oudere populatie 
heeft mogelijk een andere interpretatie van kwaliteit van leven. Nu de behandeling van 
DF aan het veranderen is, moet een onderscheid tussen de leeftijdsgroepen worden 
meegenomen. Factoren zoals cosmetische resultaten, duur van de behandeling en 
mogelijke lange termijneffecten hebben wellicht een andere waarde voor patiënten 
in andere leeftijdsgroepen. Hoewel het onderzoek wordt bemoeilijkt door de lage 
incidentie, zullen de internationale samenwerkingen bijdragen aan een hoge kwaliteit 
van onderzoek en toename van kennis. 
Chirurgie heeft een recidiefkans, welke mogelijk minimaal is bij een specifieke groep 
patiënten. Voor hen zou chirurgie een vroege en definitieve behandeling kunnen zijn, 
zonder langdurige controles. 
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Radiotherapie heeft een toegevoegde waarde in de behandeling, maar de lange 
termijneffecten zorgen ervoor dat artsen terughoudend zijn in het gebruik hiervan. Er 
zijn handvaten nodig om het effect van radiotherapie bij patiënten te voorspellen. Waar 
CTNNB1-mutaties een dergelijk handvat bieden voor chirurgie, kunnen ze dat wellicht 
ook voor radiotherapie en systemische therapie. Daarnaast zou de mate van groei een 
voorspellende factor kunnen zijn. Agressievere tumoren zijn doorgaans gevoeliger voor 
radiotherapie of systemische therapie. 
Inzicht in de verschillende wegen van pathogenese van DF neemt toe. Nog niet besproken 
factoren, zoals mRNA, kunnen de sleutel zijn voor het begrijpen van de werkings-
mechanismen van systemische behandelingen. Momenteel is de systemische behandeling 
een goede optie voor patiënten met progressieve ziekte die geen kandidaat zijn voor 
radiotherapie. De gewenste duur van de behandeling is nog onduidelijk, hoewel dit 
vaak wel belangrijk is voor de jonge populatie. Daardoor kan radiotherapie mogelijk een 
aantrekkelijkere optie zijn. 
Actieve monitoring wordt momenteel geadviseerd voor alle patiënten. Het is in het 
algemeen een veilige optie, gezien de niet-maligne aard van de ziekte en doorgaans 
trage groei. Daarbij helpt het de arts om patiënten te selecteren voor aanvullende 
behandelingen en om tijd te winnen voor multidisciplinaire besprekingen. 
ILP dient te worden gereserveerd voor patienten met vergevorderde ziekte. Omdat 
deze optie wel meegenomen moet worden, horen patienten te worden behandeld in 
gespecialiseerde centra. Huidige trends tonen een betere concentratie van zorg binnen 
gespecialiseerde ziekenhuizen. In de toekomst zal dit nog verder toenemen, wat de 
kwaliteit van de zorg bevordert en kwalitatief onderzoek faciliteert. 
Sleutelvragen in de behandeling van DF zijn wanneer en hoe te behandelen. Het is belangrijk 
om de verwachtte voordelen af te wegen tegen de potentiele gevolgen van de behandeling. 
De GRAFITI studie is opgezet om een beter begrip van het natuurlijk beloop van ziekte te 
krijgen en om factoren te identificeren welke het beloop beïnvloeden. Als we onderscheid 
kunnen maken tussen agressieve en indolente tumoren ten tijde van de diagnose, kunnen 
gerichte behandelingen worden toegepast voor het beste resultaat met minimale risico’s. 
Een beter begrip van het natuurlijk gedrag leidt tot andere doelen van de behandeling. 
Omdat DF zich in de meeste patiënten niet kwaadaardig gedraagt, is het niet essentieel 
om agressief de tumor volledig te verwijderen. Behoud van functie en kwaliteit van leven 
worden de nieuwe doelen van de behandeling en zouden de belangrijkste uitkomst 
moeten zijn in toekomstige onderzoeken. Een mogelijk raamwerk wordt geboden door 
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het PROFILES register. Dit is een register om te kijken naar de fysieke en psychosociale 
gevolgen van kanker en de behandeling van kanker vanuit een landelijke groep van 
kankerpatiënten31. 
De behandeling van DF is en blijft een aandachtspunt voor toekomstige onderzoeken. 
De fundamentele verandering van chirurgie naar conservatieve behandeling was zeer 
radicaal, maar zal zichzelf uitbalanceren. Toxiciteit is de leidende factor binnen de huidige 
richtlijnen. In de toekomst zullen de richtlijnen zich meer richten naar de verwachtte 
uitkomst van behandelingen en kwaliteit van leven. Kijkend naar de huidige praktijk wordt 
duidelijk dat de fundamentele verandering niet zo zichtbaar is als wordt geadviseerd in 
de literatuur. Gedurende de afgelopen 20 jaar is het percentage van niet-chirurgische 
behandeling als eerste behandeling toegenomen tot 12.8% in Nederland. Dit geeft aan 
dat chirurgie als eerste behandeling werd toegepast tot recent. Bewustwording van deze 
fundamentele verschuiving is onmisbaar in de behandeling van DF patiënten, waarbij de 
centralisatie van zorg een vereiste is. 
Ervaring is essentieel bij het behandelen van patiënten met DF. De jaren ervaring met 
chirurgie en radiotherapie worden niet makkelijk opzij geschoven. Gespecialiseerde centra 
verwerven meer ervaring met diverse behandelmodaliteiten en onderzoeken daarnaast 
de clinicopathologische factoren. Deze combinatie zal leiden tot een stadiëringssysteem 
waarbij een onderscheid kan worden gemaakt in de ernst van ziekte per patiënt. Zo kan 
een geïndividualiseerde behandelingsstrategie voor elke patiënt worden opgesteld. 
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Danique Louise Maria van Broekhoven werd geboren op 21 juni 1987 te Rijen. Ze 
groeide op als jongste van het gezin, met een oudere zus en broer. In 2005 ronde ze 
het eindexamen af aan de Nassau Scholengemeenschap in Breda. Datzelfde jaar werd 
ze ingeloot voor de studie Geneeskunde in Utrecht en kon ze aan haar droomopleiding 
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samenwerking van het Diakonessenhuis te Utrecht en het Erasmus MC te Rotterdam. 
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het promotieonderzoek naar desmoid tumoren, onder supervisie van prof.dr. C. Verhoef, 
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In 2017 hoopt ze te starten met de opleiding tot orthopedisch chirurg. 
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